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Summary: 
 
The family of cell penetrating peptides (CPPs) consists of small cationic or 
amphipathic peptides that aid the uptake of attached cargoes into living cells. 
This bears a tremendous potential for the introduction of yet non-deliverable 
hydrophilic compounds into living cells in vitro and in vivo. In the beginnings of 
CPP-research the bioavailability of cargoes after translocation into the 
intracellular compartments of cells was often overestimated due to the use of 
inappropriate protocols and invasive detection methods.  
In this study we employed laser scanning confocal microscopy (LSCM) as a 
non-invasive method to delineate differences between fluorescently labeled 
distinct CPPs and to understand the mechanism of uptake of arginine-rich 
CPPs with and without cargoes. We further tracked bioavailability, localization 
and functional effects of a variety of cargoes after being transduced into 
different cells.  
The subgroup of arginine-rich CPPs (RRPs) includes the well studied CPPs 
TAT and penetratin. We assessed the short- and long-termed toxic effects of 
oligo-arginines with different chain length (5-12) relative to their concentration 
in living cells. Nona-arginine gained access in an instantaneously bioavailable 
manner at a reasonable concentration and was associated with little short-
termed or no long- termed toxicity. 
Regarding the mechanism of uptake for RRPs themselves two distinct modes 
have been discussed controversially in the literature since now. (I) The 
cationic peptides enrich at the plasma membrane and become adsorptively 
endocytosed. The main portion of the CPP-cargoes remains thus extracellular 
and release from those vesicles could be detected only by strongly amplifying 
methods (TAT-Cre-recombinase reporter gene assay). (II) Transduction of 
RRPs occurs in a way that the peptide distributes homogenously inside the 
cytoplasm and nucleoplasm and accumulates inside nucleoli. We could show 
that the latter pathway is chosen as an additional option besides endocytosis, 
if a certain threshold concentration or critical concentration is exceeded. By 
inhibiting different endocytic pathways and endcytosis per se we 
unambiguously demonstrated that transduction differs fundamentally from 
pinocytic or endocytic events. Finallly, transduction only takes place if the 
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attached cargoes are small (fluorophores, peptides below 25 additional amino 
acids), large components (nanoparticles, globular protein domains) attached 
to RRPs abolish transduction and become adsorptively endocytosed.  
To understand the process of transduction of RRPs better and because 
structural information of CPPs could only be modeled until now, the method of 
analytical ultracentrifugation was utilized to delineate required features which 
permit a CPP to transduce. We show that RRPs exhibit an extended 
conformation and the only prerequisite for a peptide to transduce is a minimal 
number of arginines that are accumulated over a small peptide sequence. 
Furthermore a circular variant of TAT, that presents the arginines on a much 
smaller diameter, was delivered to a higher amount than its linear counterpart 
into living cells. Therefore a certain accumulation of arginines is the only 
determinant which permits the uptake mode of transduction. 
CPPs can be used to label subcellular structures inside living cells. 
Fluorescently labeled deca-arginine enriched inside the nucleolar 
compartment and stained the granular components and to a lesser extent the 
fibrillar components of the nucleoli. As another example a TAT fusion attached 
to a peptide derived from ventricular light chain-1 (VLC-1) showed enhanced 
presence at the I-bands of isolated cardiomyocytes 
In another approach we demonstrated that a transducible versions of a 
peptide can be utilized to modifiy protein interactions even in primary cells, 
which are usually difficult to transfect and have limited life-time. VLC-1 fused 
to TAT enhanced muscle contraction in primary cultures of adult 
cardiomyocytes. 
In order to generate an antiproliferative peptide we fused peptides derived 
from the PCNA-interacting domains of p21WAF/CIP and ligase1 to the RRP TAT 
and investigated its potential to inhibit cell cycle progression. We found that 
after being incubated with synchronized mouse myoblast for only ten minutes 
these peptides were able to decelerate cell cycle progression to 50 %.  
In summary, we provide an explanatory basis for the conflicting reports in the 
literature, leaving only RRPs or RRPs fused to low molecular weight cargoes 
the option to enter living cells via the mechanism of transduction. For this 
peptide or peptide chimeras transduction can be observed, if they are applied 
above a peptide- and cell type-specific concentration threshold in in vitro 
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experiments. Whereas transduced constructs immediately exert effects, larger 
cargoes fused to RRPs and other CPPs become internalized by an endocytic 
process and only a marginal portion of the constructs escapes from endo-or 
lysosomes. Therefore peptides fused to RRPs are ideal tools to lable 
subcellular structures and to interfere with protein function in living cells.  
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1  Introduction 
 
1.1  Bits and pieces of CPP history 
In 1988, Frankel and Pabo 1 and Green and Loewenstein 2 reported that the 
viral protein transactivator of transcription (TAT) from HIV-1 was able to cross 
biological membranes and to subsequently alter gene transcription. This 
discovery was followed by the mapping of the peptide domain responsible for 
the cellular uptake ability and termed protein transduction domain (PTD) or 
cell penetrating peptide (CPP). Subsequently, other PTDs have been 
identified, e.g., the homeobox of the antennapedia protein of Drosophila 
melanogaster 3,4, the viral tegument protein VP22 of herpes simplex virus-1 5-
7, human calcitonin derived peptides 8,9 and the PreS2-domain of hepatitis-B 
virus surface antigen 10. The homeobox of antennapedia was the first example 
of a shuttle that promoted the intracellular delivery of a part of the Rab 3 
protein as a cargo into cells in culture 3. For some of the factors mentioned 
above the minimal transducing domains were mapped and will hereafter be 
referred to as CPPs. The TAT-CPP was narrowed down to a short peptide 
motif of nine residues GRKKRRQRRR (amino acids 48-57) 11,12. The well 
studied CPP penetratin comprises the third helix of the homeobox of 
antennapedia RQIKIWFQNRRMKWKK (amino acids 43-58) 13, but a shorter 
C-terminal segment (52-58) is sufficient to induce translocation 14. To the 
panoply of CPPs derived from naturally occurring proteins artificially designed 
peptide sequences were soon added, which can be categorized as 
amphipathic or model amphipathic (MAP) 15-17, lysine-, arginine- 14,18-21, 
proline-rich 22-24 and chimeric 25-27 peptides or peptoids 21,28. Equipped with 
this armamentarium, cellular uptake of all sorts of cargoes linked to CPPs, like 
fluorophores, drugs 29, peptides 30, nucleic acids 31, proteins 11,32,33, 
nanoparticles 34 and liposomes 35 was achieved. Their internalization seemed 
to follow an energy-independent, unknown pathway. Importantly, the effects of 
interconnected cargoes measured in mammalian cells and animals raised 
hopes that biogical membranes could be conquered by any hydrophilic 
compound, if shuttled by CPPs. Unfortunately, these expectations had to be 
reconsidered, when in 2003 Richard et al. published that the CPPs TAT and 
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penetratin themselves became internalized into mammalian cells by an 
endocytic mechanism 36. Even under mild fixation conditions, fluorescently 
labeled CPPs escaped from the endosomal compartment and were 
redistributed into the cytoplasm and the nucleus. The cationic nature of CPPs 
and their consequent strong affinity to negatively charged cell membrane 
constituents, was proposed to lead to their artifactual internalization after 
treatment of cells with membrane disruptive methods 36. Thus, the uptake of 
CPPs was overestimated in many studies using flow cytometric analysis to 
quantify the amount of presumably internalized CPPs. Consequently, 
published work on CPP-mediated internalization needs to be critically 
reassessed.  
 
 
1.2  Influence of cargoes on the mode of uptake 
 
An analysis of the available data suggests a correlation between size and/or 
structure of the cargo and the mechanism of cellular uptake. This is also 
supported by the observation that peptides and proteins fused to CPPs 
simultaneously incubated with mammalian cells end up in different subcellular 
compartments 37,38. In addition, some biophysical properties of the cargoes 
might also interfere with the uptake mechanism. 
 
1.2.1  High molecular weight  cargoes 
Proteins and quantum dots fused to CPPs follow an endocytic route and 
uptake can be prevented by inhibitors of endocytosis 37-42. For TAT-fusion 
proteins caveolar-dependent endocytosis 39, lipid raft macropinocytosis 43 or 
clathrin-dependent endocytosis 44 were suggested as possible mechanisms. 
Brooks et al. promoted the idea that the CPP TAT due to its strong adherence 
to negatively charged membrane constituents gets internalized by any 
pinocytic process occurring at cell membranes 45.  Recently, arginine-rich 
CPPs (RRPs) were reported to simultaneously use at least three endocytic 
pathways 46. Hence, the term adsorptive endocytosis, as already used by the 
discoverers of TAT-mediated transduction 47, still applies. The main pathways 
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for pinocytic and endocytic uptake are depicted in Fig. 1. For the ionic 
interaction of the positively charged amino acid residues with cellular 
membranes, a crucial role of heparin sulfate proteoglycans or phospholipids 
was established 37,47-50, but the influence of particular negatively charged 
membrane constituents on the translocation event may vary for individual 
CPPs 41. Endocytic uptake is associated with storage of the internalized CPP-
species in endosomes or lysosomes for extended periods of time and thus 
reduced bioavailability and activity. Nevertheless, a sensitive and non-
invasive reporter gene assay based on Cre-mediated recombination after 
delivery of the protein TAT-Cre recombinase 51,52 indirectly revealed the 
presence and activity of the recombinase inside the nucleus 38,43. In addition,  
 
 
 
 
 
 
 
numerous examples of CPP-mediated delivery of high molecular weight 
cargoes like protein and DNA / RNA constructs with functional effects after 
internalization in vitro and in vivo have been reported and are reviewed in 53.  
Figure 1: Main pinocytic uptake pathways and transduction: 
Pinocytic events include (I) Macropinocytosis, (II) clathrin-dependent 
endocytosis, (III) caveolin-dependent endocytosis and (IV) and clathrin- 
and caveolin-independent types of endocytosis. In contrast to any 
pinocytic event  that is associated with intermediate storage of CPPs in 
vesicles, CPPs gain direct access to all intracellular compartments via the 
yet not fully understood mechanism of transduction.
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As the release from cytoplasmic vesicles is the bottleneck for a successful 
delivery of bioavailable cargoes by CPPs, several studies aimed to increase 
the efficiency of vesicular release. Using the TAT-Cre recombinase functional 
assay, lysosomotropic agents like chloroquine or endosome-disruptive agents 
like PEI (polyethylenimine) or high concentrations of sucrose (1-2 M) 54, as 
well as the co-application of the transducible and fusogenic TAT-HA2 peptide 
together with the TAT-fusion protein markedly enhanced Cre recombinase 
activity 43,55. Other methods to destabilize vesicle architecture include Ca2+ 
treatment at millimolar concentrations 56 or photochemical treatment in the 
presence of photosensitizers like CPPs themselves 54 or membrane soluble 
chemical compounds 57, e.g. aluminium phthalocyanine enhanced the 
antisense effect of a peptide nucleic acid conjugate delivered by TAT by two 
orders of magnitude 58. 
 
1.2.2  Low molecular weight cargoes 
Although an endocytic mode of uptake for high molecular weight cargoes is 
generally accepted, the entry route of low molecular weight cargoes like 
peptides (< 50 aa) attached to CPPs is still a controversial issue. Several 
groups reported that uptake of CPPs like TAT, oligo-arginines or penetratin 
did not differ from internalization of high molecular weight cargoes fused to 
CPPs and fell in the category of adsorptive endocytosis (see above) 59-61. 
From the initial studies defining the minimal transduction domains a very 
rapid, energy-independent mechanism of entry was observed concomitantly 
using non-invasive detection methods, e.g. fluorescence microscopy 
12,37,38,60,62,63. This kind of mechanism will hereafter be called transduction. 
Transduction was not affected by inhibitors of endocytosis and was reported 
to occur 12,13,21,62 or even to be enhanced at lower temperature 64. In addition, 
D-amino acid analogues of CPPs were taken up in the same rapid manner 
and a receptor-dependent mechanism could therefore be excluded 21,65-68. 
Furthermore, the process of transduction exhibited faster kinetics and lead to 
immediate overall intracellular bioavailability (Fig. 1). The uptake kinetics of 
deca-arginine into HeLa cells were recently shown to start directly after 
application of the fluorescently labeled CPP and reached a plateau after 40 
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minutes 68. The membrane potential was proposed as one of the potential 
driving forces for this mode of uptake of CPPs 38,69-71. Interestingly, there 
exists a CPP- and cell type-specific transduction threshold 38,46. For the CPP 
TAT coupled to a fluorophore transduction into mouse myoblasts occurred at 
or above 1 µM and, when fused to a 20 amino acid-long peptide, the threshold 
increased to 7.5 µM. Below these concentration thresholds internalization 
occurred only via the mechanism of adsorptive endocytosis 38. TAT, 
penetratin and oligoarginine exhibited a critical concentration or transduction 
threshold in cases where non-degradable D-amino acid variants were 
analyzed 38,46,64. Furthermore, freeze-fracture electron microscopy of DMPC-
liposomes treated with TAT at a ratio 1:20 (peptide/lipid) showed TAT 
assembled in small bundles with a spacing of about 5 nm 72 and in a recent 
atomic force microscopy analysis of TAT on DSPC/DOPC planar 
biomembranes, the peptide associated with increasing concentration on the 
fluid phase 73. For antimicrobial peptides the re-alignment and self-assembly 
of peptides in membranes was reported to be concentration-dependent also, 
e.g. a solid-state NMR study with the membrane-disruptive peptide PGLa 
revealed that with increasing peptide/lipid ratio the peptide changed from a 
monomeric surface-bound S-state over a dimeric tilted T-state to an 
oligomeric membrane-inserted I-state 74. These cooperative effects might 
explain, why for a given CPP both possible uptake modes are controversially 
reported in the literature. 
 
1.2.3  Special role of arginine-rich peptides (RRPs) in cellular 
uptake 
The unifying feature among most known CPPs is the presence of several 
lysines and/or arginines within the individual peptide motifs. The high positive 
net charge of CPPs leads to an increased local peptide concentration at the 
cellular membranes driven by electrostatic interactions 75,76. CPPs such as 
transportan, mastoparan and MAPs form a subgroup of amphipathic CPPs, in 
which hydrophobic and hydrophilic amino acid side chains are spatially 
separated in the α-helical peptide structure, a property often found in 
antimicrobial peptides. Their membrane translocation was reported to occur in 
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an energy-dependent and -independent fashion in living cells 16. A structure-
function study astonishingly revealed that membrane association due to 
positive net charge was not correlated with uptake efficiency and lysines were 
even dispensable; rather helical amphipathicity and a length of at least four 
complete helical turns were essential to allow membrane translocation 17. 
Therefore, the mechanism of translocation for this type of CPPs might differ 
from that of TAT and penetratin analogues, where positive charge is 
absolutely required for the crossing of biomembranes. But charge alone is 
insufficient to explain the process of transduction. The uptake of oligomers of 
histidine, ornithine and lysines, as well as that of branched lysines 
(loligomers) was demonstrated to be sensitive to temperature, which argues 
for an endocytic uptake 21,77,78. On the other hand a minimum of six 
consecutive arginines was enough to cause transduction 14,18 and the D-form 
as well as guanidino peptoids worked equivalently 21. These results, the 
absence of a common secondary structure element in known RRPs and the 
flexibility in the position of arginines within a given peptide sequence without 
affecting its transduction efficiency 18 suggests a decisive role for arginine in 
the mechanism of transduction, which probably resides in its guanidinium 
function 21,28.  
 
1.2.4  Relevant parameters when measuring CPP uptake 
Several parameters influence the transduction efficiency of CPP-peptides. 
Among them the type of CPP, its D or L amino acid composition and its 
concentration, the application buffer, the cell type, as well as the 
administration or application mode can influence the optimal concentrations 
for transduction. Such methodological details are usually described in the 
material & methods section. However, only few publications mention, e.g., the 
final volume in which the CPP was applied on the cells during experiments, 
although increasing peptide-to-cell ratio has been shown to influence the 
mode of uptake. Higher peptide-to-cell ratios permit, in addition to 
endocytosis, direct membrane transduction 79. Therefore, besides the 
particular CPP concentration the parameter liquid m3 / cells m2 in combination 
with cell density and cell type should be included in future work. Another 
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important determinant is the temperature, as RRPs transduce more quickly at 
lower temperatures. This is especially important to allow any meaningful 
comparison of results and to draw conclusions on CPP uptake and its 
efficiency. 
 
1.3.  Models for the mechanism of transduction 
 
Although to date the mechanism of transduction (i.e., the non-endocytic mode 
of CPP uptake with membrane permeation and direct intracellular availability) 
is still not clarified, several models have been developed to explain this 
intriguing property of CPPs. 
 
1.3.1.  Pore formation 
Some CPPs (MAPs 15) exhibit amphipathicity or adopt α-helical conformation 
in the presence of artificial micelles, e.g. mastoparan and transportan 80, 
which is also a known property of pore-forming antimicrobial or lytic peptides. 
Such peptides lead to leakage of protons, metal ions, proteins etc, finally 
resulting in cell death due to the collapse of the membrane potential 81. 
Amphipathic peptides insert into the membrane and multimerize in such a 
way, that hydrophobic residues are exposed and hydrophilic residues form the 
cavity of a channel (Fig. 2A, amphipathic peptides). Thereby short-living 
mastoparan pores permit influx of compounds < 1000 Da into mammalian 
cells 82. Moreover they are able to traverse the membrane with a flip-flop 
mechanism 83. However, this mechanism can only apply for the subgroup of 
amphipathic CPPs. RRPs do not form pores in both artificial and mammalian 
cellular membranes 13,84 and small miscible compounds applied 
simultaneously do not gain access to the intracellular millieu of the cells upon 
transduction 85. Consequently, MAPs exert rather strong toxic effects 16,17,86, 
whereas penetratin causes only little membrane perturbations 86 and TAT and 
oligo-arginines are well tolerated by living cells 12,85,86.  
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1.3.2.  Formation of inverted micelles 
The interaction of CPPs with artificial membranes has been the subject of 
several biophysical studies. The observation by 31P-NMR that penetratin 
induced micelle formation in artificial membranes led to the assumption that 
CPPs might translocate biomembranes inside the hydrophilic cavity of 
inverted micelles 87-89. In Fig. 2B the mechanism proposed starts by strong 
electrostatic interactions of the CPP with the phospholipids or glycolipids, 
which causes membrane perturbation. The cationic peptide enters the lipid 
bilayer inside of an inverted micelle and is released in the reverse process 
into the cytoplasm. Further analysis of the interaction of penetratin with 
artificial zwitterionic and anionic model membranes revealed that penetratin 
forms a β-sheet hairpin structure and orients in parallel to the membrane 75,90. 
Penetratin enriches at the lipid water interface and is anchored by its 
tryptophan residues inside the lipid bilayer. It causes a membrane curvature 
and from a certain threshold concentration on becomes internalized. The 
driving force for this event is the electrostatic field created by the differencial 
peptide concentration inside and outside the membrane 91. However, the TAT 
CPP showed weaker binding to anionic membranes than penetratin, 
presumably due to the fact, that no hydrophobic amino acid residue is 
available for anchoring inside the bilayer 76. A biophysical study compared the 
CPPs TAT, octa-arginine, octa-lysine, and other amphipathic peptides and 
their influence on artificial membranes. TAT induced a pronounced isotropic 
31P-NMR signal, (indicative of micelles, very small vesicles or cubic phases) in 
zwitterionic, but not in anionic membranes. Octa-arginine and to a lesser 
extent octa-lysine had the same effect, whereas other amphiphilic CPPs did 
not influence the line shape of the 31P-NMR signal. Moreover freeze-fracture 
electron microscopy indicated that the changes detected by 31P-NMR were 
due to the formation of rod-like structures on the membrane surface 72.  
 
1.3.3.  Adaptive translocation  
The superior transduction activity of consecutive arginines over the 
corresponding lysines, histidines and ornithines is mainly dependent on the 
guanidine function of arginine 21,78,85. The efficiency could be enhanced by 
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using polyarginines prepared from D-amino acids or polyguanidine peptoids 
with different spacers, comprising at least seven guanidine head groups 21. 
Also highly branched guanidinium-rich oligosaccharides or dendrimers were 
shown to transduce readily 67,92,93. In a two-phase partitioning experiment with 
octanol and water, fluorescent octa-arginine and less efficient octa-ornithine 
moved after addition of laurylsulfate from the aqueous phase into the octanol 
layer. As the replacement of the amino functions of arginine with one or two 
methyl groups diminished the partitioning capacity, these results suggest the 
efficient formation of lipophilic ion pairs with abundant negatively charged 
groups, e.g. phospholipids, fatty acid salts and sulfates via bidentate 
hydrogen bonds 70,71, which are able to diffuse into the interior of the 
hydrophobic lipid bilayer. A recent molecular dynamics simulation with the 
RRP TAT stated that the interaction of TAT with the phosphate groups on 
both sides of an artificial lipid bilayer membrane (DOPC) was crucial for 
translocation 94.  
The driving force for RRPs to penetrate living cells was found to be 
membrane potential dependent. Incubation of living cells with isotonic K+-
enriched buffer abolished uptake of arginine-rich CPPs 38,69,70, likewise 
pretreatment of cells with the membrane potential increasing antibiotic 
valinomycin led to higher intracellular concentration of octa-arginine 70. Hence,  
the model depicted in Fig 2C can be described as formation of lipophilic ion 
pairs and their diffusion along the membrane potential inside the cells. This 
would also imply that the transport is monodirectional and that internalized 
cargoes remain inside the cell. In addition, cargo-dependent differences in the 
uptake can be explained because the diffusion rate of higher molecular weight 
cargoes should be limited, if not prevented by structural constraints. 
Likewise several observations of CPPs themselves and TAT fused to globular 
proteins suggest that the loss of tertiary structure enhances or permits 
translocation over the cell membrane. This would be equivalent to the import 
of cytosolic proteins into cell organelles, which also requires unfolding of the  
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protein to be translocated 95,96. The protein dihydrofolatereductase (DHFR) 
fused to the protein TAT was able to translocate into HeLa cells, but the 
import failed, when the tertiary structure of DHFR was stabilized by 
methotrexate, a folate-analogue 97. In agreement with this observation it was 
shown that the activity of a variety of proteins genetically fused to the CPP 
TAT depend on the purification protocol. For TAT-fusion proteins purified 
under denaturing conditions lower concentrations were sufficient to achieve 
the same effect than their natively extracted counterparts 32,98. For instance, 
the enzyme Cu-Zn superoxide dismutase fused to TAT was able to prevent 
paraquat-induced cell damage in a concentration dependent manner when 
Figure 2: Models for the 
mechanism of trans-
duction. 
 
A Amphipathic peptides 
multimerize in a way that 
hydrophobic residues are 
exposed to the outside 
and hydrophilic residues 
line the inner parts of a 
pore inserted into the 
plasma membrane. 
 
 
B Cationic CPPs induce 
the formation of a vesicle, 
in which they become 
internalized. In addition 
some CPPs exploit the 
unordered structure at the 
joints between vesicle 
and plasma membrane, 
to gain directly access to 
the intracellular space. 
 
 
C Arginine-rich peptides 
form uncharged ion pairs 
with negatively charged 
constituents of the 
plasma membrane. They 
translocate along the 
membrane potential over 
the biomembrane.  
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the purification scheme included denaturation in urea, but had no effect when 
purified natively 99. The requirement for unfolding for translocation through the 
membrane is more relevant for proteins fused to CPPs than for the CPPs 
themselves and/or fused to short peptides, as the total number of residues in 
the latter would permit, if at all, the formation of short secondary structures.  
 
1.4.  Toxicity of cell penetrating peptides (CPPs) 
 
1.4.1.  In vitro  
A number of studies have assessed the toxicity of cell penetrating peptides in 
vitro. In general, comparative toxicity studies support the division of CPP into 
subgroups, namely RRPs and amphipathic peptides. Thus, the induction of 
membrane leakage by amphipathic peptides could be correlated with the 
hydrophobic moment 86. The assessment of the toxicity of unmodified CPPs 
using a LDH-leakage, DiBAC4(3)-(membrane depolarization) and hemolytic 
assay showed rather severe toxic effects of MAP and transportan 10 as 
representatives of the amphipathic CPPs, but only mild effects of the RRPs 
TAT and penetratin 100. Using mouse myoblasts, oligoarginines consisting of 
minimal five and maximal 12 amino acids at different concentrations were 
analyzed for transduction and concomitant toxicological effects. Nona-arginine 
was identified as the oligoarginine of choice, combining high transduction 
frequencies with low short and long termed toxicological effects 85. Among the 
RRPs the toxicity decreases in the series oligoarginine>penetratin>TAT 101,102. 
The toxicological properties can be dramatically changed also upon the 
attachment of low molecular weight cargoes, e.g. labels or other peptides 
101,103. The toxicity of TAT fused to the anti-apoptotic Nemo-binding domain 
peptide as well as to the scrambled variant increased the detected toxicity in 
several cell types 100-fold 103.  As the attachment of high molecular weight 
cargoes shifts the uptake mechanism to an endocytic pathway only, a 
reduction in toxicity in these cases most likely reflects the lower amount of 
bioavailable intracellular CPP-cargo 37,38,101.  
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1.4.2.  In vivo  
As with in vitro cell culture systems, in vivo data are difficult to compare due to 
the variety of CPPs used and the differences between the cargoes attached. 
In addition, the modes of administration of the CPP-cargoes to the animals 
and the type of animal used, further complicates a delineation of toxic effects. 
The RRPs TAT and penetratin alone were shown to reduce p38 mRNA levels 
in lung tissues after intracheal administration 104. The RRP (RXR)4 105,106 (X = 
6-aminohexanoic acid) fused to a phosphorodiamidate morpholino oligomer 
(PMO) cargo was evaluated on the basis of mortality, changes in physical 
appearance, animal behaviour, body weight and serum biochemistry profile 
and appeared to be non-toxic below a concentration of 15 mg/kg in Sprague-
Dawley rats when administrated once by intravenous bolus injection 107. A 
Grb7 peptidic inhibitor fused to penetratin was intraperitoneally injected into 
BALB/c nu/nu mice every third day for 4 weeks at 100 mMol / kg and no 
clinically significant adverse effects as assayed by histological changes in the 
major tissues became apparent 108. Unfortunately, only few studies to date 
mention toxicological observations, in addition to the biological effect under 
study.  
 
 
1.5  Applications of CPP-mediated intracellular delivery in 
molecular medicine 
 
The non-invasive CPP-mediated delivery of hydrophilic compounds into living 
cells bears a tremendous potential for fundamental research as well as for 
therapeutics. Furthermore, this delivery method is virtually unlimited in the 
size of the shuttled cargo, provided that endocytically internalized cargoes can 
be released from endosomes efficiently. In this section, the versatile 
applicability of CPP-mediated delivery approaches is illustrated on the basis 
of selected examples.  
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1.5.1  Labeling and imaging 
CPP-mediated delivery has proven useful in labeling cells or subcellular 
structures. TAT CPP coupled to magnetic nanoparticles was shown to be 
taken up by CD34+ cells 34,109,110, which, after intravenous injection into mice, 
could be tracked in vivo. Therefore, endocytic loading of nanoparticles 
connected to CPPs into particular cells ex vivo is a non-invasive cell labeling 
method allowing subsequent tracking of injected cells in vivo 111. Also TAT 
linked to the radiolabel 99mTc and injected intravenously into mice was 
detectable in all organs, although at higher levels in the liver and the urinary 
tract 112-114. In addition to magnetic and radiolabel TAT-species, delivery of 
fluorescently labeled CPPs has been used for the visualization of tumor 
xenografts in mice 115. In the latter study, the specific label of the tumor cells 
was achieved by release of the positively charged CPP from a negatively 
charged linked peptide via metalloproteinases presented by the tumor cells. 
Another interesting application of CPPs in animal imaging is the in vivo uptake 
via the skin of the low-molecular weight cargo luciferin coupled to an oligo-
arginine CPP transporter into living transgenic mice expressing luciferase. 
Intracellular luciferin is converted by the luciferase to the photo-emitting form 
oxyluciferin, which can be detected with a cooled charge-coupled device 
camera in living animals 29.  
Peptides fused to CPPs have also been used to specifically label subcellular 
structures in living cells. The deca-arginine itself was used as a cell 
permeable marker of the nucleolar compartment in a variety of cells 68 and the 
TAT CPP fused to a peptide derived from human ventricular myosin light 
chain 1 transduced into primary cardiomyocytes and highlighted sarcomeric 
structures 116.  
 
1.5.2  Modulation of intracellular function 
 
1.5.2.1  Drug delivery 
Only few groups have worked on the facilitation of delivery of synthetic 
macromolecules or therapeutics by CPPs. In a transport feasibility study TAT 
was shown to be able to shuttle a N-(2-hydroxypropyl)methacrylamide 
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(HPMA) copolymer and the anthracyclin doxorubicin into a human ovarian 
carcinoma cell line 117,118. The same drug and benzylpenicillin fused to the 
CPP SynB1 were able to cross the blood brain barrier as shown by an in situ 
rat brain perfusion technique after intravenous administration 119,120. 
Cyclosporin A connected to hepta-arginine applied within a lotion entered the 
epidermis and dermis of murine and human skin. Furthermore, a similar 
construct that releases cyclosporin A at physiological pH inhibited 
inflammation in mouse contact dermatitis 29. 
 
1.5.2.2  Delivery of peptides and proteins 
To date the vast majority of studies using CPP-mediated intracellular delivery, 
evaluated the uptake of either peptides or proteins into living cells and/or the 
corresponding effects on intracellular functions. Several studies have focused 
on their potential use as anti-tumor delivery agents, whereas others deal with 
their advantage to deliver protective agents in model systems of cellular 
damage (ischemia, neurodegeneration, etc.). 
As a potential tumor therapy agent a peptidic inhibitor of growth factor 
receptor-bound protein 7, a factor highly expressed in metastatic pancreatic 
cancer, was fused to penetratin and after frequent intraperitonal injections into 
mice containing pancreatic cancer cells, it was shown to diminish the number 
of metastatic nodules to 2% 108. Also the DNA replication licensing protein 
geminin shuttled by a novel PTD had an anti-proliferative effect in cultured 
cancer cells 121. Another example of a potential anti-tumor approach consisted 
on the delivery of the apoptotic (KLAKLAK)2, mitochondrial membrane 
disruptive peptide fused to hepta-arginine, which caused rapid cell death 
when injected subcutaneously into tumor xenografts in mice 122.  
On the other hand, a large number of studies showed cellular protective 
effects of various CPP-fusions. Delivery of TAT-BH4 protein and TAT-Bcl-xL 
peptides prevented apoptosis in models of sepsis 123, irradiation 124 and 
ischemia or reperfusion 125. Targeting the JNK pathway with a c-Jun inhibitory 
peptide fused to TAT minimized the lesion size in a rat model of ischemia. 
The same peptide was able to cross the blood-brain barrier after intraperitonal 
injection 126. Another neuroprotective TAT-fusion to an isozyme specific 
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inhibitor of d protein kinase C increased the number of microvessels and 
improved blood flow in a rat model of ischemia. In addition, prophylactic 
treatment reduced infarct size in hypertensive Dahl rats following an acute 
stroke. Another study used delivery of a TAT-Cu, Zn-superoxide dismutase to 
prevent injury caused by reactive oxygen species after transient forebrain 
ischemia in gerbils 127. Besides its anti-inflammatory properties, Cavtratin – a 
chimera from penetratin and an hydrophobic peptide derived from caveolin-1 
– that negatively regulates the activity of endothelial nitric oxide synthase - 
reduced microvessel permeability 128. Intranasal delivery of a STAT-6 derived 
peptide fused to the CPP PTD4 reduced lung inflammation in murine models 
of rhinitis and asthma inhibited many features of allergic airways disease 129. 
Strikingly, frequent TAT-mediated intracellular delivery of the protein purine 
nucleoside phosphorylase rescued the immunodeficiency and 
neurodegenerative defects of the respective knock-out mice with no apparent 
toxicity 130.  
Finally, uptake of a striated muscle specific human ventricular light chain-1 
peptide fused to TAT CPP into living adult rat primary cardiomyocytes and its 
localization to sarcomeric structures was measured. This cell permeable 
peptide was able to enhance muscle contractility  without affecting the 
intracellular  Ca2+. These properties and the fact that this peptide only has 
targets in striated muscle, makes it a novel potential therapeutic tool to 
improve cardiac function 116,131.  
 
1.5.2.3  Delivery of oligonucleotides (ON) 
Although CPP-mediated pinocytic delivery is independent of cargo size, the 
introduction of DNA or RNA seems to be technically more demanding. Due to 
the complexation of the intrinsically basic CPP with the negatively charged 
phosphate backbone of nucleic acids, the transducing moiety becomes less 
available for the interaction with negatively charged membrane constituents, 
which is crucial for the initiation of the internalization event 115.   
Nevertheless, a 16-mer peptide nucleic acid (PNA) stably linked to the CPPs 
TAT, Transportan and Tp10 inhibited Tat-dependent trans-activation 132 and a 
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18-mer steric block oligonucleotide linked to the CPP R6-Penetratin  enhanced 
splice correction activity 133 in a HeLa cell reporter assay.   
The usage of the RNA analogues phosphorodiamidate morpholino oligomers 
(PMO) replaces the phosphordiester- with a neutral phosphorodiamidate 
linkage and therefore results in a neutral nucleic acid compound that is 
resistant to nucleases and RNase H. Conjugated via a thioether linkage to 
several types of RRPs it redirected the splicing of targeted mRNAs in primary 
murine leukocytes 19. With a similar alteration in pre-mRNA splicing the 
excision of a nonsense mutation in exon 23 was skipped in a mouse model of 
muscular dystrophy and functional dystrophin expression was restored 134.  
Another innovative approach fused TAT to the RNA-binding domain of U1 
small nuclear ribonucleoprotein as an adaptor moiety and used this shuttle for 
delivery of shRNA and si-RNA constructs into CHO cells 135. A further 
possibility to shuttle ONs is to use complexes of CPPs with ON at optimized 
ratios, e.g. to deliver si-RNA 136,137 into cell culture systems. 
 
1.5.2.4  Gene therapy 
CPPs are also capable to aid viral mediated gene delivery in vitro and in vivo. 
Penetratin mixed with an adenoviral GFP expressing construct markedly 
enhanced the infectivity after luminal application into mouse carotid arteries 
138. A recombinant TAT-M2S (multisubunit DNA binding protein) was mixed 
with a therapeutical plasmid encoding a-galactosidase A (AGA) and injected 
into muscles of AGA-knockout mice, suffering from a lysosomal storage 
disease. This chimera significantly enhanced AGA expression in skeletal 
muscle in comparison to the DNA injected alone 139. 
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2.  Results 
 
2.1 Live cell analysis of cell penetration ability and toxicity of 
oligoarginines 
Journal of Peptide Science
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Abstract: Cell penetrating peptides (CPPs) are useful tools to deliver low-molecular-weight cargoes into cells; however, their mode
of uptake is still controversial. The most efficient CPPs belong to the group of arginine-rich peptides, but a systematic assessment
of their potential toxicity is lacking. In this study we combined data on the membrane translocation abilities of oligo-arginines in
living cells as a function of their chain length, concentration, stability and toxicity. Using confocal microscopy analysis of living
cells we evaluated the transduction frequency of the L-isoforms of oligo-arginines and lysines and then monitored their associated
toxicity by concomitant addition of propidium iodide. Whereas lysines showed virtually no transduction, the transduction ability
of arginines increased with the number of consecutive residues and the peptide concentration, with L-R9 and L-R10 performing
overall best. We further compared the L- and D-R9 isomers and found that the D-isoform always showed a higher transduction as
compared to the L-counterpart in all cell types. Notably, the transduction difference between D- and L-forms was highly variable
between cell types, emphasizing the need for protease-resistant peptides as vectors for drug delivery. Real-time kinetic analysis
of the D- and L-isomers applied simultaneously to the cells revealed a much faster transduction for the D-variant. The latter
underlies the fact that the isomers do not mix, and penetration of one peptide does not perturb the membrane in a way that
gives access to the other peptide. Finally, we performed short- and long-term cell viability and cell cycle progression analyses
with the protease-resistant D-R9. Altogether, our results identified concentration windows with low toxicity and high transduction
efficiency, resulting in fully bioavailable intracellular peptides. Copyright  2007 European Peptide Society and John Wiley &
Sons, Ltd.
Supplementary electronic material for this paper is available in Wiley InterScience at http://www.interscience.wiley.com/jpages/
1075-2617/suppmat/
Keywords: arginine-rich peptides; cell cycle; cell penetrating peptides; cell viability; membrane integrity; membrane
translocation; oligo-lysines; oligo-arginines
INTRODUCTION
Cell penetrating peptides (CPPs) possess the unique
ability to shuttle linked cargoes such as drugs [1], pep-
tides [2–6], proteins [7–9], peptide nucleic acids (PNAs)
[10–12] and nanoparticles [13,14] across the plasma
membrane which is otherwise virtually impermeable
for hydrophilic compounds. CPPs can be subdivided
into two major groups: model amphiphilic peptides
(MAPs) [15,16] developed on the basis of spatial sep-
aration of positively charged and hydrophobic amino
acid residues; and arginine-rich peptides (R-RPs) delin-
eated from natively occurring minimal transduction
domains of proteins, e.g. TAT from HIV-1 TAT pro-
tein [7,17–19] and penetratin from the homeobox of
antennapedia protein [20–22]. However, plasma mem-
brane translocation of MAPs structurally requires at
*Correspondence to: M. Cristina Cardoso, Max Delbrueck Center for
Molecular Medicine, Robert-Roessle-Str. 10, D-13125 Berlin, Germany;
e-mail: cardoso@mdc-berlin.de
‡ This article is part of the Special Issue of the Journal of Peptide Science
entitled ‘‘2nd workshop on biophysics of membrane-active peptides’’.
least four helical turns but does not depend on the
positively charged amino acid residues [15], whereas
the transduction ability of R-RPs depends on a mini-
mum number of arginines [23,24], suggesting that the
entry mechanisms of both types of CPPs are unrelated.
The translocation ability of R-RPs does not seem to
be solely a matter of charge, but has been proposed
to reside in the guanidinium group of the arginine
itself [25]. The formation of lipophilic ion pairs with
abundant sulfate, phosphate or carboxylate groups of
membrane constituents via the two amino functions
of arginine provides a mechanistic framework for the
translocation of a highly charged compound through
the plasma membrane [26]. CPP-mediated delivery of
cargoes into the cytoplasm can be achieved by at least
two independent mechanisms: (i) adsorptive endocyto-
sis and subsequent release of the enclosed compounds
from endosomes or lysosomes [7,27–29]; and (ii) rapid
crossing of the membrane by a seemingly energy-
independent, not-well-understood mechanism referred
to as transduction [5,30–32]. Whereas R-RPs coupled
Copyright  2007 European Peptide Society and John Wiley & Sons, Ltd.
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to high-molecular-weight cargoes are restricted to the
endocytic mode of uptake [5,33,34], R-RPs themselves
or interconnected to low-molecular-weight cargoes have
both options. Above a certain concentration (trans-
duction threshold), which varies between 1 and 10 µM
depending on the cell type and the size of the cargo [5],
R-RPs directly translocate across the plasma membrane
into the cell. Several live-cell studies have shown that
functional peptides attached to R-RPs exert biological
effects after the transduction event [2–6]. Importantly,
R-RP-mediated transduction circumvents the inefficient
step of release from cytoplasmic vesicles after the endo-
cytic uptake. However, a systematic evaluation of the
cell penetration ability, in combination with an assess-
ment of potential short- and long-term toxic effects of
R-RPs, is lacking. In this study, we combined data on
the membrane translocation abilities of oligo-arginines
in living cells as a function of their chain length, con-
centration, stability and toxicity.
MATERIAL AND METHODS
Peptides
Consecutive arginines (5–12) and lysines (5–12) as L-isomers
and TAMRA-R9 and Fluos-R10 also as D-isomers were
synthesized and coupled directly to fluorescein (Fluos) or 5,6-
TAMRA at the N-terminus by Peptide Specialty Laboratories
GmbH (Heidelberg, Germany). The peptides were purified
by HPLC and their appropriate masses confirmed by mass
spectrometry. The isoelectric points (pI ) were estimated using
the freeware tool ProtParam.
Cells
All cell types were cultured in Dulbecco’s modified Eagle
medium (DMEM) with fetal calf serum (FCS) (Life Technologies,
Inc., USA) at the following concentrations: C2C12 mouse
myoblasts 20%, human HeLa cells 10%, MDCKII dog epithelial
kidney cells 10% and BJ-hTERT human fibroblasts 10%.
Primary cultures from male WKY rats aged 3 months were
performed as described previously [35].
Transduction Experiments
As peptide transduction is influenced by the peptide-to-
cell ratio [36], for all transduction experiments µ-Slide
VI observation chambers were used (Ibidi, Martinsried,
Germany), which guarantee a defined and equal liquid volume
above the cells throughout the entire observation channel.
The respective cell types were seeded at 70% confluency into
the observation chambers and incubated overnight at 37 °C
at 5% CO2. Special care was taken that cell densities were
equal throughout sets of experiments. The oligo-arginines and
oligo-lysines were diluted in DMEM medium without FCS
to avoid precipitation of the peptides. For the chain-length-
dependent transduction assay, 2 µg/ml propidium iodide (PI)
was added directly to the diluted peptide solution prior to
the transduction experiment. The culture medium was gently
aspirated from the cells and exchanged against the respective
peptide dilutions in a volume of 60 µl. The cells were kept
for 1 h in the incubator until imaging at the microscope
under the same conditions. For each peptide concentration,
between 140 and 250 cells were analyzed and the experiments
were performed in duplicate. The images were collected with
two different laser settings, one set resulting in images
without overexposed signals and one set with higher laser
intensities, so that weaker signals could not be missed. The
microscope settings per concentration and within these two
sets were identical. Acquired images were analyzed visually,
and cells unambiguously showing fluorescent signal inside
the nucleus were scored as transduced. The graphics were
generated using the Origin version 7.5 software (OriginLab
Corp., Northampton, USA).
Cell Cycle and Viability Assays
For the modified (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl-
tetrazolium-bromide (MTT) assay, C2C12 cells were incubated
for 2 h with different concentrations of the peptides D-
R9 and L-R9. MTT was dissolved at 0.4 mg/ml in DMEM.
Subsequently, the cells were washed once, followed by addition
of 100 µl of the MTT solution and were returned to the
incubator for 5 h. Cells were then analyzed by confocal laser
scanning microscopy (CLSM). The transduction frequency
was monitored by the fluorescence of the Fluos- or TAMRA-
labeled peptides, respectively, and the formation of the blue-
violet formazan complex was monitored by excitation with
488 nm and detection in the transmission channel. For each
peptide concentration, five fields of view with a 40× objective
corresponding to a total number of ∼150 cells were collected.
Cells with less formazan signal intensity than the control cells
were counted as nonviable.
For the analysis of the plasma membrane integrity during
and after transduction, we used 2 µg/ml PI mixed together
with the transducing peptides in DMEM to detect transient
pore formation or membrane perturbations, and 0.5% (V/V)
trypan blue to distinguish, after the transduction period of
2 h, the cells with permanently compromised membranes.
Data were displayed by using Microsoft Excel.
To analyze relatively short-term effects on DNA condensa-
tion by the peptides, C2C12 cells were preincubated for 10 min
with the DNA dye DRAQ5 (Biostatus Limited, UK) as described
[37] and then incubated with different concentrations of the
D-R9 peptide. Cells were imaged by CLSM before and after the
treatment. Long-term effects on the cell cycle progression were
determined by fluorescence activated cell sorting (FACS) anal-
ysis of PI-stained C2C12 cells. For this purpose, C2C12 cells
were plated onto 150 mm diameter dishes and incubated with
different concentrations of the respective peptides at a density
of 40% in DMEM for 2 h. Then the medium was replaced by
DMEM with 20% FCS and the cells were cultivated for further
16 h until they reached a density of 60%. For FACS analysis
the cells were trypsinized, washed with PBS, fixed with ice-cold
90% EtOH, washed with PBS, treated with 0.1 mg/ml RNAse
and stained with 33 µg/ml PI, and DNA content was measured
with a FACSCalibur (Becton Dickinson). Data were analyzed
and plotted with the flow cytometry software FLOWJO (Tree
Star, Inc., USA).
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Microscopy, Image Acquisition and Analysis
Confocal images were acquired with a Zeiss confocal laser
scanning microscope, LSM510 Meta, mounted on an Axiovert
200M inverted microscope equipped with a live-cell microscope
incubation cage (Okolab, Italy) using either a 40× plan-
neofluar NA1.3 or a 63× plan-apochromat NA1.4 oil-
immersion, phase-contrast objectives. For all settings the main
beam splitter was HFT UV/488/543/633, and the specific
parameters for the single fluorophores were as follows: Fluos,
excited at 488 nm, detected with a 500–530 nm band-pass
filter; TAMRA, excited at 543 nm, detected with 565–615 nm
band-pass filter; and trypan blue, PI and DRAQ5, excited with
633 nm, detected with 650 nm long-pass filter. Phase contrast
images were recorded with excitation at 488 nm and detection
in the transmission channel. Laser power for observation was
typically 1–5% (488 nm, 25 mW), 50–60% (543 nm, 1 mW) and
3–5% (633 nm, 5 mW) unless otherwise indicated. Settings
were adjusted in a way that image pixels were not over- or
underexposed with the range indicator function in the Zeiss
LSM software version 3.2. To ensure that weak intracellular
fluorescence signals of the peptides were not missed, a set of
overexposed images were collected in addition.
RESULTS AND DISCUSSION
The decisive role of arginine clusters for translocation
over the plasma membrane has been known for
some time. Therefore, several studies were aimed
at determining the optimal number of arginines or
minimal structural requirements that permit efficient
transduction. Surprisingly, most of them analyzed
either fixed cells [23,24,38] and/or used FACS analysis
without a protocol to efficiently remove the cationic
peptides sticking to the extracellular side of the plasma
membrane [39]. To exclude the above artifacts, we
analyzed the transduction frequency of oligo-arginines
and -lysines with chain length from 5 to 12 directly by
CLSM of living cells. In addition, we compared only data
from experiments using the same incubation times for
all peptides and at the same cell density and varied
only the concentrations for each peptide. Figure 1(A)
displays the possible uptake phenotypes of C2C12
mouse myoblasts after addition of the fluorescent
peptide for 1 h. The images on the left side, upper panel,
show cells that endocytosed the L-R9 peptide incubated
at a concentration of 10 µM, where the fluorescence of
the peptide solely resided in cytoplasmic vesicles, and
no free cytoplasmic peptide was detectable by means of
fluorescence microscopy. The images on the right side,
upper panel, depict cells that incorporated L-R6 peptide
added at a concentration of 50 µM with fluorescence
detected throughout the cytoplasm and nucleus, which
we hereafter refer to as transduction. Cells with mixed
phenotypes (Figure 1(A), lower panel) that show in
addition to transduction vesicular uptake were also
scored as transduced cells. Only the uptake mode of
transduction yields peptide available in all intracellular
compartments and, therefore, is able to reach all
potential targets. In order to detect any possible
membrane perturbations or transient pore formation,
the vital dye PI was added to mouse myoblast cultures
simultaneously with the oligo-arginines (see scheme
in Figure 1(A)). The plots in Figure 1(B) summarize
the transduction results for all oligo-arginine peptides.
None of the oligo-arginines tested (R5–R12) was able
to transduce at a concentration of 0.5, 1 or 5 µM in a
total volume of 60 µl. Transduction could be observed at
10 µM for the peptides R8–R12, with frequencies over
50% for the peptides R10–R12. Whereas R5 did not
transduce over the whole concentration range tested
(between 0.5 to 100 µM), R6 appeared intracellularly
only in 4% of the cells at 50 µM and 28% at 100 µM.
R7–R9 transduced between 18 and 42% of the cells at
50 µM and reached frequencies between 75 and 90%
at 100 µM. The peptides R10–R12 transduced already
to a level of 70–90% at 10 µM concentration and the
percentage of transduction increased only slightly at
5- or 10-fold higher concentration. In stark contrast,
either no or very low frequency of cell penetration could
be detected with all the oligo-lysines tested (K5–K12)
at an even wider concentration range (data not shown).
The uptake of PI by the oligo-arginine transduced cells
(Figure 1(B)) indicated severe toxicity only with R8,
R10, R11 and R12 at the highest peptide concentration
tested (100 µM) and for R11 and R12 already at 50 µM.
For the transducing peptides with lower chain length,
the percentage of PI-stained cells in all cases was below
10%. At 10 µM, except for R12 all transducing peptides
caused no membrane damage that could be detected by
simultaneous PI staining. Notably, PI was not observed
inside transduced cells by peptides with a low number
of arginines or at low concentrations. This fact argues
against the formation of transient pores or strong
membrane perturbations. Whereas previous studies
found an optimum number of consecutive arginines
for transduction [24,38], our results support a linear
dependence of the transduction frequencies on the
number of consecutive arginines. Considering also the
PI uptake data, R9 or R10 peptides combine a medium
to high transduction level associated with a tolerable
toxicity. To verify and extend our live-cell analysis, we
selected three oligo-arginine peptides (namely, R5, R7
and R9) and tested their uptake potential into artificial
membranes. The R5 peptide was chosen, as it did
not transduce into cells, whereas the R7 was able
to transduce, albeit at a low level, and R9 was the
most efficient while still retaining low toxicity. The 7-
nitro-2-1,3-benzoxadiazol-4-yl (NBD) labeled peptides
were applied to large unilamellar vesicles (LUVs) and
the percentage of transduced peptide over time was
measured with a spectrofluorometer after quenching
the outer fluorescence with the NBD quencher,
dithionite. The percentage of transduction rose with
the number of consecutive arginines in a manner
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Figure 1 Assessment of dose-dependent transduction frequency of oligo-arginine peptides. (A) Confocal microscopy images
displaying examples of endocytic uptake (upper, left panel, L-R9 at 10 µM) versus transduction (upper, right panel, L-R6 at 50 µM)
of oligo-arginines (L-Rn; n = 5–12) into mouse C2C12 myoblasts. Two mixed forms of transduction + endocytosis are shown below:
transduction and endocytic peptide vesicles (left panel L-R9 at 10 µM) versus transduction and peptide enclosed in endocytic
vesicles (+) as well as excluded from endocytic vesicles (−) (right panel L-R6 at 50 µM). Scale bars 10 µm. The experimental
procedure is shown above. Only cells showing the transduction mode of uptake (including the mixed phenotypes shown in the
lower panels) were counted for the quantification in B. (B) The peptide transduction frequency shown as a fraction of C2C12
cells (in %) was scored as explained in A. Peptide transduction frequencies are shown plotted against peptide concentration (0.5,
1, 5, 10, 50, 100 µM) and corresponding estimated isoelectric point (pI ). The fraction of PI-stained C2C12 cells (in %) within
the transduced cell population is plotted similarly. The lower peptide concentration plots are also shown magnified for better
visualization. Error bars display the standard deviation of two independent experiments. The total number of cells counted was
between 140 and 250 for each experiment.
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analogous to that in the living-cell uptake analyses
(Supplementary Figure S1).
Octa-, nona- and deca-arginines have been shown to
transduce successfully into living cells under noninva-
sive conditions and at lower concentrations [31,32,40],
but different cell types as well as D- and L-isomers were
used in those studies. Therefore, we next assessed the
influence of D- and L-isomeric forms on the transduc-
tion efficiencies in different cell types. For that purpose,
we incubated different cell types of various mammalian
species and also primary cells with 10 µM of the TAMRA-
labeled D-isomer and the Fluos-labeled L-isomer of R9
and determined the percentage of transduced cells after
1 h incubation (Figure 2(A)). In general, the transduc-
tion frequencies for the L-form in all cell types were
lower than that of the D-form, illustrating that pep-
tide stability is an important issue for transduction.
By calculating the index for the percentage of cells
transduced by the L-isomer divided by the percentage
of cells transduced by the D-isomer, we found char-
acteristic values for individual cell types, which most
probably reflect their extracellular proteolytic activity
[41]. Whereas diploid human fibroblasts were very inef-
ficiently transduced, rat cardiomyocytes and mouse
myoblasts showed higher levels of transduction for the
L-form, approaching the level of the D-form. As the D-
isomer of R9 reached transduction efficiencies of over
95% in all cell types, the isomer-specific differences can-
not be due to cell-type-specific membrane composition.
The loss of only one arginine from L-R9 would already
reduce the transduction efficiency to half at a concen-
tration of 10 µM and lead to the disappearance of the
transduction potential with further proteolysis (see plot
in Figure 1(B)). To ensure that the different indices were
not a result of the distinct fluorescent labels attached
to the peptides, the same set of experiments was per-
formed with Fluos-labeled D- and L-isomers of R10
with the same outcome (data not shown). The overview
images of the different cell types after transduction also
revealed that the fluorescence intensity varied between
individual cells. This variation was not correlated to
(A)
(B)
Figure 2 Cell-type-specific differences in transduction frequencies and kinetics of L- and D-isomers of R9. (A) Confocal microscopy
sections of different cell types from various mammalian species 1 h after application of 10 µM of the Fluos-labeled L-isomer (upper
panel, green fluorescence) and the TAMRA-labeled D-isomer (lower panel, red fluorescence) of R9. For each cell type, merge images
of phase contrast and fluorescence and fluorescence images alone are displayed. The index corresponds to the ratio (% transduced
cells by L-isomer/% transduced cells by D-isomer) ± standard deviation. (B) Confocal microscopy time lapse (minutes : seconds)
of the transduction of the L- and D-isomers of R9 simultaneously applied to C2C12 mouse myoblasts at a concentration of
10 µM each. Red and green arrowheads indicate the initial detection of the transduced corresponding peptides in intracellular
compartments. The cells are counterstained with the live-cell DNA dye DRAQ5 (blue). Scale bar 50 µm.
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the size and, therefore, to the total accessible mem-
brane surface of the transduced cells. Next, we tested
whether kinetic differences between the transduction of
D- and L-isomers occurred. For this, we applied 20 µM
of a 1 : 1 mixture onto mouse myoblasts and moni-
tored the uptake in real time by CLSM. Surprisingly,
several cells selectively took up the TAMRA-labeled D-
isomer but not the Fluos-labeled L-form, although some
cells also showed yellow color seen in the overlay of
the two fluorescence images (Figure 2(B) and Movie 1).
Nevertheless, the kinetics of transduction was quite dif-
ferent for both isomers, even though after a certain time
both species had been internalized. This result argues
against the formation of mixed D- and L-isomers into
multimeric assemblies. We can, however, not rule out
the existence of single-species multimers. In addition,
no change in the transduction efficiency of the indi-
vidual D- or the L- chiral forms was observed, which
would be expected from the higher total peptide con-
centration. Finally, these data clearly show the absence
of membrane damage by the penetration of one peptide
species since the other species in the same cell at the
same time was not taken up concomitantly.
In view of the therapeutic potential of peptide vectors
for the delivery of low-molecular-weight compounds
and considering the relatively high transduction rate
and low percentage of PI-stained cells (Figure 1(B)
and 2), we selected the nondegradable D-isomer of
R9 for further detailed analysis of toxicity on mouse
myoblasts. Transduction was observed starting from
a concentration threshold of 5 µM with a transduction
frequency of about 10% (Figure 3(A)). Ten micromolar
D-R9 was transduced into more than 50%, and 25 µM
into 70% of the cells. For concentrations of 50 and
100 µM, transduction was nearly complete. Next, we
examined the viability of mouse myoblasts after 2 h of
incubation with different concentrations with D-R9. The
ability of the cells to exclude the vital dye trypan blue
was used to judge membrane integrity. Furthermore, we
assessed by an MTT assay whether the transduction of
D-R9 influences enzymatic activities inside the cells
detected here by their ability to produce formazan
[42]. Starting from the transduction threshold of 5 µM,
a constant decrease in viability by both assays was
observed, which was mild between 5 and 25 µM peptide
concentration. At a concentration of 50 µM, about 17%
of the cells stained positive for trypan blue, and 15%
of the cells produced formazan to a lesser extent than
the controls. Cell death in 60% of cells resulted from
100 µM of D-R9, and also the formazan levels of those
cells were greatly reduced in comparison to the control
cells. The slope of the trypan blue exclusion curve
is steeper than that of the viability assayed by the
MTT test, indicating that the membranes are the first
location where massive damage occurs. Arginine-rich
clusters can be found in RNA-binding proteins and are
targeted to the nuclear compartment. To test long-term
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Figure 3 Short- and long-term dose-dependent effects
of D-R9 transduction on cell viability and proliferation.
(A) Transduction frequencies of D-R9 in C2C12 mouse
myoblasts determined as in Figure 1. (B) Cell viability deter-
mined by trypan blue exclusion and enzymatic activity MTT
assay after 2 h of incubation with different concentrations
of D-R9. (C) Long-term effects on the cell cycle distribution
assayed by flow cytometry analysis of DNA content stained
with PI. The respective experiments are explained in the
schemes. For (A) and (B) the error bars display the standard
deviation of two independent experiments. The total number
of cells counted was between 140 and 250 for each experi-
ment. In (C), one example of three independent experiments is
depicted.
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effects on DNA replication and cell cycle progression,
mouse myoblasts were incubated for 2 h with the D-R9
peptide, the medium was exchanged and they were kept
in culture until the next day. Cultures were then fixed,
DNA was stained with PI and the cell cycle distribution
was analyzed by flow cytometry. The cell cycle profiles
and the statistics are displayed in Figure 3(C) and show
no concentration-dependent effect of the D-R9 peptide
on the cell cycle. Altogether, the toxicological effects of
the D-R9 peptide in a range of 5–25 µM can be classified
as mild and cell proliferation was also not affected.
CONCLUSIONS
In summary, we evaluated the transduction frequency
of the L-isoforms of oligo-arginines and monitored
their associated toxicity. This risk-benefit analysis of
transduction led us to the selection of R9 for further
analysis. With its nondegradable counterpart D-R9, we
established an assay that allows the quantification
of the proteolytic activity of different cell types, and
emphasize the need for protease-resistant peptides
as vectors for drug delivery. Importantly, the D-
isoform always showed a higher transduction as
compared to the L-counterpart in all cell types. The
transduction difference between D- and L-forms was
highly variable between cell types. Finally, our toxicity
results indicate concentration windows with low toxicity
and high transduction efficiency, not requiring further
treatments to force endocytic vesicle rupture.
Supplementary Material
Supplementary electronic material for this paper is avail-
able in Wiley InterScience at: http://www.interscience.wiley.
com/jpages/1075-2617/suppmat/
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Supplementary Figure 1     Penetration of artificial membranes by oligo-arginines. 
LUVs (Large Unilamellar Vesicles) were prepared from a mixture from 70 mol% of DOPC 
(dioleoylphosphatidylcholine) and 30 mol% of DOPS (dioleoylphosphatidylserine). In total 1 
mol of lipids were mixed in chloroform. A dry lipid film was formed by solvent evaporation 
under a nitrogen stream. The dried lipids were resolubilized in 2 ml of PBS (pH 7.4) by 5 min 
of vortexing. To yield LUVs the lipid suspension was processed by freeze/thaw-cycles (5x) 
and extrusion through a 0.1 m filter (10x). Consecutive arginines (R5, R7, R9) as D-isomers 
were synthesized and coupled directly to the NBD (7-nitro-2-1,3-benzoxadiazol-4-yl)-group 
at the N-terminus by Peptide Specialty Laboratories GmbH (Heidelberg, Germany). For the 
quenching assay 740 l of PBS were mixed with 60 l of LUV suspension and incubated with 
the NBD-labeled peptides at 5 M for different time spans. NBD fluorescence from peptides 
remaining in the exterior of the LUVs was then quenched by adding 25 mM of the non 
membrane permeable sodium dithionite. Fluorescence was detected with a FluoroMax-4-
spectrofluorometer (Horiba Jobin Yvon, Edison, USA). NBD was excited at 460 nm and the 
fluorescence was recorded at 544 nm. For measuring the maximal quenchable fluorescence of 
the peptides present in the exterior and also in the interior of the LUVs, 0.5 % Triton X-100 
was added afterwards to dissolve the vesicles. Counts for total fluorescence and fluorescence 
after quenching were corrected by subtracting this non-quenchable fraction. The 
intravesicular peptide in LUVs was displayed as percentage of total fluorescence after 
dithionate quenching for the different NBD-peptides () R5-NBD, () R7-NBD and () R9-
NBD. At a first glance the percentage of transduction as measured by the non-quenched intra-
LUV peptide fluorescence seemed to be low in comparison to the experiments in living cells. 
However, under our experimental conditions the total volume of LUVs corresponded to about 
0.2 % of the suspension volume assuming a LUV diameter of 100 nm and a surface area of 
lipids of 0.6 nm2. In the light of this estimate the results indicate an enrichment of peptides 
in the lumen of LUVs at least for R9.  
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Arginine-rich peptides are a subclass of cell-penetrating pep-
tides that are taken up by living cells and can be detected freely
diffusing inside the cytoplasm and nucleoplasm. This phenom-
enon has been attributed to either an endocytic mode of uptake
and a subsequent release from vesicles or to direct membrane
penetration (transduction). To distinguish between both possi-
bilities, we have blocked endocytic pathways suggested to be
involved in uptake of cell-penetrating peptides. We have then
monitored by confocal microscopy the uptake and distribution
of the cell-penetrating transactivator of transcription (TAT)
peptide into living mammalian cells over time. To prevent side
effects of chemical inhibitors, we used genetically engineered
cells as well as different temperature. We found that a knock-
down of clathrin-mediated endocytosis and a knock-out of
caveolin-mediated endocytosis did not affect the ability of TAT
to enter cells. In addition, the TAT peptide showed the same
intracellular distribution throughout the cytoplasmandnucleus
as in control cells. Even incubation of cells at 4 °C did not abro-
gate TAT uptake nor change its intracellular distribution. We
therefore conclude that this distribution results from TAT pep-
tide that directly penetrated (transduced) the plasma mem-
brane. The formation of nonselective pores is unlikely, because
simultaneously added fluorophores were not taken up together
with the TAT peptide. In summary, although the frequency and
kinetics of TAT transduction varied between cell types, it was
independent of endocytosis.
Thediscovery that the transactivator of transcription (TAT)2
protein of human immunodeficiency virus type 1 was able to
traverse cellular membranes and subsequently affected gene
transcription (1, 2) led to the emergence of a new research field
on cell-penetrating peptides (CPPs), also known as protein
transduction domains (PTDs) or membrane transduction pep-
tides (3). CPPs opened up the possibility to effectively deliver
cell-impermeable hydrophilic compounds into living cells. The
cargos reported to be shuttled to intracellular compartments
include drugs (4), fluorophores (5), peptides (6–8), nucleic
acids (9), proteins (10–12), nanoparticles (13), and liposomes
(14, 15). The exact mechanism of cellular entry of CPPs
remained unknown, but it was thought to be receptor-, energy-,
and temperature-independent. In 2003 this unique mode of
uptake was refuted as a methodological artifact, and endocyto-
sis was suggested as the main pathway of cellular uptake of
CPPs in live cells (16, 17). Arginine-rich peptides (RRPs) were
not only historically the first (TAT) (1, 2) type of CPPs
described, but they combined high uptake ability with moder-
ate toxicity (18). Some groups observed a nonendocytic inter-
nalization pathway (8, 18–21), whereas others assigned CPP
uptake to endocytic pathways, as CPPs were internalized and
stored inside the vesicles. Endocytosis is broadly subdivided
into phagocytosis and pinocytosis. Whereas phagocytosis is
restricted to specialized cells like macrophages and leukocytes,
pinocytosis occurs in all eukaryotic (or mammalian) cell types
through at least four different endocytic pathways (22). Three
of them have been implicated as routes for internalization
depending on the CPP sequence and cargo of the CPPs as fol-
lows: clathrin-mediated endocytosis (23), caveolae-mediated
endocytosis (24, 25), macropinocytosis (26–28), as well as the
involvement of more than one endocytic pathway (16, 19).
However, most of the studies so far utilized chemical inhibitors
to characterize the contribution of a distinct endocytic pathway
and could not exclude inhibitor-associated side effects.
RRPs such as TAT linked to high molecular weight cargos
(e.g. proteins) were taken up into cells solely by endocytosis.
When conjugated to lowmolecularweight cargos (e.g.peptides)
however, in addition to be present in vesicles, they could be
found freely diffusing in the cytoplasm and the nuclear com-
partment (8). However, a consensus regarding the latter uptake
mode has not been reached. Our translocation studies of oli-
goarginines and oligolysines of various chain lengths and con-
centrations into living cells demonstrated the coexistence of
two uptake modes (8, 18). Whereas a subset of the intracellular
peptidewas found inside cytoplasmic vesicles (Fig. 1A), some of
the peptide displayed a rather homogeneous distribution
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throughout the cytoplasm and high accumulation inside the
nucleolar compartment (Fig. 1, B and C). The latter is hence-
forth termed transduction. It is still unclear whether transduc-
tion reflects CPPs that enter living cells by a not yet defined
mechanism and/or CPPs that are released from endo- or lyso-
somes after endocytosis. To understand if both intracellular
phenotypes are two distinct intermediate stages of the same
process or indicate different uptake routes, we monitored the
cytoplasmic and nucleolar localization of RRPs upon inhibition
of endocytosis. In addition to TAT, we used the peptide PTD4,
which is an artificial, more amphipathic CPP with a reduced
number of arginines and increased -helical content compared
with TAT (29). Most importantly, to suppress endocytic path-
ways, we restricted ourselves to the usage of genetically induc-
ible systems, knock-out (KO) cell cultures, or physicalmethods,
thus avoiding any potential side effects of chemical inhibitors of
endocytosis.
EXPERIMENTAL PROCEDURES
Cells andCultureConditions—The following cells were used:
BHK21 (C-13) fibroblasts (baby hamster kidney clone 13,
American Type Culture Collection), BHK21-tTA/anti-clathrin
heavy chain (CHC) cell line (30), cav-1-KO and cav-1-wtmouse
endothelioma cell lines (31), C2C12mouse myoblasts (32), and
3T3 mouse fibroblasts (Invitrogen). The cells were cultured in
Dulbecco’s modified Eagle’s medium (high glucose, with
sodium pyruvate and L-glutamine) (PAA, Pasching, Austria)
supplemented with 10 or 20% (the latter for C2C12 cells only)
fetal calf serum (PAA, Pasching, Austria), 2 mM L-glutamine
(Invitrogen), 50 g/ml gentamicin (PAA, Pasching, Austria).
For the cav-1-KO and cav-1 wild type (WT) endothelioma cell
lines, the growthmedia was additionally supplementedwith 1%
nonessential amino acids (Sigma), 1% sodium pyruvate
(Invitrogen), and 2 mM 2-mercaptoethanol diluted in phos-
phate-buffered saline (Invitrogen). For the BHK21-tTA/anti-
CHC cell line, the following additives were added: 10% tetracy-
cline-negative fetal calf serum (PAA, Pasching, Austria), 0.2
mg/ml geneticin (G418, Invitrogen), 0.5 g/ml puromycin
(Sigma), 2 g/ml tetracycline (Sigma). For the induction of
CHC antisense RNA expression, tetracycline was removed
from the medium.
Peptides, Proteins, and Fluorophores—Peptides 5,6-car-
boxytetramethylrhodamine (TAMRA)-TAT (GRKKRRQRRR)
and TAMRA-PTD4 (YARAARQARA) (29) were synthesized as
D-isomers and coupled directly to TAMRA at the N terminus
(Peptide Specialty Laboratories GmbH, Heidelberg, Germany).
Peptides and labelswere diluted inRPMI 1640mediumwithout
phenol red (PAA, Pasching, Austria) and applied at 10 M final
concentration to the cells. At lower concentrations, as we have
shown previously (8), only the endocytic mode of uptake was
detected (supplemental Fig. S1). To monitor CHC expression
and function, transferrin (Tf) conjugated to Alexa Fluor 633
(Invitrogen) was added as a marker for clathrin-dependent
endocytosis. Nonreactive forms of the fluorophores FITC (flu-
orescein isothiocyanate) and TAMRA were generated by incu-
bation with Tris buffer (indicated by an asterisk) and used as a
small molecule to monitor the generation of pores during the
transduction event. To control for the complete inhibition of
endocytosis at 4 °C, the globular protein TAT-biotin-streptavi-
din (TAT-bt-SAv) labeled with the fluorophore cyanine dye
was used as an additional marker for fluid-phase uptake (sup-
plemental Fig. S2).
Live Cell Uptake Experiments—For all experiments either
8-well -slides or 35-mm -dishes (Ibidi, Martinsried, Ger-
many) were used. The cells were seeded onto the observation
chambers and incubated overnight at 37 °C with 5% CO2. The
peptides TAMRA-TAT and TAMRA-PTD4 (10 M), the flu-
orophores FITC* and TAMRA* (10 M), and Tf (10 g/ml)
were diluted in RPMI 1640 medium (PAA, Pasching, Austria)
without phenol red and used at the indicated concentrations.
Special care was taken to ensure that the volume of the peptide
solution above the cells was comparable in the two different
observation chambers and that the exchange against the appro-
priate peptide (label, marker) dilutions was performed very
gently. Immediately after addition of the peptide (label,marker)
to the cells, time lapses over 60 min (with time intervals of one
image per min) were recorded. The experimental settings for
the confocal microscope were identical for all experiments.
For the uptake experiments at 4 °C a custom-built cooling
chamber was used. The height of this cooling chamber occupy-
ing the cooling flow and the radius of the loophole at the bottom
were optimized to guarantee a constant temperature exchange
between the 35-mm -dish observation chamber and the cool
water flux. The temperature was regulated by a thermostat, and
the exact temperature of 4 °C inside themedium above the cells
was verified by measurements with a thermometer before and
after the 1-h time lapses.
Microscopy, Image Acquisition, and Analysis—Confocal
optical sections were acquired with a Zeiss confocal laser scan-
ning microscope, LSM510 Meta, mounted on an Axiovert 200
M inverted microscope equipped with a live cell microscope
incubation cage (Okolab, Ottaviano, Italy) using a 63 plan-
apochromat NA1.4 oil immersion, phase-contrast objective.
FIGURE 1. Schematic illustration (upper panel), corresponding represent-
ative cell images, and relative proportions of the observed intracellular
distributions of TAT CPP in different cell types after 1 h of incubation.
A, TAT peptide is present in the medium and in endocytic vesicles, but not
freely available inside the cytoplasmor thenuclear compartment. B, TATpep-
tide reached all intracellular compartments and accumulated, in addition, in
vesicles. C, TAT peptide is homogeneously distributed throughout the cyto-
plasm and accumulated in the nucleolus. Scale bar, 10 m.
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The microscope incubation cage maintained a humidified
atmosphere of 5% CO2 and 37 °C, which was used throughout
except for the low temperature experiments. For all settings the
main beam splitter was HFT UV/488/543/633, and the specific
parameters for the single fluorophores were as follows: FITC
excited at 488 nm, detectedwith a 500–530-nmbandpass filter;
TAMRA-TAT and TAMRA-fluorophore excited at 543 nm,
detected with a 565–615-nm bandpass filter, transferrin-Alexa
Fluor 633 excited with 633 nm, detected with a 650-nm long
pass filter. Phase contrast images were recordedwith excitation
at 488 nm and detection in the transmission channel. The laser
power for observation was 1% (488 nm, 25 milliwatts), 7% (543
nm, 1 milliwatt), and 25% (633 nm, 5 milliwatts). Settings were
adjusted in a way that image pixels were not over- or underex-
posed with the range indicator function in the Zeiss laser scan-
ning microscopy software version 3.2. To ensure that weak
intracellular fluorescence signals of the peptides were not
missed, a set of overexposed images was additionally collected.
For the quantification of transduction, 100–150 cells per
transduction experiment were evaluated to obtain the percent-
age of transduced cells (indicated by nucleolar appearance of
the labeled peptide), and the kinetics of TAT transduction was
further characterized by the earliest time point when transduc-
tion could be detected within a field of view (initiation time of
transduction).
Western Blotting—ForWestern blot analysis of the cav-1-KO
andWT cells, half a million cells were counted, resuspended in
100 l of phosphate-buffered saline, and boiled in Laemmli
sample buffer for 10 min, and cell lysates were analyzed by
SDS-PAGE followed by blotting onto polyvinylidene difluoride
membranes. Signals were detected with the following primary
antibodies: rabbit anti-Cav-1 polyclonal antibody (LifeSpan
BioSciences, Inc., Seattle,WA) andmouse anti-Cav-2 and anti-
Cav-3 monoclonal antibodies (1:2000 dilution, BD Transduc-
tion Laboratories). Anti-rabbit IgG-HRP (Sigma) and anti-
mouse IgG-HRP (enhanced chemiluminescence, Amersham
Biosciences) were used as secondary antibodies. Immunoreac-
tive signalswere visualized using enhanced chemiluminescence
plus detection solution (Amersham Biosciences) and recorded
using a luminescence imager (Luminescent Image Analyzer
LAS-1000, FUJI Photo Film, Tokyo, Japan).
RESULTS
Because of their particularly high transduction ability, which
solely depends on a minimal number of arginines, RRPs play a
special role among CPPs (18, 33–35). To clarify the role of
endocytosis in the uptake mode of CPPs with low molecular
weight (LMW) cargos into living cells, we investigated the
occurrence and extent of transduction of TAT and PTD4 as
CPPs with high and low transduction frequency, respectively
(8). The intracellular distribution of peptides in living cells was
analyzed by laser scanning confocalmicroscopy. To unravel the
relevance of endocytic routes for the uptake and intracellular
distribution of peptides, endocytic pathways were specifically
inhibited by genetic approaches orwere blocked in ensemble by
incubation of cells at low temperature.
Role of Clathrin-mediated Endocytosis in CPP Uptake—
Clathrin-dependent endocytosis represents a major endocytic
pathway. For example, transferrin is taken up exclusively by this
route, and several enveloped viruses (36), such as equine arte-
ritis virus (37), exploit this route (38). As an early step of this
route, upon binding of an extracellular ligand to specific cell-
surface receptors, clathrin together with other adapter proteins
builds an endocytic coat at the plasmamembrane (Fig. 2A). The
coated membrane buds and pinches off to form a cargo-filled
vesicle (Fig. 2A).
Clathrin-dependent endocytic uptake of TAT has been
repeatedly reported as a possible mechanism for CPP entry (23,
39, 40). To clarify the contribution of clathrin-dependent endo-
cytosis in the uptake mode of arginine-rich CPPs, we used the
BHK21-tTA/anti-CHC (30) cell line. This cell line expresses
antisense CHC RNA under the control of a tetracycline-re-
sponsive element (Fig. 2B). More specifically, the transcription
activator (tTA) is composed of the DNA binding domain of
tetracycline repressor protein and a C-terminal activation
domain of VP16 (herpes simplex virus protein) that functions
as a strong transcription activator (41). The presence of tetra-
cycline prevents binding of the transactivator tTA to the oper-
ator sequence and thus transcription of antisense RNA. In
the absence of tetracycline the transactivator tTA binds to its
operator sequence and activates the transcription of antisense
RNA.As a consequence, the synthesis and functionality ofCHC
protein is significantly reduced, thereby suppressing clathrin-
dependent endocytosis (30). The absence of tetracycline for 2
days was reported to inhibit 90% of transferrin internalization,
and the expression of theCHCproteinwas reduced to 10%over
6 days in the absence of tetracycline (30). Therefore, to explore
to what extent transduction of TAT depends on clathrin-de-
pendent endocytosis, uptake of TAMRA-tagged TAT and
PTD4 was investigated in the presence (tet) and absence
(tet) of tetracycline over 6 days. To simultaneously control
the level of clathrin-dependent endocytosis, internalization of
Alexa Fluor 633-labeled transferrin was monitored (Fig. 2C).
The control cells (tet cells) are shown on the left panel of
Fig. 2C and supplemental Fig. S3. TAT was homogeneously
distributed throughout the cytoplasm and accumulated in the
nucleolus (Fig. 2C, arrowheads) and therefore displayed the
uptake mode of transduction. In addition, the labeled peptide
was also present in cytoplasmic vesicles.
PTD4 applied at the same concentration and monitored at
identical confocal microscope settings did not show any trans-
duction-associated cytoplasmic localization comparable with
TAT. However, we observed the presence of PTD4-containing
vesicles (Fig. 2C, left side, lower panel). Fluorescent transferrin
was internalized at high rates and enriched in the trans-Golgi
network (42).
Inhibition of the clathrin-dependent endocytic pathway in
tet cells (Fig. 2C and supplemental Fig. S3A, right panel) was
verified by the suppression of uptake of transferrin. TAT dis-
played the same intracellular distribution regarding the vesicu-
lar uptake as well as transduction, indicated by similar intensi-
ties inside the nucleolar compartment compared with the
control (tet) cells (Fig. 2C and supplemental Fig. S3). Similar
to the control cells, no diffuse intracellular occurrence was
observed for PTD4, but in contrast to tet cells the vesicular
internalization of PTD4 was almost completely abolished.
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FIGURE 2. Transduction of TAT is independent of clathrin-mediated endocytosis. A, schematic diagram illustrating clathrin-dependent endocytosis. The
clathrin coat is required for membrane invagination, and for the scission of clathrin-coated vesicles dynamin is needed. B, schematic representation of the
Tet-Off system, allowing a conditional knockdown of CHC in the BHK21-tTA/anti-CHC cell line. The binding of the transcriptional activator tTA to an operator
sequence in the absence of tetracycline (tet) results in activation of transcription of CHC-antisense RNA and thereby repression of the CHCmRNA translation.
C, confocal optical sectionsof living cells during incubationwith the fluorescentCPPs TAT (upper panel) or PTD4 (bottompanel) in thepresenceof the transferrin
(Tf) as a marker for clathrin-dependent endocytosis. Each panel displays high magnification images of the phase contrast (PC) and the fluorescently labeled
compound to show the details of their intracellular distribution and lowmagnification images to highlight the frequency of CPP transduction and Tf internal-
ization (see also supplemental Fig. S3). Arrowheadsmark the position of nucleoli. Transduction experiments were performed in the presence (left panel) and
absence (right panel) of tetracycline. Although uptake of Tf is nearly abolished after tetracycline removal over a period of 6 days, the TAT CPP is still capable of
reaching all intracellular compartments (diffuse, nonvesicular fluorescence, and accumulation inside nucleoli), indicating that this mode of uptake is not
influenced by clathrin-dependent endocytosis. Vesicular uptake of the CPP TATwas still detected undertet conditions albeit at reduced levels. Scale bar, 10
m for high and 20 m for lowmagnification images.
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We confirmed that TAT transduction was observed in most
cells by acquiring low magnification images (Fig. 2C and sup-
plemental Fig. S3). To control for any potential side effects of
tetracycline, the parental BHK21 cells (43, 44) were incubated
with the CPPs and transferrin in the presence and absence of
tetracycline. However, no difference of peptide transduction
and vesicle formation was observed (data not shown). There-
fore, we conclude that clathrin-dependent endocytosis is not
required for transduction of the RRP TAT fused to an LMW
cargo.
Role of Caveolin-mediated Endocytosis in CPP Uptake—Be-
sides the classical clathrin-mediated endocytic pathway, caveo-
lae-mediated endocytosis is one of the main endocytic entry
routes into living cells (22, 45). For example, it is exploited by
bacterial toxins and by simian virus 40 (36). Caveolae are flask-
shaped, small (50–70 nmdiameter) invaginations in the plasma
membrane (Fig. 3A) that constitute membrane domains
enriched in cholesterol and sphingolipids, called lipid rafts (46).
Caveolae are characterized by the presence of the integral
membrane protein caveolin-1 and are involved in the intracel-
lular transport of lipid raft-associated molecules (47). This
pathway has been repeatedly reported as an uptake route for
CPPs into the cells (24, 25). Former studies used fluorescently
labeled -subunit of cholera toxin as a marker to monitor
caveolar uptake. However, the pathway chosen by cholera toxin
subunit  depends on the cell type (48) and hence may not be a
faithful indicator for a single internalization pathway. To spe-
cifically inhibit only the caveolin-dependent route and to pre-
vent the potential side effects caused by chemical inhibitors of
endocytosis, we made use of an endothelial heart cell line gen-
erated from a knock-out (KO) mouse deficient for caveolin
(cav-1) and the respective wild type (WT) cell line. As reported
previously (31), in the absence of caveolin-1, caveolin-2 protein
is degraded. This was corroborated by Western blot analysis
(Fig. 3B). In contrast to WT cells, no cav-1 and cav-2 were
detected in the KO cells, and in addition, antibodies directed
against muscle cell-specific cav-3 gave a much weaker signal in
the extract of KO cells compared with those from wild type
cells.
To elucidate if caveolae-dependent endocytosis plays a role
in the uptakemode of TATwith the LMWTAMRA,we applied
TAT (Fig. 3C, upper panel, and supplemental Fig. S4) and PTD4
(Fig. 3C, middle panel) to the medium of wild type cells and
cav-1-KO cells. To control whether the tagged fluorophore
supports peptide internalization, the uptake of TAMRA* alone
at the same concentration as the peptides was studied (Fig. 3C,
bottom panel). For each experiment confocal optical sections
are displayed at high and low magnification. Because of the
large size of these cells, it was not possible to show a higher
number of cells per field and at the same time keep imaging
parameters constant throughout all experiments. No difference
of TAT transduction between WT and cav-1-KO cells was
found. TAT also became internalized by an endocytic route, as
indicated by the punctated intracellular fluorescence. This sig-
nalwas still present in the caveolin-deficient cells. In contrast to
TAT, the PTD4 peptide entered the cells only by the endocytic
mode and could not be detected freely inside the cyto- and
nucleoplasm and the nucleolus (Fig. 3C, middle panel, arrow-
FIGURE 3. Transduction of TAT is independent of caveolin-mediated
endocytosis. A, schematic diagram illustrating structural features of flask-
shaped caveolae, which are lined by caveolin. Caveolae-mediated endocyto-
sis is driven by a coat made of the integral membrane proteins caveolin-1, -2,
or -3. Dynamin is required for the scissionof caveolae. B,Westernblot analysis
of the integral membrane proteins caveolin (cav) -1, -2, and -3 in WT and
caveolin 1 KO endothelioma cells. -Tubulin is used to control for loading.
C, confocal optical sections of living cells during incubation with the fluores-
cent CPPs TAT (upper panel) or PTD4 (mid panel) and the fluorophore TAMRA*
(bottompanel). Each panel displays images of the phase contrast (PC) and the
peptide or fluorophore fluorescence at high magnification to display their
intracellular distribution and at lowmagnification to highlight the frequency
of CPP transduction inWT and cav-1-KO cells (see also supplemental Fig. S4).
Whereas the amphipathic control peptide PTD4 and the fluorophore TAMRA*
were not transduced, the CPP TAT was homogeneously distributed in the
cytoplasm, and it reached the nucleuswhere it accumulated inside the nucle-
olar compartment (marked by arrowheads). Both CPPs displayed vesicular
uptake inWT and cav-1-KO cells. Scale bar, 10m for high and 20m for low
magnification images.
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heads). TAMRA was excluded from the cytoplasm and intra-
cellular compartments providing strong evidence that peptide
uptake is not aided by the fluorophore. Based on these results,
we conclude that caveolae-mediated endocytosis is not
involved in the uptake mode of transduction of TAT conju-
gated to an LMW cargo.
Uptake of CPPs upon Shutting Off Endocytic Pathways—Be-
cause neither clathrin- nor caveolin-dependent endocytosis
inhibits CPP uptake and in both cases we could still find TAT-
containing vesicles concomitantly with freely available cyto-
plasmic TAT peptide, we tried next
to inhibit all endocytic pathways
simultaneously.
For this purpose, we followed the
internalization of TAT and PTD4 at
low temperature, 4 °C. Fig. 4A
depicts all potential endocytic
uptake routes in cells that are
expected to be inhibited under
such conditions. Previous reports
addressing the uptake of arginine-
rich CPPs with LMW cargos into
living cells are inconsistent. Al-
though some reports insisted on the
inability of CPPs to penetrate cells
at low temperature and hence endo-
cytosis would be required for inter-
nalization (49), according to other
reports, CPP uptake is not inhibited
at 4 °C (14, 19, 20). Fig. 4B displays
the experimental setup for assessing
the transduction ability of TAT and
PTD4 in C2C12 mouse myoblasts
(data not shown) and in BHK21
hamster fibroblasts in the presence
(37 °C) and absence (4 °C) of endo-
cytosis by time-lapse confocal
microscopy. To make sure that
potential membrane lesions gener-
ated by low temperature conditions
would not corrupt the transduction
assay, the fluorophore FITC* was
applied simultaneously with the
TAMRA-labeled peptides to the
cells. In case of severe membrane
damage or pore formation induced
by the peptides, the 389-Da-sized
FITC* molecule should also be
detectable intracellularly. Our
observations displayed as high and
low magnification images in Fig. 4C
and supplemental Fig. S5 reveal that
even at 4 °CTAT entered living cells
and distributed over the cytoplasm
and nucleus, where it accumulated
inside nucleoli. At the same time the
fluorophore FITC* did not gain
access to intracellular compart-
ments indicating that the plasma membrane was not compro-
mised. The complete obstruction of endocytosis was further
confirmed by the absence of fluorescently labeled vesicles at
4 °C.Vesicleswere not observed for theCPPTATnor for PTD4.
Furthermore, uptake of the globular TAT fusion protein TAT-
bt-SAv that is restricted to endocytosis (8) was also blocked on
the level of the plasma membrane at 4 °C (supplemental Fig.
S2). These results prove unambiguously that arginine-rich
CPPs like TAT are capable of reaching intracellular compart-
ments of living cells by a mechanism that is independent of
FIGURE 4. Transduction of TAT is independent of endocytosis. A, schematic overview of the different path-
ways of endocytic internalization that are suppressed at 4 °C: clathrin- and caveolin-dependent endocytosis,
clathrin- and caveolin-independent endocytosis, andmacropinocytosis. B, experimental strategy for transduc-
tionexperimentsperformedat37and4 °C.C, confocal optical sectionsof livingcells during incubationwith the
fluorescent CPPs TAT (upper panel) or PTD4 (lower panel) in the presence of the fluorophore FITC* as a small
moleculemarker to control formembrane pores or damage. Each panel displays highmagnification images of
the phase contrast (PC) and the fluorescently labeled peptide or fluorophore to show their uptake and intra-
cellular distribution and low magnification images to highlight the frequency of transduction at 37 and 4 °C
(see also supplemental Fig. S5). Arrowheadsmark the position of nucleoli. The transduction experiments were
performed in BHK21 cells kept at 37 and 4 °C. Although no intracellular vesicles were found at 4 °C, the trans-
duction of TAT (nonvesicular, diffuse fluorescence with accumulation inside nucleoli) remained unchanged
both at 37 and 4 °C. In contrast, the amphipathic control peptide PTD4 and fluorophore FITC* were not trans-
duced at 37 °C nor at 4 °C. Scale bars are 10 m for high and 20 m for lowmagnification images.
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endocytosis. However, the data also clearly show that aminimal
number of arginines is crucial to permit transduction.
Frequency and Initiation Time of TAT Transduction—To
quantify our results on the transduction ability in the absence of
a distinct pathway or all pathways of endocytosis, we evaluated
the percentages of transduced cells after 60 min of incubation
with theCPPTATand the initiation
time of transduction (Fig. 5 and
supplemental movies S1–S10). The
control cells (tet, day 0) showed a
transduction frequency of 83%.
While over the first 3 days after
induction of the conditional knock-
down of CHC (tet) the transduc-
tion percentages were reduced to
68%, they recovered back to 84%
transduction frequencies by day 6,
although the internalization of
fluorescently labeled transferrin
was reduced by 90%. The fre-
quency of transduced cells was
identical in cav-1-deficient and
isogenic WT cells (54%), although
in these cells it was lower than in
the BHK21-tTA/anti-CHC cells.
Finally, the inhibition of all poten-
tial pinocytic pathways at 4 °C
determined in BHK21 fibroblasts
revealed that the transduction of
the TAT peptide is diminished
about 12% in comparison with
transduction occurring in cells
kept at 37 °C, but still 63% of the
cells displayed nucleolar accumu-
lation of TAT.
In BHK21-tTA/anti-CHC cells,
the transduction mode of uptake
initiated between 15 and 30 min of
peptide addition after CHC knock-
down as well as in control cells. The
kinetics of peptide uptake in cav-
1-KO and wild type cells displayed
an uptake initiation at 45 min after
application of TAT. The fastest
uptake of TAT occurred in BHK21
fibroblasts within 1 min of addition
to the medium and independent of
temperature. A summary of the
uptake kinetics ofTATpeptide in all
conditions tested is presented in
Fig. 5.
In conclusion, the frequency and
initiation time of TAT transduction
was unchanged within a given cell
type independent of endocytosis.
However, both parameters were cell
type-specific, suggesting that the
membrane composition influences
the velocity of transduction.
DISCUSSION
Despite the controversy and uncertainty regarding the
uptake mechanism, the property of CPPs to deliver nonperme-
ablemolecules into living cellsmakes them attractive vectors to
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FIGURE 5. Kinetic and quantitative analysis of transduction. Assembly of confocal optical sections of living
cells with time intervals of 15 min derived from the 60-min time lapses (see supplemental movies S1–S10)
displaying the kinetics of TATuptake in the different cell lines. All cell lines showed anunchanged transduction
behavior in the control cells and the cells that were inhibited for a distinct or all pinocytic events. But the
average entry time point of the TAT peptide is cell type-specific. The last column summarizes the transduction
frequencies of TAT after 60 min of incubation in cells, where distinct or all endocytic pathways were sup-
pressed. Transduction frequency was scored by counting the percentage of cells showing the intracellular
freely available peptide (see Fig. 1, B and C). Scale bar, 10 m.
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be used in biological sciences as well as in medicine and bio-
technology. Former studies used chemical inhibitors of endo-
cytosis to assign the uptake of CPPs to a particular endocytic
pathway. However, the potential side effects and lack of speci-
ficity of such inhibitorsmake these studies difficult to interpret.
Either the chemical compounds affect more than one specific
pathway, like methyl--cyclodextrin that affects both lipid raft
(26) and caveolin-coated vesicle formation (50) hence also
caveolin-dependent endocytosis, or they have other side effects
that may impact the import of RRPs, e.g. chlorpromazine was
shown to interface with a number of Ca2-dependent signaling
pathways (51) and to bind to dopamine receptors (19, 52). Thus,
we have used genetically modified systems or physical methods
to clarify the role of endocytosis in the translocation of RRPs.
The different phenotypes shown in Fig. 1 permit at least two
explanations for the occurrence of free RRPs inside the cyto-
plasm and nucleoplasm. Either RRPs become endocytosed and
a portion of the peptide stored in vesicles gets released into the
cytoplasm or a second nonendocytic entry route that allows
RRPs to directly cross the plasma membrane has to be
considered.
Earlier reports associated uptake of RRPs with and without
attached cargos to distinct endocytic pathways (16, 23–28, 39,
40, 49). However, our results unambiguously demonstrate that
the transduction of TAT into living cells is not dependent on
any endocytic or pinocytic events. We could exclude the path-
way of clathrin-mediated endocytosis by a carefully controlled
knockdown experiment. Also caveolin-mediated endocytosis
was not involved in TAT translocation, because caveolin
knock-out cells showed an identical transduction frequency to
the wild type cells. Most importantly, TAT was not excluded
from cells that were gently transferred to 4 °C, a state where all
potential endocytic pathways are inhibited.
It is noteworthy to mention that the amount of TAT trans-
duced into a cell varies between cells within a single experi-
ment, but its intracellular distribution does not. This phenom-
enon was observed in every cell type and was independent of
which endocytic route was down-regulated. (Fig. 2–5 and sup-
plemental Fig. S3–S5).
Comparing the transduction frequencies of the specific cell
types, a variation from68 to 84% for the BHK21-tTA/anti-CHC
cell line, over 63–75% in BHK21 cells, and to 54% in the mouse
endothelioma cells can be found, suggesting that the particular
membrane composition of different cell types impacted on
transduction (Fig. 5). This was further corroborated by the
observation that the average initiation time of transductionwas
cell type-specific, but it did not change upon the inhibition of
endocytosis within a given cell type. All experiments were con-
ducted in addition to PTD4 as a representative CPP (29) with a
reduced number of arginines compared with TAT. At the same
concentration, this peptide did not gain access to the intracel-
lular compartments in a freely diffusing form and was internal-
ized exclusively by endocytosis. This could be explained by the
fact that aminimal number of six arginines is required to permit
transduction (18). Instead, PTD4 was predominantly internal-
ized by the clathrin-dependent pathway. Although not capable
of performing transduction, the CPP PTD4 was endocytosed
more efficiently than non-CPP compounds added to the
medium, e.g. the fluorophore TAMRA* alone (Fig. 3C).
Recentmechanistic studieswith artificialmembrane systems
described the formation of pores as a consequence of the inter-
action with intermediate concentrations of the RRP TAT (53).
However, the fluorophore FITC*, concomitantly applied to the
cells together with the TAT peptide, remained outside of the
cells, whereas TAT transduced selectively into the cells (Fig.
4C), arguing against the formation of nonselective pores.
In summary, our data indicate that TAT CPP internalization
is independent of endocytosis and occurs without disruption of
the cell membrane. These properties and its high intracellular
bioavailability make TAT CPP a very effective tool to deliver
small compounds into living cells.
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SUPPLEMENTARY FIGURES 
 
 
 
 
Fig. S1. Concentration-dependent mode of uptake of TAT CPP. TAT was incubated with the cells 
indicated at 1 and 10 µM concentration for one hour. Confocal optical sections of living cells are 
displayed with phase contrast (PC) and fluorescence images to show the uptake mode and intracellular 
distribution of TAT. Each panel contains high and low magnification images. Below a certain 
threshold concentration, transduction of TAT CPP, (visualized by the presence of peptide freely 
available in the cytoplasm and accumulation in the nucleolus (arrowheads) as shown in Fig. 1-5) does 
not occur whereas endocytosis of the TAT CPP persists as shown here. Scale bar 10µm for high and 
20 µm for low magnification images. 
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Fig. S2. Low temperature incubation abrogates all endocytic pathways. Mouse fibroblasts were 
incubated at 37°C and 4° C with the globular protein TAT-biotin-streptavidin-Cy5 (TAT-bt-SAv) as 
an additional fluid phase marker to the peptide PTD4 and the fluorophore FITC* shown in Fig. 4. 
Confocal optical sections of living cells are shown as high and low magnifications after one hour 
incubation with the globular TAT-fusion protein. Arrowheads mark the nucleoli. Protein uptake was 
blocked at the level of the plasma membrane at a temperature of 4°C, whereas at 37°C the protein 
became rapidly internalized into vesicles. Scale bar 10µm for high and 20 µm for low magnification 
images. 
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Fig. S3. Transduction of TAT is independent of clathrin-mediated endocytosis. Additional examples to 
the ones depicted in Fig. 2 are shown as high magnification images (A) and images magnified from the 
online supplementary movies S1 and S7 (B) after incubation with the TAT peptide for 60 minutes. 
Confocal optical sections of living cells during incubation with the fluorescent CPP TAT in the 
presence of transferrin (Tf) as a marker for clathrin-dependent endocytosis (only A). The control cells 
(left panel) and the cells after knockdown of the clathrin heavy chain (right panel) are shown as 
images of the phase contrast (PC) and the peptide (A) or of the peptide alone (B). Arrowheads mark 
the position of nucleoli (A). While uptake of Tf is nearly abolished after tetracycline removal over a 
period of six days (A) and vesicular uptake of TAT is reduced, the TAT CPP is still capable of 
reaching all intracellular compartments (non-vesicular, cytoplasmic and nucleolar fluorescence), 
indicating that this mode of uptake is not influenced by clathrin-dependent endocytosis. Scale bar 10 
µm. 
 21
 
 
Fig. S4. Transduction of TAT is independent of caveolin-mediated endocytosis. Additional examples 
to the ones depicted in Fig. 3 are shown as high magnification images (A) and images magnified from 
the online supplementary movies S8 and S9 (B) after incubation with the TAT peptide for 60 minutes. 
Confocal optical sections of the wild type (left panel, wt) and caveolin-1 knockout (right panel, cav-1-
KO) cells during incubation with the fluorescent CPP TAT. A-panels display images of the phase 
contrast (PC) and the peptide, B-panels only the peptide fluorescence images. Neither vesicular uptake 
of the CPP TAT nor the amount of TAT that was homogeneously distributed in the cytoplasm and 
accumulated inside the nucleolar compartment (marked by arrowheads), was different in both cases. 
Scale bar 10 µm.  
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Fig. S5. Transduction of TAT is independent of endocytosis. Additional examples to the ones depicted 
in Fig. 4 are shown as high magnification images (A) and images magnified from the online 
supplementary movie S10 (B) after incubation with the TAT peptide for 60 minutes at 37°C (left 
panel) and at 4°C (right panel). In A each panel displays the phase contrast (PC) and the fluorescently 
labelled peptide. Arrowheads mark the position of nucleoli as unambiguous sign of freely diffusing 
intracellular TAT. In B the fluorescence of the labelled TAT-peptide is displayed. The transduction 
experiments were performed in BHK21 cells kept at the indicated temperatures before and during the 
experiment. Whereas there was no vesicle formation at 4°C (A) the transduction of TAT remained 
unchanged both at 37°C and 4°C (A and B). Scale bar 10 µm. 
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Little is known about the mechanism enabling hydrophilic cell penetrating 
peptides to traverse biological membranes in a non-endocytic mode 
termed transduction. Here we demonstrate that transduction not only 
requires arginines but its efficiency depends on their clustering. 
Consequently, a cyclic TAT showed enhanced kinetics of uptake relative to 
its linear counterpart. We propose that the rigid geometry of arginine side 
chains in the cyclic TAT increases membrane contacts thus enhancing cell 
penetration. 
 
Beginning with the observation in 1988 that the protein HIV-1 TAT crossed 
membranes of living cells and altered gene expression1,2, a variety of so called 
protein transduction domains (PTDs) or cell penetrating peptides (CPPs) have 
been identified and utilized to introduce attached cargoes into living cells, organs 
or animals. For CPPs containing a low number of arginines3 or carrying large 
globular cargoes4, the mode of cellular uptake is restricted to endocytosis. The 
well studied CPPs TAT and artificial oligoarginines belong to the class of 
arginine-rich CPPs (RRPs) and have, in addition, the option to reach the 
intracellular space in an immediately bioavailable4 and non-toxic5 manner, 
hereafter referred to as transduction. RRPs facilitate the delivery of low molecular 
weight cargoes via this mechanism, e.g. peptides up to 30 amino acids, and thus 
are appealing tools to modulate protein function in living cells. Nonetheless, it 
has remained poorly understood which characteristics of RRPs permit their 
transduction over the plasma membrane in view of their hydrophilicity. 
In this study, we applied laser scanning confocal microscopy of cellular uptake of 
fluorescently labeled peptides and analytical ultracentrifugation to delineate 
sequence and structural requirements for transduction. First, the transduction 
abilities and frequencies of several CPPs (Table S1), as well as the RRP TAT 
fused to different peptide cargoes and the respective cargoes alone were studied 
in a live-cell transduction assay. From the class of CPPs three RRPs, namely the 
well studied CPP TAT 6,7, ten consecutive arginines R10 8,9 and a cyclic variant of 
the native TAT sequence cTAT, were selected. PTD4 was chosen in addition as 
a CPP with an assumed higher alpha-helical content10. In stark contrast to PTD4 
 
 
 2 
with 0.5 % transduction frequency all RRPs transduced with efficiencies over 96 
% (Fig. 1A, i). To further define which isoelectric properties allow for the 
transduction of peptides, we tested next a peptide without positive charges NBD 
(Nemo-binding domain)11 (iv), a peptide containing four lysines VLC-1 (iii), one 
containing a bipartite nuclear localization sequence consisting of two lysines and 
five arginines (p21 peptide) (ii), as well as their corresponding TAT-fusion 
peptides. None of the TAT-free peptides was able to cross the plasma 
membrane whereas upon fusion to TAT these peptides translocated into living 
cells in the same manner as the TAT alone, albeit with lower transduction 
frequencies in the range of 75-85 %. In Fig. 1C i) the transduction frequencies of 
the peptides as a function of their pI are plotted and clearly demonstrate that 
positive charge is necessary but not sufficient for a peptide to be able to 
transduce. Furthermore, the fact that VLC-1 with four lysines but no arginines as 
well as nona-lysine (K9, Fig. S2) were not able to transduce into cells implies that 
arginines are essential and additional lysines, as present in p21, cannot 
substitute for a suboptimal number and/or arrangement of arginines.  
Next we asked whether structural features could explain the high transduction 
efficiencies of TAT and oligoarginines compared to the other peptides devoid of 
TAT. All peptides from the transduction assay (Fig. 1A) were subjected to a 
sedimentation velocity analytical ultracentrifugation experiment. The frictional 
ratio f/f0 determined by this analysis allowed the estimation of the gross 
conformation and dimensions of the peptides (Fig. 1B; see supplementary 
information and Table S2 for all parameters). Frictional ratios around 1 imply 
sphere-like particles and with increasing values the macromolecules can be 
modeled to more extended and rigid structures. Interestingly, all TAT-containing 
peptides and R10 exhibited a f/f0 between 1.29 and 1.55 and thus appeared to 
be extended and rigid, whereas the values found for the non-transducing 
peptides (without TAT) range from 1.00 to 1.16 and hint towards a globular 
shape (Fig. 1B). Only the non-transducing p21 peptide exhibited a f/f0 of 1.40 
indicating elongated shape, which was though less extended than the 
corresponding TAT-fusion counterpart. The fact that this peptide sediments 
with a high frictional ratio equivalent to the one from the transducing peptides 
but was not able in itself to transduce into living cells (Fig. 1A, ii) suggests that 
the extended conformation is not per se sufficient. Corroborating this 
conclusion, the f/f0 value for cyclic TAT was significantly reduced (1.14) 
compared to the linear TAT (1.39) and similar to the value for non-transducing 
peptides although both TAT peptides transduced into living cells. 
To understand if rigidity and elongated structure are correlated with the pI the 
f/f0 was plotted as a function of the pI (Fig.1C, ii). NBD with an acidic pI and 
VLC-1 with a slightly basic pI have a f/f0 around 1, all other peptides form a basic 
cluster with pI ranging from 11.70 to 12.95 and corresponding frictional ratio 
varying between 1.14 and 1.55. TAT (8+) and R10 (10+) are both 10 amino acids 
long and, thus, the difference of 0.10 in the frictional ratio should reflect the 
number of evenly charged residues. Although the frictional ratio did not perfectly 
reflect the pI, above a certain basic charge, the peptides exhibited a stretch 
conformation. We conclude that a stretched conformation should be an intrinsic 
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structural property for RRPs and other equally charged peptides but both 
features do not ensure transduction ability. 
Therefore, we checked whether transduction ability was correlated with the 
number and density of charge (arginines) within the peptides. Indeed, the cyclic 
form of TAT was not only able to translocate into living cells with comparable 
frequencies as the linear TAT (Fig. 1A and C, iii) but even exhibited enhanced 
transduction kinetics (Fig. 2, supplementary movie 1), which is in contrast to a 
cyclic form of penetratin that lost most of its translocation capacity 
12
. Although 
both forms were identically charged, the cyclic TAT variant entered living cells 
on average 15 minutes earlier than the linear form and the concentration of 
peptide was higher inside the cells (Fig. 2). As both peptides harbor eight 
positive charges, the kinetic uptake difference can be attributed to different 
clustering of charges (Fig. 1C, iii). The gradual and steady increase of peptide 
inside the cell (Fig. 2A) argues against the formation of transient pores as 
suggested by a molecular dynamics simulations
13
.  
The molecular dimensions determined by analytical ultracentrifugation (Fig. 
1B) describe cTAT as a disk-like structure and linear TAT as a thin rod-like 
structure. We and others have previously reported a concentration threshold for 
transduction 
4,14
 and an enrichment of RRPs on the membrane surface 
15-17
. 
The planar shape accompanied by increased clustering of arginines in cTAT 
might facilitate the formation of RRP assemblies on the cell membranes 
initiating transduction earlier.  
In summary, we show that the non-endocytic mode of entry by RRPs termed 
transduction depends solely on the number and clustering of arginines. We 
propose that the stable and outwards geometrical orientation of arginine side 
chains in one plane within the cyclic TAT create optimal interfaces to the 
negatively charged membrane surface constituents and results in a higher 
transduction efficiency. This finding will lead to the development of a new 
generation of more efficient delivery vectors in the future. 
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Figure legends 
 
Fig. 1: Comparison of live-cell transduction ability of RRPs as a function of 
their charge and shape: 
(A) RRP-containing peptides transduced into living mouse myoblast cells after 
incubation for one hour at 15 M in a volume of 200 l. Representative 
transmission images of the phase contrast (PC) and confocal optical sections of 
the fluorescent peptides are shown. Scalebars = 10 m. Sequences are 
indicated, with D-amino acids as small letter and L-amino acids as capital letters. 
Linker sequences are underlined. Fl = fluorescein, R = tetramethyl-rhodamine. 
(B) Results from the sedimentation velocity ultracentrifugation experiments and 
subsequent analysis: f/f0: frictional ratio, d: diameter, edge length. (C) Results of 
the Replica Exchange Molecular Dynamics (REMD) Simulations displayed as the 
number of structures in clusters, histogram of the distance distribution of peptide 
termini, 3D-structure from the cluster with the highest frequency. (D) Correlations 
between transduction frequencies, pI and charge distribution. Filled diamonds 
denote transducible peptides. pI was estimated with ProtParam (ww.expasy.ch) 
and charge clustering was derived from the number of positive charges divided 
by the length taken from the ultracentrifugation analysis. 
 
 
Fig. 2: Kinetic uptake characteristics of a linear and cyclic form of TAT: 
(A) Mean fluorescence intensity of fluorescein-labeled linear and cyclic TAT 
inside the nucleolus was monitored over 95 minutes at a frame rate of one image 
every 80 seconds. Curves display the mean of 22 and 30 cells for cyclic and 
linear TAT, respectively, from two experiments. Error bars show the standard 
deviation.  
(B) Selected confocal optical sections of timelapse movies (see movie S1) show 
the uptake of fluorescently labeled linear and cyclic TAT (20 M). Arrowheads 
indicate the appearance of fluorescence in nucleoli albeit with weak intensities, 
which is better visualized in the contrast stretched images shown in the insets. 
Scalebar = 10 m. Average uptake initiation times from three timelapses 
including 40 cells total are indicated with the standard deviation.  
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Supplementary information 
 
 
1. Cells, transduction experiments, 
microscopy and image analysis 
 
C2C12 mouse myoblasts were seeded at 70% 
confluency into 8-well microscope observation 
chambers (ibidi, Martinsried, Germany) and 
the growth medium (Dulbecco’s modified 
Eagle medium; PAA, Pasching, Austria) 
supplemented with 20% fetal calf serum (Life 
Technologies Inc.; Grand Island, NY, USA) 
and gentamycin was exchanged against the 
peptide solutions. The peptides (Table S1) 
were synthesized using standard Fmoc-
chemistry (Peptide Specialty Laboratories, 
Heidelberg, Germany; BioTez, Berlin, 
Germany). The circularization of the cTAT 
peptide was realized between an additional 
lysine and glutamic acid, which results in a 
TAT-ring with the same overall charge as in 
the native linear form (Fig.1A). Peptides 
were diluted to 15 M final concentration in 
200 l phosphate buffered saline, pH 7.4 
(PBS) and incubated with the cells for 60 
minutes at 37 
o
C. Subsequently, the peptide 
solution was gently exchanged against growth 
medium. For the timelapse microscopy over a 
time of 110 minutes the cells were treated as 
described above, with the exception that the 
peptides were diluted in DMEM without FCS 
to a final concentration of 20 M.  
 
 
 
Peptide Sequence Label (linker) MW [kDa] 
TAT rrrqrrkkrg (Ahx) 1396.6 
TAT rrrqrrkkrg  Fl (Ahx) 1866.0 
TAT rrrqrrkkrg FITC (Ahx) 1897.0 
TAT rrrqrrkkrg TAMRA (Ahx) 1921.1 
cTAT KrRrGrKkRrq Fl (K1) 1866.0 
R10 rrrrrrrrrr Fl(Ahx) 1692.1 
R10 rrrrrrrrrr Fl 2050.2 
PTD4 YARAARQARA Biotin (Ahx) 1542.8 
PTD4 araqraaray TAMRA (Ahx) 1615.5 
TAT-p21 rrrqrrkkrgaaAGRKRRQTSMTDFYHSKRRLIFS Fll 4914,6 
p21 GRKRRQTSMTDFYHSKRRLIFS Fl 3327.7 
VLC-1-TAT MAPKKPEPKDDAKAPAGRKKRRQRRRC  3175.7 
VLC-1 MAPKKPEPKDDAKAPAC  1737.1 
VLC-1-TAT MAPKKPEPKDDAKAPAGRKKRRQRRRC TAMRA  3856.9 
VLC-1 MAPKKPEPKDDAKAPAC TAMRA  1737.1 
TAT-NBD YGRKKRRQRRRTALDWSWLQTE  2891.7 
TAT-NBD YGRKKRRQRRRTALDWSWLQTE Fl (Ahx) 3559.7 
NBD TALDWSWLQTE  1348.7 
NBD TALDWSWLQTE Fl (Ahx) 1819.8 
K9 KKKKKKKKK Fl 1528.9 
 
Table S1: Summary of peptides used. Lower case letters indicate D- and upper case letters L-
amino acids. The labeled form of PTD4 as well as several other peptides were synthesized in the 
retro-inverso (retro-all D) form. Linker sequences are underlined. The fluorophores are given 
together with the amino acid or chemical compound used for coupling at the N-terminus.  
 
 
 
 9
 
 
To ensure, that different labels did not 
influence the transduction assay, TAT (amino 
acids (aa) 48-57 from the transactivator of 
transcription of the human HIV-1 protein) 
coupled to several variations of fluorophores 
used in the experiments was tested for its 
transduction frequencies and localization (Fig. 
S1). Confocal microscopy images were 
acquired with a LSM510 Meta system 
mounted on an Axiovert 200M inverted 
microscope and using a 63 x phase contrast 
plan apochromat oil objective NA1.4 (Zeiss, 
Jena, Germany). The microscope was 
equipped with a live-cell incubation chamber 
maintaining a humidified atmosphere of 5% 
CO2 and 37 
0
C (Okolab, Ottaviana (NA), Italy). 
For all settings the main beam splitter was 
HFT UV/488/543/633, and the specific 
parameters for the single fluorophores were 
as follows: TAMRA (R) labeled peptides were 
excited at 543nm, detected with 565–615 nm 
band-pass filter and FITC (F) or fluorescein 
(Fl) labeled peptides were excited at 488 nm 
and detected with a 500–530 nm band-pass 
filter. Phase contrast images were recorded 
with excitation at 488 nm and detection in the 
transmission channel. Laser power for 
observation was 1%, 488 nm, 25mW and 50 
%, 543 nm, 1mW. Settings were adjusted in a 
way that image pixels were not over or 
underexposed with the range indicator 
function in the Zeiss LSM software version 
3.2. The macro ‘Multi Time Series Rev. 3.2m 
(Zeiss, Jena, Germany) was used to record in 
parallel the uptake of the linear and cyclic 
variants of TAT in two different wells of the 
observation chambers. This methodology 
guaranteed an identical peptide to cell ratio for 
the measurement, which is crucial for 
transduction experiments. Movies of the 
collected images over time were generated 
with the macro ‘Concatenate Macro for LSM 
3.2’
18
. For the analysis of transduction kinetics 
the movies were cropped to the size of single 
cells using the open source program suite 
ImageJ and the cells were aligned with the 
help of the plugin ‘Stack reg’
19
. Subsequently, 
the increase in intensity after peptide 
application was graphed as average intensity 
over a square of 20 x 20 pixels inside the 
nucleolar compartment over a time of 110 
minutes. 22 and 30 cells for cyclic and linear 
TAT, respectively, from two different 
experiments were evaluated. For the 
transduction comparison of the linear and 
cyclic forms of TAT the respective peptides 
Figure S1:  
Fluorescent labels have no effect on CPP 
uptake and distribution. 
Different fluorophores attached to linear TAT 
transduced with similar efficiencies (given as 
% total cells in the images) and exhibited the 
same intracellular distribution. PC: phase 
contrast, R: TAMRA, Fl: fluorescein, F: FITC. 
Scalebars = 10 m for high and 50 m for 
low magnification images. 
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were normalized to their peptide content via 
UV-spectroscopy at 280 nm, leading to slight 
differences in the detected intensity by laser 
scanning fluorescence microscopy, as the 
peptide to label ratio differed. However, the 
transduction characteristics did not change, 
when the intensity levels were normalized 
after acquisition.  
 
 
 
2. Sedimentation velocity 
ultracentrifugation analysis 
 
The shape parameters of the peptides listed in 
the Table S2 were determined by analytical 
ultracentrifugation. Molecular mass studies 
were carried out using an analytical 
ultracentrifuge XL-A (‘Beckmann, Palo Alto, 
Ca, USA). About 400 l of the peptides 
dissolved in 4 mM phosphate buffer, pH 7.45, 
containing 0.3 M NaCl were centrifuged in 
standard double sector cells at 50,000 rpm 
and at 20 
o
C. From the moving boundary the 
following parameters sedimentation (s) an 
diffusion (D) coefficients were calculated using 
the program LAMM
20
. Together with the partial 
specific volumes the molecular masses were 
determined via the Svedberg equation and 
corresponded in all cases to the expected 
values for the monomeric peptides. 
Surprisingly, the hydrodynamic mobilities of 
the TAT fusion peptides were despite of their 
longer sequences clearly lower than those of 
the fusion peptides alone. Therefore, as an 
estimate for the gross conformation, the 
frictional ratio (f/f0) was calculated. 
 
f/f0=10
-8 1 p 
 
 
 	 
 
 
 
1/ 3
                            (1) 
(f/f0) is influenced by the two unknown 
variables shape and hydration. Assuming an 
average hydration of about 0.3 g bound water 
per g peptide, a hydration-dependent fraction 
(f/f0)hy can be obtained using  
 
(f/f0)hy  = 10
-8
 ((1w) / )1/ 3                (2) 
where w is the portion of bound water. 
Division of f/f0 by the factor (f/f0)hy yields  a 
shape dependent frictional ratio (f/f0)shape, that 
permits the rough estimation of the molecular 
dimensions. With the knowledge of M and the 
dry volume (V) can be calculated according to 
equation (eq) 3, with the Avogadro number NA: 
 
V = (M• )/NA                                 (3) 
 
The dry volumes of the peptides were 
calculated based on the formulas 4 and 5 for 
the description of sphere-like molecules 
 
V =1.33 • r3                                      (4) 
 
with the particle radius corresponding to 
 
r =
0.75V

 
  
 
  
1/ 3
                                    (5) 
 
formula 6 for rod-like shaped molecules 
assuming a prolate ellipsoids of revolution with 
the half axis a and b (a>b) or in case of the 
TATcirc an oblate ellipsoid of revolution with 
the half axis a and b (a>b) 
  
V = 1.33  ab2                                    (6) 
and using the a/b ratios derived from the 
Oncley-diagram
21
 the dry volumes of the 
peptides were determined.
Fig. S2: Oligolysines refuse to 
transduce: 
Incubation C2C12 mouse myoblast with 50 
M of fluos-labeled K9 for two hours. 
Confocal analysis did not detect K9 freely 
diffusing intracellularly. Scalebar = 50 m 
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Construct s20,W D20,W 
[107 cm2 s-1] 
Mexp. 
[kDa] 
(f/f0) 
shape 
Vdry 
[nm3] 
d sphere 
[nm 
d a 
[nm] 
d b 
[nm] 
shape 
TAT 0.291 18.6 1.445 1.39 1.71 1.48 5.21 0.79 rod 
TAT (R) 0.416 20.21 1.899 1.28 2.21 0.808 3.65 1.07 rod 
R10 0.303 16.83 1.692 1.49 2.08 1.58 5.60 0.84 rod 
PTD4 3.75 21.55 1.542 1.16  1.158 3.70 0.98 rod 
cTAT (Fl) 0.368 19.99 1.87 1.14 2.31 1.64 2.50 0.70 ellipsoid 
TAT-p21 (Fl) 0.606 10.97 4.843 1.50 5.92 2.24 10.00 1.06 rod 
P21 (Fl) 0.521 13.30 3.081 1.40 3.76 1.55 7.39 0.98 rod 
VLC-1-TAT 0.410 12.43 3.135 1.55 4.07 1.00 9.20 0.46 rod 
VLC-1 0.420 24.26 1.626 1.00 2.00 1.56 1.56 1.56 sphere 
TAT-NBD 0.539 14.80 3.274 1.29 3.97 1.96 6.24 1.11 rod 
NBD 0.397 25.96 1.349 1.00 1,61 1.45 1.45 1.45 sphere 
Table S2: Measured and calculated parameters determined by analytical ultracentrifugation with 
s - sedimentation coefficient, D - diffusion coefficient, MW - molecular weight, V - volume and d - 
diameter. 
 
Movie S1 
Timelapse confocal microscopy of the uptake of linear and cyclic TAT CPP into C2C12 mouse 
myoblasts. For details see Fig.2. 
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Abstract In the recent molecular and cell biological
research, there is an increasing need for labeling of
subcellular structures in living cells. Here, we present
the use of a Xuorescently labeled cell penetrating pep-
tide for fast labeling of nucleoli in living cells of diVer-
ent species and origin. We show that the short peptide
with ten amino acids was able to cross cellular mem-
branes and reach the nucleolar target sites, thereby
marking this subnuclear structure in living cells. The
treatment of cells with actinomycin D and labeling of
B23 protein and Wbrillarin provided evidence for a
localization to the granular component of the nucleo-
lus. The Xuorescently conjugated nucleolar marker
could be used in combination with diVerent Xuoro-
phores like Xuorescent proteins or DNA dyes, and
nucleolar labeling was also preserved during Wxation
and staining of the cells. Furthermore, we observed a
high stability of the label in long-term studies over 24 h
as well as no eVect on the cellular viability and prolifer-
ation and on rDNA transcription. The transducible
nucleolar marker is therefore a valuable molecular tool
for cell biology that allows a fast and easy labeling of
this structure in living cells.
Keywords Cell penetrating peptides · Fluorescence 
microscopy · Living cells · Nucleolus · Transducible 
nucleolar marker
Abbreviations
AMD Actinomycin D
DRAQ5 Deep red Xuorescing anthraquinone Nr. 5
DMEM Dulbecco’s modiWed eagle medium
FACS Fluorescence activated cell sorting
FCS Fetal calf serum
FITC Fluorescein isothiocyanate
FU Fluorouridine
GFP Green Xuorescent protein
HEPES N-2-hydroxyethylpiperazine-N!-2-ethane-
sulfonic acid
HIV Human immunodeWciency virus
mRFP Monomeric red Xuorescent protein
PI Propidium iodide
PCNA Proliferating cell nuclear antigen
TAT Transactivator of transcription
Introduction
The nucleolus is the most prominent substructure in
the cell nucleus and it was Wrst described in 1836 by
Gabriel Gustav Valentin (Franke 1988). It took more
than one century to establish its role in ribosome bio-
genesis (Brown and Gurdon 1964; Perry 1962). The
nucleolus is a very dynamic structure and it forms
around the rDNA loci (Andersen et al. 2005). The
inner nucleolar structure is organized into Wbrillar cen-
ters (FC, where rDNA is located and at the periphery
of which transcription takes place) surrounded by the
dense Wbrillar component (DFC, into which nascent
Electronic supplementary material The online version of this 
article (doi:10.1007/s00418-006-0256-4) contains supplementary 
material, which is available to authorized users.
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M. C. Cardoso (&)
Max Delbrück Center for Molecular Medicine, 
Robert-Roessle-Str. 10, 13125 Berlin, Germany
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transcripts migrate) and all around the granular com-
ponent (GC), which is Wlled with ribosomal precursors
(Cheutin et al. 2002; Derenzini et al. 2006; Scheer and
Hock 1999). Long ago, it has been noted that the
nucleolus size reXects the cellular activity, proliferation
and diVerentiation (Hernandez-Verdun 2006). Fur-
thermore, the nucleolus bears the hallmark of other
subnuclear compartments, in that is not delimited by
membranes, as is the case for cytoplasmic organelles.
Owing to its higher density and refractility in compar-
ison to the surrounding nucleoplasm, the nucleolus can
be visualized with phase contrast or diVerential interfer-
ence contrast microscopy. However, the three-dimen-
sional volume and localization within the nucleus as well
as its exact borders are hard to identify by contrast
microscopy alone and require a Xuorescence label (Lam
et al. 2005). In addition, such a marker would facilitate
high throughput analysis to sort nuclear proteins accord-
ing to their intranuclear localization. Finally, the devel-
opment of new high-resolution optical techniques allows
for the Wrst time optical analysis down to the nanometer
scale but require Xuorescent labels. This gain in informa-
tion could help to elucidate the functional nuclear and
genome organization in relation to the nucleolus in the
three-dimensional nuclear structure. SpeciWc antibodies
to nucleolar proteins or the transfection of cells with
plasmids encoding for Xuorescent fusions of nucleolar
proteins allow the visualization of the nucleolus by Xuo-
rescence microscopy. However, these methods require
either Wxation of the sample and immunostaining in the
case of antibodies or transfection of cells and expression
of the Xuorescence marker in the case of Xuorescent pro-
teins. The latter strategy has the advantage of allowing
live-cell microscopy but is Wrst time consuming and sec-
ond restricted to transfectable cells, which is not the case
of most primary cells. Furthermore the analysis of drug
eVects on the nucleolar organization and function could
be simpliWed by using a fast nucleolar label for living
cells. A membrane-permeable Xuorescent label for the
nucleoli, which is fast and easy to apply on living cells,
would therefore be a very useful molecular tool for diag-
nostics and cell biological research.
The ability of certain peptides and proteins with
concentrated basic charges to cross cellular membranes
was earlier discovered in 1988 for the HIV TAT pro-
tein (Frankel and Pabo 1988; Green and Loewenstein
1988), and the peptide domain responsible for mem-
brane transduction was mapped a decade later (Vives
et al. 1997). Further comparison of native and artiWcial
membrane transducing peptides indicated that argi-
nines are superior to lysines in transduction potential
(Mitchell et al. 2000; Thoren et al. 2003). Independent
studies found that peptide sequences present in several
viral and cellular proteins containing a stretch of 6–10
basic amino acids could serve as a targeting sequence
for the nucleus and the nucleolus (Dang and Lee 1989;
Hatanaka 1990). In this work we reasoned that if both
properties, membrane transduction ability and nucleo-
lar targeting signal, could be combined in the same
peptide made of a series of basic amino acids we could
exploit these independent biological functions to
directly label the nucleolus in living cells.
Materials and methods
Peptides and plasmids
Amino-terminal Xuorescein labeled deca-arginine pep-
tide (FITC-R10) was synthesized with D-amino acids by
Peptide Specialty Laboratories (Heidelberg, Ger-
many), dissolved in ddH2O and, for application on liv-
ing cells, further diluted in growth medium.
The mRFP-PCNA expression construct was
described before (Sporbert et al. 2005).
Cell culture and transfection
Human HeLa cells as well as Flp 3T3 mouse Wbroblast
cells were cultivated in DMEM with 10% FCS + 5 mM
L-glutamine and 5 !g/ml Gentamycine. C2C12 mouse
myoblasts were grown in DMEM with 20% FCS and
the same additives. Transfection of C2C12 cells with
mRFP-PCNA was carried out by CaPO4 precipitation
method as described (Cardoso et al. 1997). For live cell
microscopy the cells were plated onto 4- or 8-well Lab-
Tek coverglass chambers (NalgeNunc) or 8-well Ibidi
chambers (Ibidi). Adult ventricular cardiomyocytes
were enzymatically isolated by retrograde perfusion
from excised adult male Wistar rat hearts at a constant
Xow of 6 ml per min with a Ca2+-free HEPES solution
containing collagenase (Worthington type II, 60 IU per
ml). The freshly dissociated cells were kept at physio-
logical solution with 0.3 mM Ca2+ and 0.5% bovine
serum albumin at room temperature (Alvarez et al.
2004). DRAQ5 (Biostatus Ltd) staining of DNA in liv-
ing cells was as described (Martin et al. 2005).
Transduction assays
All peptide transduction experiments were performed
with living cells plated on 4- or 8-well coverglass cham-
bers. Before observation, the medium was removed
and growth medium with the diVerent peptide concen-
trations was directly applied to the cells. To remove the
background Xuorescence of extracellular peptides a
Histochem Cell Biol 
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washing step with PBS was included after 30 min of
incubation followed by incubation in growth medium
without peptide. For the concentration dependent
uptake (Fig. 3a) the cells were incubated with the pep-
tides for 1 h before washing with PBS while for the
continuous time series to study the uptake dynamics
(Fig. 3b) no washing step was performed. The uptake
of the marker peptide was studied under a Xuorescence
microscope for 1 h starting with the peptide applica-
tion. After observation and imaging of the nucleolar
label the cells were returned to the incubator and fur-
ther image collection was performed 24 h later. Trans-
duction eYciencies were determined in two
independent experiments by counting the number of
transduced cells with nucleolar label directly on the
Xuorescence microscope in ten Welds of view (n = 130–
180 cells).
Cell viability and proliferation assay
Cell viability and label stability after nucleolar marker
application were monitored by the ability of the cells to
undergo complete mitotic cell cycles and grow to
conXuency as well as monitoring the label intensity in
the nucleoli 24 h after application.
The membrane integrity was ascertained by the try-
pan blue exclusion assay. Into each well of a 4-well
LabTek chamber with 400 !l medium 2 !l trypan blue
solution (Sigma) was added and mixed by pipetting up
and down. The number of trypan blue positive cells
was counted at 30 min and in separate samples at 24 h.
The impact of the nucleolar marker on cell viability
and cell cycle progression was assayed by plating equal
number of cells and 1 day later adding or not 10 !M
FITC-R10 to the media for 1 h followed by a washing
step in PBS and incubation in growth medium. The
next day, cells were trypsinized, Wxed with methanol
for 20 min and stained with 50 !M propidium iodide
(PI) (Sigma) for 1 h in the presence of 0.1 mg/ml
RNase A (Sigma). DNA content was analyzed by Xow
cytometry (Becton Dickinson FACSVantage using
488 nm laser excitation and 675/20 nm bandpass Wlter
for detection) as a measure of cell cycle progression
(Plander et al. 2003). Five sets of 1 £ 104 cells and Wve
sets of 2 £ 104 cells were analyzed, and all the data sets
were used for the calculation of mean values of cells in
Fig. 1 Transducible nucleolar marker uptake into diVerent cell
types and in combination with other Xuorophores a This Wgure
shows the Xuorescently labeled nucleolar marker taken up into
cells of diVerent species and origin, which are either from cultured
cell lines (Wbroblasts, mouse; HeLa, human) or primary cells that
are terminally diVerentiated (adult cardiomyocyte, rat). The cells
were incubated with a medium containing the transducible nucle-
olar marker for 30 min and then washed in PBS and supplied with
the medium. In both cases the marker transduced fast into the cells
where it accumulated in the nucleoli and thereby marked this sub-
nuclear structure. b Displays a C2C12 mouse myoblast transfected
with a plasmid coding for mRFP-PCNA (red) and with DNA
stained by DRAQ5 (blue). The transducible nucleolar marker la-
beled with FITC (green) can be used in combination with Xuores-
cent protein labels like mRFP as well as Xuorescent dyes such as
the live cell DNA stain DRAQ5. Scalebar: 5 !m
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G1, S and G2/M phase for FITC-R10 labeled and con-
trol cells using ModFit 3.0 software.
In situ transcription assay and inhibition 
with actinomycin D
Cells were grown on glass coverslips and 1 day later
incubated with FITC-R10 for 1 h or 24 h in a 12-well
plate. Actinomycin D (AMD) treatment was per-
formed at 0.04 mg/l for 2 h before adding FITC-R10 at
10 !M to the same growth medium or for 2 h after the
incubation of cells with FITC-R10 for 1 h. For the
labeling of nascent RNA cells were incubated with
1.5 mM FU in growth medium for 10 min and washed
in PBS.
After the incubation schemes cells were Wxed in
3.7% formaldehyde in PBS for 10 min and permeabi-
lized with 0.25% (0.5% for AMD experiments) Triton
X100 in PBS for 10–12 min. The samples were immu-
nostained with anti-B23 mouse monoclonal antibody
(clone FC82291; Sigma) followed by detection with
donkey anti-mouse IgG antibody conjugated with Tex-
asRed (Jackson) and #346 anti-Wbrillarin human auto-
antibody (kind gift from P. Hemmerich, FLI Jena)
followed by donkey anti-human IgG biotin SP (Lot:
47441 Jackson) and streptavidin-Cy5 (Amersham).
Fluorouridine incorporated into RNA was detected
with anti-BrdU rat monoclonal antibody (clone BU1/
75; Harlan Sera Lab) followed by incubation with don-
key anti-rat IgG antibody conjugated with Cy5 (Jack-
son). For the labeling of DNA cells were
counterstained with TOPRO-3 at 1.3 !M Wnal concen-
tration in PBS (Molecular Probes) and mounted with
Moviol.
Microscopy, image acquisition and analysis
Live cell microscopy was performed with a Zeiss
LSM510Meta confocal setup mounted on an Axiovert
200 M inverted microscope using a 63£ phase contrast
plan-apochromat oil objective NA 1.4 heated to 37°C.
For all acquisition settings the main beam splitter was
HFT UV/488/543/633 and the parameters speciWc for
each Xuorochrome are listed below: 
Imaging of AMD treated cells was done at a Leica
TCS SP5 confocal setup mounted on a Leica DMI
6000 CS inverted microscope using a 63£ HCX plan-
apochromat DIC oil objective NA 1.4. The image
acquisition was done sequentially to minimize poten-
tial crosstalk between the Xuorophores. The trypan
blue exclusion was determined with brightWeld illumi-
nation on the Zeiss LSM510 microscope setup. The
uptake kinetics analysis (Fig. 3b) was performed by
selecting ten nucleoli in ten individual cell nuclei in
the image of the last time point and determining their
mean Xuorescence intensity (FI) at each time point.
The Xuorescence intensity data for all individual
nucleoli were averaged and plotted against the time-
scale. Labeling of nascent RNA by FU was analyzed
by selecting 60 nuclei from confocal images and deter-
mining the mean Xuorescence intensity. Background
correction was done by applying a threshold according
to the mean Xuorescence intensity in images from con-
trol cells without primary antibody (anti-BrdU).
Image analysis was performed with Zeiss LSM Image
examiner 3.2 (Zeiss) and Origin 7.5 software (Origin
Lab Corp.).
Results and discussion
Our goal was to develop an easy to use live cell Xuores-
cent marker for the nucleolus. Therefore, we tested
whether nucleolar targeting ability could be combined
with cell penetrating ability in one peptide. The latter
would allow non-invasive application to all sorts of
cells. We chose a peptide composed of 10 arginines,
which had been shown to eYciently transduce into cells
(Wender et al. 2000). To prevent proteolytic degrada-
tion the peptide was synthetized with D-amino acids.
The Xuorescent label (FITC) was added to the N-ter-
minal end.
First, we tested the ability of this peptide (FITC-
R10) to be taken up by diVerent cells and its intracellu-
lar localization. We selected diVerent cell types (Wbro-
blasts, epithelial, muscle) from diVerent species
(mouse, rat, human) and not only cell lines (Flp 3T3,
HeLa) but also primary cultures (cardiomyocytes).
FITC-R10 was diluted in growth medium and applied
directly to the cells for 30 min. After the incubation
time the cells were washed and analyzed by confocal
microscopy. In all cells tested (Fig. 1a) the Xuorescence
label was found accumulated in the nucleoli identiWed
by the phase contrast images (except in cardiomyo-
cytes where the nucleoli cannot be detected due to the
sarcomeric structures) and also diVusely distributed in
the cytoplasm. The transfection of the cells with an S-
phase marker (mRFP-PCNA; Sporbert et al. 2005 and
simultaneous DNA labeling with DRAQ5 Martin et al.
2005) indicated that uptake of the peptide was not cell
Fluorochrome Ex (nm) Em (nm)
FITC 488 BP500–530
mRFP, L-Rhodamine 543 BP565–615
DRAQ5, Cy5 633 LP650
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cycle dependent. Indeed, cells in diVerent stages of the
S-phase as well as in G1/G2 exhibited nucleolar label-
ing and also mitotic cells had taken up the marker
although the nucleus and the nucleoli are not present
(Fig. 1b and data not shown). These data also indicate
that combinations with other Xuorochromes (e.g., live
cell DNA staining with DRAQ5) and Xuorescent pro-
teins (e.g., mRFP) are possible. Since any other Xuo-
rescent label can be selected for the nucleolar marker
peptide, this allows multiple combinations with other
Xuorochromes.
The FITC-R10 label colocalized with the dark struc-
tures in the phase contrast images, which were sur-
rounded by dense chromatin detected by TOPRO-3
staining (Fig. 2a). To conWrm the nucleolar localization
of FITC-R10 we performed colocalization studies with
nucleophosmin/B23 (Fig. 2b), a protein present in the
granular component of the nucleolus and Wbrillarin
localized in the dense Wbrillar component (reviewed in
Olson and Dundr 2005). The FITC-R10 label
colocalized with the B23 antibody signal at the periph-
ery of the nucleoli and Wlled the nucleolar interior
showing a decreased concentration in the dense Wbril-
lar components labeled by Wbrillarin (Fig. 2b). This
demonstrated that the FITC-R10 peptide possesses
intracellular nucleolar targeting ability and further-
more localizes to the granular component of the
nucleolus.
To further test the exclusion of FITC-R10 from Wbril-
lar components we treated cells with AMD. Exposure
of cells to this transcription inhibitor leads to a separa-
tion of Wbrillar and granular components into distinct
caps (Reynolds et al. 1964; Chen et al. 1999). The
AMD treatment of cells before or after (data not
shown) labeling the nucleoli with FITC-R10 showed the
persistent localization of FITC-R10 to the granular
component remnant separated from the caps formed
by the Wbrillar components without FITC-R10 (Fig. 2b).
In contrast to B23, the nucleolar marker did not redis-
tribute throughout the nucleoplasm after AMD
Fig. 2 Intracellular localiza-
tion of the FITC-R10. a HeLa 
cells incubated for 1 and 24 h 
with 10 !M FITC-R10 as well 
as unlabeled controls were 
Wxed in 3.7% formaldehyde in 
PBS and stained with TO-
PRO-3 to label the DNA. The 
FITC-R10 label colocalize 
with the nucleoli identiWed in 
the phase contrast during 
short- and long-term incuba-
tion of the cells. b The HeLa 
cells were immunolabeled for 
B23/nucleophosmin to high-
light the granular component 
of the nucleolus and Wbrillarin 
to label the dense Wbrillar 
components. One sample was 
treated with actinomycin D 
(AMD), which leads to a stop 
in rDNA transcription and the 
formation of nucleolar caps 
containing the Wbrillar compo-
nents. The FITC-R10 label was 
still localized to the nucleolar 
interior unlike B23, which was 
redistributed to the nucleo-
plasm and excluded from the 
nucleoli. The nucleolar mark-
er does not colocalize with the 
Wbrillarin labeled caps in 
AMD treated cells. Scalebar: 
5 !m
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treatment indicating that it interacts with other mole-
cules of the granular component. Thus, the FITC-R10
can also be used in cells where rDNA transcription was
stopped to label the granular components of disassem-
bled nucleoli.
Furthermore, these immunostaining experiments
after live cell application of FITC-R10 demonstrated
that Wxation and further treatments could be per-
formed without loosing the label or changing its locali-
zation (Fig. 2 and suppl. Fig. 1A). When FITC-R10 was
applied to pre-Wxed samples though, it did not stain the
nucleolus (suppl. Fig. 1A).
The kinetics of uptake of the peptide into cells was
then studied by time-lapse confocal microscopy. The
time series analysis is shown in Fig. 3b and in the sup-
plementary online movie. The images at the Wrst and
last timepoints display the accumulation of the marker
over time inside the cells and on the cell membrane.
The graph represents the Xuorescence increase in the
nucleoli of 10 diVerent cells. The peptide was rapidly
internalized and labeling of the nucleoli started around
20 min and reached the equilibrium at 40 min. Earlier
nucleolar labeling could have been missed due to the
strong extracellular Xuorescence of non-internalized
peptides.
In a separate set of experiments we performed a dose
response uptake analysis. DiVerent concentrations of
the marker in the growth medium were applied for 1 h
to HeLa cell cultures. A threshold minimal concentra-
tion for nucleolar labeling was found at 2.5 !M. Lower
peptide concentration (1 !M) resulted in no uptake of
the marker into the cells (Fig. 3a). A possible explana-
tion for this Wnding is that a certain concentration of the
basic CPP on the cell membrane needs to be reached to
enable the membrane transduction process (Dietz and
Bdeltahr 2004; Tunnemann et al. 2006). Alternatively,
the Xuorescence detection method used might not be
sensitive enough to detect very low concentrations of
Xuorescent peptide over the background signal.
Next, we wanted to test the intracellular stability of
the marker and its localization. This was examined by
applying the transducible Xuorescent nucleolar marker
to living C2C12 myoblasts for 30 min, which as before
resulted in nucleolar accumulation, removing the
excess extracellular Xuorescent peptide by a washing
step with PBS and analyzing the cells by confocal
microscopy 24 h later. The Xuorescent nucleolar label
was surprisingly stable showing very bright nucleolar
signal 1 day later without detectable decrease in Xuo-
rescence intensity or the number of cells marked
(Fig. 3c). No proteolytic degradation or intracellular
recycling of the FITC-R10 was observed within this
time period. In addition, the morphology of the cells
was not changed, and the cultures grew to conXuency
indicating no overt eVect of the nucleolar marker on cell
cycle progression and mitotic division. The structure
Fig. 3 Kinetics of uptake and intracellular stability of the nucle-
olar marker The images in a show the concentration dependent
labeling of the nucleoli in HeLa cells with a threshold at a concen-
tration of 2.5 !M FITC-R10. The kinetics of uptake in b display
the increase of the Xuorescent label in the nucleoli directly after
application of 10 !M FITC-R10 in medium to living C2C12 cells
without a washing step. The uptake started immediately after the
application of the nucleolar marker and was clearly visible after
20 min. A maximum of the nucleolar label was reached 40 min af-
ter the start of the experiment (see supplementary movie). c
C2C12 cells were incubated for 30 min with FITC-R10 in a medi-
um followed by washing in PBS and imaged 24 h later. Represen-
tative images are shown and demonstrate the stability of the
transducible nucleolar marker over the 1 day period tested (see
also Fig. 2a). Scalebar: 5 !m
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and localization of components of the granular compo-
nent visualized by antibody labeling of B23 was also
not altered between untreated cells and samples
labeled for 1 and 24 h with FITC-R10 (Fig. 2a and data
not shown).
To measure the eYciency of nucleolar labeling we
determined the percentage of labeled cells at diVerent
times after application. Nearly 89% of the cells showed
nucleolar Xuorescence after 30 min and the number even
increased to 98% at 24 h (Fig. 4a). Having FITC-R10 in
the growth medium for the initial 30 min or during the
entire 24 h period yielded no diVerence in the nucleolar
label and the cellular viability (Fig. 4a and data not
shown). To further investigate the impact of the peptide
transduction on membrane integrity we used the trypan
blue exclusion test. No diVerence was measured between
labeled and unlabeled control cells in the number of try-
pan blue positive cells, which was 1–2% (Fig. 4a).
Next, cells labeled for 24 h with FITC-R10 were incu-
bated for 10 min with Xuorouridine (FU), which is
preferentially incorporated into rRNA, and the incor-
porated nucleotide was detected by immunostaining to
determine the amount of synthesized RNA in compari-
son to cells without nucleolar marker (Boisvert et al.
2000). The diagram in Fig. 4b displays the mean Xuo-
rescence intensity of 60 nuclei measured from low mag-
niWcation confocal images. FU labeled cells with and
without FITC-R10 exhibited no diVerence in the level
of incorporated nucleotide, i.e., no eVect was detected
on rDNA transcription.
Finally, to assess potential eVects of FITC-R10 on
cell proliferation, we subjected HeLa cells with labeled
nucleoli and unlabeled control cells to PI staining and
Xow cytometric analysis of cellular DNA content. The
cells were incubated for 1 h with 10 !M FITC-R10 and
then washed in PBS and grown at 37°C for 24 h. After
Fig. 4 EVect of the nucleolar marker on the cellular viability,
proliferation and rDNA transcription The table in a summarizes
the percentage of cells with labeled or unlabeled nucleoli and the
trypan blue exclusion test after short- and long-term incubation
of living cells with 5 !M FITC-R10. In both cases a small number
of cells remained unlabeled, whereas the majority of cells showed
nucleolar labeling after 30 min and also after 24 h incubation with
the nucleolar marker. The quantity of trypan blue positive cells
during short- and long-time incubation is comparable to the con-
trol cells. The diagram in b displays in each bar the mean intensity
of Xuorescently labeled FU incorporated into rRNA from 60 nu-
clei measured in confocal images. The signals of labeled rRNA in
FITC-R10 labeled or unlabeled control cells diVered only a little
and within the range of the standard deviation. In c the histo-
grams represent Wtted curves of Xow cytometry measurements.
HeLa cells were incubated or not with the transducible nucleolar
marker for 1 h following a washing step in PBS and staining with
PI in the presence of RNase. The percentage of cells in the respec-
tive cell cycle stage, and the standard errors were calculated from
ten measurements each
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this incubation scheme the labeled and untreated con-
trol cells were methanol Wxed and stained with PI
including RNase treatment to measure the DNA
amount for cell cycle distribution analysis. The control
cells showed a cell cycle proWle with 52% of cells in G1/
G0, 32% in S-phase and 16% in G2/M. In comparison
the cells incubated with 10 !M of the nucleolar marker
for 1 h showed some deviations from the control cell
cycle proWle 24 h post-labeling. The quantity of cells in
G1/G0 was decreased to 43%, whereas the cells in S-
phase increased to 42% concomitantly. The fraction of
G2/M cells remained similar to the control cells (15%;
Fig. 4c). These data suggest some delay in cells pro-
ceeding through S-phase indicated by an increase and a
corresponding decrease of cells in G1/G0. The quantity
of cells that exit the S-phase and continued to G2 and
the mitotic division was stable also under the inXuence
of the nucleolar marker, which Wts the observation of
increased conXuency in cultures after 24 h.
Altogether, no major eVect of the nucleolar marker
on either membrane integrity, cell viability and prolif-
eration, RNA synthesis or distribution of nucleolar
components was observed at short- or long-incubation
times.
Such a label is totally non-invasive and importantly
works well in combination with other Xuorochromes
such as autoXuorescent proteins or various dyes. More-
over, most cells not only established cell lines but also
non-transfectable primary cultures were transduced
with 90% or higher eYciency, and the nucleolar label-
ing needed only about 20 min to be readily visualized.
Curiously, always a few cells remained unlabeled,
which could be due to genetic or epigenetic diVerences
in gene expression among the cells in the culture
(Tyagi et al. 2001).
We conclude that the FITC labeled deca-arginine
peptide does not interfere with major cellular pro-
cesses at the concentrations tested. The combination of
membrane permeability and nucleolar targeting in one
peptide makes this transducible Xuorescent marker for
the nucleoli applicable to most mammalian cells and a
novel and non-invasive tool for live cell microscopy.
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Supplementary Figure 1. The nucleolar marker is not removed by fixation. A) HeLa cells were 
treated with 10 µM FITC-R10 for 60 min then washed and incubated for 1h in growth medium. 
Finally the cells were fixed with 3.7% formaldehyde in PBS and the sample was mounted on a 
coverslip for microscopy analysis. The nucleolar label was comparable to the label in living cells and 
stable during the washing, fixation and mounting treatments. In B) the cell was fixed in 3.7% 
formaldehyde before the application of FITC-R10 and the fluorescent peptides did not label the 
nucleoli. Scalebar 5 µm (PDF 52 kb) 
Kinetics of FITC-R10 uptake into living C2C12 cells. For description see Fig. 3b
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Abstract In contrast to immortal cell lines, primary cells are
hardly susceptible to intracellular delivery methods such as
transfection. In this study, we evaluated the direct delivery of
several cell-permeable peptides under noninvasive condi-
tions into living primary adult rat cardiomyocytes. We
specifically monitored the functional effects of a cell-
permeable peptide containing the 15 amino acid N-terminal
peptide from human ventricular light chain-1 (VLC-1) on
contraction and intracellular Ca2+ signals after electrical
stimulation in primary adult cardiomyocytes. The trans-
ducible VLC-1 variant was taken up by cardiomyocytes
within 5 min with more than 95% efficiency and localized
to sarcomeric structures. Analysis of the functional effects
of the cell-permeable VLC-1 revealed an enhancement of
the intrinsic contractility of cardiomyocytes without affect-
ing the intracellular Ca2+. Therefore, peptide transduction
mediated by cell-penetrating peptides represents not only a
unique strategy to enhance heart muscle function with no
secondary effect on intracellular Ca2+ but also an invaluable
tool for the modulation and manipulation of protein
interactions in general and in primary cells.
Keywords Ventricular light chain-1 (VLC-1) .
Cell penetrating peptide (CPP) . Peptide transduction .
Cardiomyocytes . Drug delivery
Introduction
Therapeutical delivery of protein or peptides into living
primary cells is hampered by the lack of a suitable and
efficient method for the introduction of macromolecules.
Most commonly used transfections methods work in immor-
talized cells but mostly fail in primary cells or require
specialized and time-consuming protocols, i.e., production
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of viral vectors. Moreover, the limited life span of primary
cells often does not provide sufficient time for expression of
gene products and subsequent analysis of their effects.
Physical methods such as microinjection and bead loading
are highly invasive procedures and are not tolerated by several
cell types. It has been known for quite some time that basic
proteins like histones or poly-ornithine as well as stretches of
basic amino acids within proteins aid the uptake of proteins
into mammalian cells [14, 17, 20, 30]. In the 1990s,
transducible peptides like penetratin-1 from the homeodo-
main of Antennapedia [11] and amino acids 48–57 from the
transactivator of transcription of human immunodeficiency
virus (HIV)-1 [14] were identified and exploited to introduce
drugs or biological macromolecules into mammalian cells.
Together with other native and synthetic transducing
peptides, they are referred to as cell-penetrating peptides
(CPPs) [12]. However, it became evident that the invasive
methods used to analyze the transduction mediated by CPPs
or effects of interconnected cargoes had led to overestimated
transduction results and overrated effects of cargoes fused to
CPPs [27]. Nevertheless, CPPs mediate the introduction of
fused cargoes into living cells, with cargo-dependent
mechanistical differences. One uptake mechanism can be
described as a slow adsorptive endocytosis and is preferen-
tially used by globular proteins, whereas small compounds
like peptides linked to CPPs favor a rapid membrane
potential-dependent uptake with overall intracellular avail-
ability of the transduced species [33]. CPP-mediated peptide
transduction has recently been used to deliver cardioprotec-
tive peptides derived from protein kinase C [4, 7–9, 24], the
antiapoptotic BH4 peptide derived from the apoptosis
regulator protein Bcl-xL [26, 28] and a Nox2-derived
peptide [34] into isolated cardiomyocytes or whole hearts.
We have tested the feasibility of this approach to study
muscle function in living adult primary cardiomyocytes.
Therefore, we targeted the interaction between actin and the
essential myosin light chain (MLC-1) of cardiac type II
myosin by a peptide competition approach. Transgenic
overexpression of the N terminus of the human ventricular
MLC-1 (residues 1–15; hereafter termed VLC-1), which
binds to actin and targets actin/MLC-1 interaction, signif-
icantly increased the magnitude and kinetics of the contrac-
tion of isolated perfused hearts [21]. We fused the same
human VLC-1 peptide to the TAT CPP (VLC-1-TAT) and
investigated its uptake, intracellular distribution, and function-
al consequences in primary living adult rat cardiomyocytes.
Materials and methods
Isolation of adult rat cardiomyocytes Primary cultures of
cardiomyocytes from male WKY rats aged 3 months were
performed as described previously [1].
Peptides The peptides consisted of either L-amino acids
(capital letters) or of D-amino acids (lower case letters). In
case of D-amino acid peptides, functional motifs were
synthesized as retro-all D-variants (underlined) to maintain
their functionality. Peptides were either labeled with the
fluorophore 5,6-carboxy-tetramethylrhodamine (TAMRA)
or fluorescein isothiocyanate (FITC). TAT (TAMRA- or
FITC-rrrqrrkkrg), PTD4 [23, 33] (TAMRA-araqraaaray),
and TAT-p21 (TAMRA-rrrqrrkkrgaaAGRKRRQTSMT
DFYHSKRRLIFSa-amide) [33] were labeled directly at
their N termini with the indicated fluorophores (Peptide
Speciality Laboratories, Heidelberg). In the case of VLC-1
(MAPKKPEPKKSSAKA-C-TAMRA-ME-amide) and
VLC-1-TAT (MAPKKPEPKDDAKAPAGRKKRRQRRR-
C-TAMRA-ME-amide; Biosyntan, Berlin) the TAMRA
fluorophore was coupled via an additional cysteine at the
C terminus leaving the N terminus free for the interaction
with actin.
Uptake of transducible peptides and controls To analyze
the transduction ability of different compounds into living
adult ventricular cardiomyocytes, the primary cells were
plated into a laminin-coated μ-slide eight-well ibiTreat
(ibidi, Martinsried) or four-well labtek (Nunc, Wiesbaden)
microscopy observation chamber. The respective peptides
and controls were added directly to Hank’s balanced salts
solution buffered with 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid at pH 7.4 (HBSS) or
medium and gently shaken to yield a final concentration
of 10 μM in case of the peptides and 5,6-TAMRA-
fluorophore. Trypan blue (Sigma-Aldrich) was added to a
final concentration of 0.5% (v/v) to the HBSS buffer. For
the experiments summarized in Fig. 1 confocal images
were acquired 1 h after addition of the respective
compounds to living cardiomyocytes. To study the
intracellular localization of transducible peptides in
Fig. 3, after 15 min of peptide incubation, the medium
was removed, and the cells were washed twice with the
HBSS buffer. For subsequent confocal image collection,
the cells were kept in medium or buffer. To study the
effect of the peptide on muscle contraction and intracel-
lular Ca2+ (Fig. 4), cardiomyocytes were electrically
stimulated (see below) to permit the access of the peptides
to all actin molecules with potential binding sites. During
confocal image collection, the electric stimulation was
temporarily switched off.
Microscopy, image acquisition, and analysis Confocal
images were acquired with a Zeiss laser scanning micro-
scope LSM510 Meta mounted on an Axiovert 200M
inverted microscope using a 63× phase-contrast oil immer-
sion plan-apochromat objective NA1.4 or a 100× phase-
contrast oil immersion plan-neofluar objective NA1.3. For
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all settings, the main beam splitter was HFT UV/488/543/
633, and the specific parameters for the single fluorophores
were: FITC, excited at 488 nm light, detected with a 500–
530-nm bandpass filter; TAMRA or rhodamine excited at
543 nm, detected with 565–615 bandpass filter; and trypan
blue, excited with 633 nm, detected with 650 longpass
filter. Phase-contrast images were recorded with excitation
at 488 nm and detection in the transmission channel. Laser
power for observation was typically 1–5% (488 nm,
25 mW) and 50–60% (543 nm, 1 mW) unless otherwise
indicated. Settings were adjusted in a way that image pixels
were not over- or underexposed with the range indicator
function in the Zeiss LSM image acquisition and examiner
software version 3.2.
Measurement of cardiomyocyte shortening and Ca2+
transients Attached cardiomyocytes were washed with
HBSS. Cells were loaded with Fura-2-AM for 30 min at
room temperature in the dark. The dye solution was removed,
and cells were left on HBSS for another 15 min. Only
cardiomyocytes of optically intact rod-shaped morphology
with clear cross-striation were analyzed. Cardiomyocytes
were electrically stimulated until a stable steady-state
contraction and Fura-2 signal could be monitored.
Cell shortening and Fura-2 signals were simultaneously
measured at 30°C on an Ionoptix Contractility and
Fluorescence System (Ionoptix). Cardiomyocytes were
electrically stimulated with bipolar pulses of 5 ms duration
at 1 Hz. Cell shortening, expressed as percentage of resting
cell length, was measured using the video-edge technique at
a sampling rate of 240 per second. Ca2+ transients were
monitored as ratio of fluorescence emission at 510 nm was
obtained by alternate excitation at 340 and 380 nm (340/
Fig. 1 Peptide uptake and in-
tracellular distribution in living
adult cardiomyocytes. To study
the uptake capacity of different
compounds into primary rat
cardiomyocytes, different fluo-
rescent compounds were direct-
ly added for 1 h to the medium
or buffer of freshly isolated
cardiomyocytes. After the incu-
bation period, confocal images
of the cells were taken without
exchange of the medium and
after removal of the fluorescent
solution and exchange against
the fresh medium. Internaliza-
tion into healthy adult cardio-
myocytes occurred after
application of 10 μM of the
transducible peptides FITC-TAT
shown at low (a) and high
magnification (b) and TAMRA-
TAT-p21 shown at low (c) and
high magnification (d) but not
with application of 10 μM of a
basic control peptide PTD4 (e).
Moreover, 0.5% of the vital dye
trypan blue (f) or 10 μM of the
TAMRA-fluorophore (g) itself
were not able to enter healthy
cardiomyocytes (rod-shaped
cells in culture). Scale bar,
10 μm. Stars indicate the nuclei
and arrowheads the nucleoli (N)
in the higher magnification
images. PC Phase contrast, NP
nucleoplasm
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380 ratio). Data files from 15 consecutive beats recorded at
intervals were averaged for analysis. Subsequently, the
cardiomyocytes were incubated with the peptides for
15 min without electrical stimulation. The peptide was then
removed by replacing the peptide-containing HBSS buffer
with normal HBSS buffer without the peptide. The
cardiomyocytes were subsequently electrically stimulated,
and both the shortening and Fura-2 signals were simulta-
neously recorded. The effect of the peptide on shortening
amplitude and the Fura-2 signal was expressed in percent
change compared to the steady-state signals obtained in the
preincubation period.
Results and discussion
We recently demonstrated by live-cell confocal microscopy
that the TAT CPP was able to shuttle fused peptides into
primary blood cells and subsequently modulated their
functional properties [10]. In this study, we tested whether
TAT CPP could penetrate and if a peptide derived from the
N terminus of VLC-1 fused to TAT is able to modulate the
contractile function of primary adult cardiomyocytes.
Different basic peptides were incubated with freshly
prepared cultures of cardiomyocytes, and peptide internal-
ization was analyzed live by laser-scanning confocal
microscopy. The fluorescently labeled minimal transduction
domain TAT CPP of the transactivator of transcription from
HIV-1 was readily taken up into cardiomyocytes and
displayed a strong affinity to the nuclear compartment
(Fig. 1a). It could also be visualized in a punctate pattern
throughout the entire cardiomyocyte (Fig. 1a). To determine
whether the TAT CPP is able to shuttle an attached peptide
into cardiomyocytes, we used the TAMRA-labeled TAT-
p21WAF/CIP (TAT-p21) fusion peptide [33], which in
addition to the transducing moiety contains 26 amino acids
derived from the C terminus of human p21WAF/CIP protein.
The uptake of this cargo peptide (assessed by appearance in
nucleoli) occurred on a timescale of 5 to 10 min after
peptide application. Its pattern of localization inside the
cardiomyocytes was similar than that seen for TAT alone
(Fig. 1c). Basic amino acid residues are a prerequisite for
the transduction ability of CPPs [13, 25, 35], and peptides
containing a minimum of six basic amino acids have been
shown to traverse biological membranes [5, 18]. As a
nontransducing control peptide, we chose the TAMRA-
labeled peptide PTD4, which contains three arginines in
total [23, 33]. More than 1 h after application of this peptide
to the cardiomyocyte culture, none of the healthy intact
cardiomyocytes took up the fluorescent peptide (Fig. 1e).
Similar results were obtained for the vital dye trypan blue
(Fig. 1f) and the TAMRA fluorophore (Fig. 1g). Approx-
imately 5% of cardiomyocytes in the cultures were dead or
Fig. 2 Molecular hypothesis for the enhancement of cardiomyocyte
contractility by the cell-permeable VLC-1 peptide. a Primary
sequence of VLC-1-TAT peptide color-coded orange for the VLC-1-
and yellow for the TAT-moiety. b Schematic sliding filament model
displaying actin in violet and the MHC in red. The higher
magnification shows the catalytic domain (CD) and the neck domain
(ND) of one molecule of the MHC. MLC proteins are colored green
with the N-terminal SE inside the essential MLC-1 protein highlighted
in red. Upon intramolecular conformational changes in the CD of
MHC, the ND swings out, exposing the SE of MLC-1 to an actin
molecule in direction to the Z-line. Treatment of cardiomyocytes with
the transducible TAT peptide (yellow ball) fused to the SE-peptide
(orange) blocks potential binding sites of the native MLC-1 N
terminus. After the MHC rearrangement, the MLC-1 protein can no
longer interact with actin and downregulate the myosin motor activity.
The scheme is based on the pre- and postpower stroke model [19]
developed with respect to crystallographic data on the Dicytostelium
myosin motor domain [15, 32]
1408 J Mol Med (2007) 85:1405–1412
harmed (visible in the phase-contrast images as not rod
shaped and with no striations). These cells were flooded
with both the CPPs as well as any other control dyes
(Fig. 1c,e–g). The cell-permeable TAT-derived peptides
displayed a similar enrichment in the nuclear compartment
with strong accumulation inside nucleoli (arrowheads) as
can be seen in the higher magnification images (Fig. 1b,d).
This intranuclear distribution is basically determined by the
TAT moiety, which includes a nuclear localization sequence
[22, 29, 33].
Having shown that CPP TAT was able to shuttle fused
peptides into living cardiomyocytes, we designed a trans-
ducible peptide comprising the actin-binding element of the
ventricular isoform of human MLC-1 (VLC-1), i.e., the N-
terminal residues 1–15 (VLC-1 peptide) connected to TAT,
termed VLC-1-TAT (Fig. 2). The hearts of transgenic
animals harboring minigenes encoding for the VLC-1
peptide revealed enhanced myosin motor activity and
positive inotropic effects [21]. A possible molecular
mechanism for the increase in myosin motor activity and
contractility is illustrated in the scheme in Fig. 2. MLC-1
isoforms of vertebrate striated muscle play a regulatory role
in myosin motor function: The N-terminal part of MLC-1
contains a sticky element (SE), which consists of several
positively charged amino acids that bind to the C terminus
of actin [3, 6, 16, 31]. The 46 N-terminal amino acids of
MLC-1 have previously been modeled on the basis of
contemporary crystallographic data [2]. Interactions be-
tween the sticky MLC-1 element and actin serve as a
negative modulator and decrease the activity of the myosin
motor domain. Intracellular delivery of a synthetic sticky
MLC-1 element by TAT-mediated transduction therefore
would antagonize MLC-1/actin interaction. We predict this
would increase myosin motor activity and enhance the
shortening amplitude without change of the systolic free
Ca2+ activation level of intact cardiomyocytes.
To first test whether the VLC-1 peptide itself might be
taken up by isolated cardiomyocytes because of its basic
charge, VLC-1 and VLC-1-TAT were applied for 15 min to
freshly isolated cardiomyocytes under resting conditions or,
Fig. 3 Transduction and intracellular localization of VLC-1-TAT in
isolated adult cardiomyocytes. a Scheme for the application of the
VLC-1-derived peptides and confocal imaging. Peptides were applied
at a concentration of 1 μM, incubated for 15 min to freshly isolated
cardiomyocytes. After removal of the peptide solution, the cells were
washed twice and kept in buffer or medium for direct live-cell
confocal imaging microscopy. Subsequently, the transduced cardio-
myocytes were electrically stimulated with 1 Hz for maximally 1 h. b
The negative control peptide TAMRA-labeled VLC-1 stained only
dead cardiomyocytes (low magnification, upper panel) but failed to
get internalized into healthy cardiomyocytes even when 100% laser
power was used to detect potentially weak signals (lower panel). c
Application of TAT-VLC-1 to living cardiomyocytes led to rapid
internalization of the peptide (upper panel). The lower panel shows
transduced VLC-1-TAT at higher magnification in an overlay of the
phase contrast and the TAMRA-fluorescence. The arrow indicates the
direction of the intensity profile of gray and red intensities in the line
scan for the localization analysis of VLC-1-TAT, which was present at
sarcomeric structures with enrichment at the actin-containing I-bands
(light bands in phase-contrast image)
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in another set of experiments, constant electric stimulation
(1 Hz, 20 V). After the fluorescent peptides were washed
away, the cells were analyzed live by confocal laser-
scanning microscopy (Fig. 3a). VLC-1 alone was not
internalized into healthy cardiomyocytes and stained only
compromised cells (upper panel, Fig. 3b). To ensure that
low concentrations of intracellular VLC-1 were not missed,
the laser intensity was increased to its maximum, and still
no fluorescent signals were measured (lower panel,
Fig. 3b). In contrast, VLC-1-TAT reached the intracellular
Fig. 4 Functional effects of cell
permeable VLC-1-TAT in living
adult cardiomyocytes. a Original
registration of cell length (top)
and cytosolic Ca2+ signals
(Fura-2 signal, expressed as ra-
tio R between 340 and 380
excitation; bottom) of electrical-
ly paced adult rat cardiomyo-
cytes before (basal) and after
incubation with 1 μM VLC-
1-TAT or 1 μM TAT as control.
b Statistical evaluation of the
effects of different concentra-
tions of transducible peptides
(0.5, 1 μM) on fractional short-
ening (FS; given in percent of
basal contraction obtained be-
fore incubation with the pep-
tide), maximal rate of FS (+dFS/
dtmax), and maximal relaxation
rate (-dFS/dtmax; both given in
percent of basal values obtained
before peptide incubation) of
control peptide (TAT) and VLC-
1-TAT. c Statistical evaluation of
the effects of different concen-
trations of transducible peptides
(0.5, 1 μM) on peak Fura-2
fluorescence signal (expressed
as ratio R between 340 and 380
excitation, given in percent of
basal R340/380 obtained before
incubation with the peptide),
maximal rate of R340/380
(+dR340/380/dtmax), and maxi-
mal rate of fluorescence decline
(-dR340/380/dtmax; both given
in percent of basal values
obtained before peptide incuba-
tion) of control peptide (TAT)
and VLC-1-TAT. Values are
means±SEM, n=6–9 different
cardiomyocytes at each peptide
concentration used. Double as-
terisk, p<0.01; triple asterisk,
p<0.001 (t test for paired
values)
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compartments of more than 95% of adult cardiomyocytes
(Fig. 3c).
Unlike the localization of the TAT and TAT-p21 peptides
(Fig. 1), the VLC-1-TAT was not detected in the cell
nucleus. Detailed analysis of the intracellular distribution of
transduced VLC-1-TAT and correlation of the fluorescent
signals with the phase contrast images (merge image, lower
panel, Fig. 3c) demonstrated that the peptide associates
with sarcomeric structures. It showed strong enrichment at
the I-bands representing the nonoverlapping zones of the
thin actin filaments with the thick myosin filaments
(linescan, lower panel, Fig. 3c). After transduction, the
VLC-1-TAT peptide remained inside the sarcomeric compart-
ments of the cardiomyocytes for at least 1 h after transferring
the loaded cardiomyocytes into the peptide-free buffer
solution.
Using the same incubation protocol, we studied the
effects of the cell-permeable VLC-1 peptide on muscle
function by simultaneously monitoring the shortening
amplitude and the systolic and diastolic cytoplasmic Ca2+
fluctuations (measured by Fura-2 fluorescence) of paced
adult rat cardiomyocytes (Fig. 4a). As shown in Figs. 4b
and c, 1 μM, but not 0.5 μM, of VLC-1-TAT significantly
increased the shortening amplitude of adult cardiomyocyte,
while the cytosolic Ca2+ signal remained unchanged. The
same concentrations of control TAT peptide alone did not
change the contractile state or the Fura-2 signals if
compared to the basal state during the preincubation period.
Higher concentrations of both control and test peptides
induced deleterious effects on the cardiomyocyte contrac-
tion. It is interesting to note that not only the maximal
amplitude of shortening rose but also the maximal rate of
shortening and the maximal relaxation velocity increased
significantly. Because the Fura-2 signal remained un-
changed, the selective effect of the VLC-1-TAT peptide
on the contraction parameters suggests a selective and
direct effect on the function of the myosin cross-bridges.
The Ca2+-sensitizing effect of the VLC-1-TAT peptide
could be predicted from the mechanism of action, as the
inhibition of the MLC-1/actin interaction may rise selec-
tively myosin motor activity and therefore muscle contrac-
tion at a given activating free Ca2+ concentration, i.e., an
inotropic effect without additional recruitment of Ca2+. It
should be noted that the VLC-1-TAT peptide left the
intracellular Ca2+-handling system unchanged, as seen by
the fact that the kinetic parameters of the Fura-2 fluores-
cence signals remained normal (Fig. 4c).
In summary, we demonstrate by live-cell microscopy
that CPPs and CPPs fused to peptides were taken up by
adult cardiomyocytes with high efficiency and localize to
their targets inside the cytoplasm and/or nucleus. The cell-
permeable peptide VLC-1-TAT accumulated in the actin-
containing I-band of the sarcomeres and was able to
enhance the contractility of isolated adult cardiomyocytes
without changing the myoplasmic Ca2+ levels. Importantly,
the fact that VLC-1-TAT did not affect intracellular Ca2+
concentration and that it only has targets in striated muscle
cells makes this peptide uniquely suited as a novel potential
therapeutic tool to modulate heart function. VLC-1-TAT is a
powerful new drug candidate to improve the contractile
state of the failing heart.
Acknowledgments We thank W.-P. Schlegel and P. Pierschalek for
technical assistance, R.M. Martin for invaluable help with confocal
microscopy, and Jeff Stear for comments. G.T. was supported by the
European Union (ESF Program). This work was funded in part by
grants of the Deutsche Forschungsgemeinschaft and the Volkswagen
Foundation to M.C.C and Deutsche Forschungsgemeinschaft to I.M.
References
1. Alvarez J, Hamplova J, Hohaus A, Morano I, Haase H, Vassort G
(2004) Calcium current in rat cardiomyocytes is modulated by
the carboxyl-terminal ahnak domain. J Biol Chem 279:12456–
12461
2. Aydt EM, Wolff G, Morano I (2007) Molecular modeling of the
myosin-S1(A1) isoform. J Struct Biol. 159:158–163
3. Bottinelli R, Betto R, Schiaffino S, Reggiani C (1994) Unloaded
shortening velocity and myosin heavy chain and alkali light chain
isoform composition in rat skeletal muscle fibres. J Physiol 478(Pt
2):341–349
4. Brandman R, Disatnik MH, Churchill E, Mochly-Rosen D (2007)
Peptides derived from the C2 domain of protein kinase C epsilon
(epsilon PKC) modulate epsilon PKC activity and identify
potential protein-protein interaction surfaces. J Biol Chem
282:4113–4123
5. Cardoso MC, Leonhardt H (2002) Protein transduction: a novel
tool for tissue regeneration. Biol Chem 383:1593–1599
6. Chalovich JM, Stein LA, Greene LE, Eisenberg E (1984)
Interaction of isozymes of myosin subfragment 1 with actin:
effect of ionic strength and nucleotide. Biochemistry 23:4885–
4889
7. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D,
Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW 2nd, Mochly-
Rosen D (2001) Opposing cardioprotective actions and parallel
hypertrophic effects of delta PKC and epsilon PKC. Proc Natl
Acad Sci USA 98:11114–11119
8. Chen L, Wright LR, Chen CH, Oliver SF, Wender PA, Mochly-
Rosen D (2001) Molecular transporters for peptides: delivery of a
cardioprotective epsilonPKC agonist peptide into cells and intact
ischemic heart using a transport system, R(7). Chem Biol 8:1123–
1129
9. Chen M, Won DJ, Krajewski S, Gottlieb RA (2002) Calpain and
mitochondria in ischemia/reperfusion injury. J Biol Chem
277:29181–29186
10. Choi M, Rolle S, Wellner M, Cardoso MC, Scheidereit C, Luft FC,
Kettritz R (2003) Inhibition of NF-kappaB by a TAT-NEMO-
binding domain peptide accelerates constitutive apoptosis and
abrogates LPS-delayed neutrophil apoptosis. Blood 102:2259–2267
11. Derossi D, Chassaing G, Prochiantz A (1998) Trojan peptides: the
penetrating system for intracellular delivery. Trends Cell Biol 8:84–87
12. Dietz GP, Bahr M (2004) Delivery of bioactive molecules into the
cell: the Trojan horse approach. Mol Cell Neurosci 27:85–131
J Mol Med (2007) 85:1405–1412 1411
13. Dom G, Shaw-Jackson C, Matis C, Bouffioux O, Picard JJ,
Prochiantz A, Mingeot-Leclercq MP, Brasseur R, Rezsohazy R
(2003) Cellular uptake of Antennapedia Penetratin peptides is a
two-step process in which phase transfer precedes a tryptophan-
dependent translocation. Nucleic Acids Res 31:556–561
14. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B,
Barsoum J (1994) Tat-mediated delivery of heterologous proteins
into cells. Proc Natl Acad Sci USA 91:664–668
15. Fisher AJ, Smith CA, Thoden JB, Smith R, Sutoh K, Holden HM,
Rayment I (1995) X-ray structures of the myosin motor domain of
Dictyostelium discoideum complexed with MgADP.BeFx and
MgADP.AlF4. Biochemistry 34:8960–8972
16. Fodor WL, Darras B, Seharaseyon J, Falkenthal S, Francke U,
Vanin EF (1989) Human ventricular/slow twitch myosin alkali
light chain gene characterization, sequence, and chromosomal
location. J Biol Chem 264:2143–2149
17. Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein
from human immunodeficiency virus. Cell 55:1189–1193
18. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K,
Sugiura Y (2001) Arginine-rich peptides. An abundant source of
membrane-permeable peptides having potential as carriers for
intracellular protein delivery. J Biol Chem 276:5836–5840
19. Geeves MA, Holmes KC (1999) Structural mechanism of muscle
contraction. Annu Rev Biochem 68:687–728
20. Green M, Loewenstein PM (1988) Autonomous functional
domains of chemically synthesized human immunodeficiency
virus tat trans-activator protein. Cell 55:1179–1188
21. Haase H, Dobbernack G, Tunnemann G, Karczewski P, Cardoso
C, Petzhold D, Schlegel WP, Lutter S, Pierschalek P, Behlke J,
Morano I (2006) Minigenes encoding N-terminal domains of
human cardiac myosin light chain-1 improve heart function of
transgenic rats. FASEB J 20:865–873
22. Hauber J, Malim MH, Cullen BR (1989) Mutational analysis of
the conserved basic domain of human immunodeficiency virus tat
protein. J Virol 63:1181–1187
23. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF
(2001) Synthetic protein transduction domains: enhanced
transduction potential in vitro and in vivo. Cancer Res
61:474–477
24. Inagaki K, Hahn HS, Dorn GW 2nd, Mochly-Rosen D (2003)
Additive protection of the ischemic heart ex vivo by combined
treatment with delta-protein kinase C inhibitor and epsilon-protein
kinase C activator. Circulation 108:869–875
25. Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD (2002)
Efficiency of protein transduction is cell type-dependent and is
enhanced by dextran sulfate. J Biol Chem 277:30208–30218
26. Ono M, Sawa Y, Ryugo M, Alechine AN, Shimizu S, Sugioka R,
Tsujimoto Y, Matsuda H (2005) BH4 peptide derivative from Bcl-
xL attenuates ischemia/reperfusion injury thorough anti-apoptotic
mechanism in rat hearts. Eur J Cardiothorac Surg 27:117–121
27. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ,
Chernomordik LV, Lebleu B (2003) Cell-penetrating peptides. A
reevaluation of the mechanism of cellular uptake. J Biol Chem
278:585–590
28. Rohrbach S, Muller-Werdan U, Werdan K, Koch S, Gellerich NF,
Holtz J (2005) Apoptosis-modulating interaction of the neuregu-
lin/erbB pathway with anthracyclines in regulating Bcl-xS and
Bcl-xL in cardiomyocytes. J Mol Cell Cardiol 38:485–493
29. Ruben S, Perkins A, Purcell R, Joung K, Sia R, Burghoff R,
Haseltine WA, Rosen CA (1989) Structural and functional
characterization of human immunodeficiency virus tat protein. J
Virol 63:1–8
30. Ryser HJ, Hancock R (1965) Histones and basic polyamino acids
stimulate the uptake of albumin by tumor cells in culture. Science
150:501–503
31. Seharaseyon J, Bober E, Hsieh CL, Fodor WL, Francke U, Arnold
HH, Vanin EF (1990) Human embryonic/atrial myosin alkali light
chain gene: characterization, sequence, and chromosomal loca-
tion. Genomics 7:289–293
32. Smith CA, Rayment I (1996) X-ray structure of the magnesium
(II).ADP.vanadate complex of the Dictyostelium discoideum
myosin motor domain to 1.9 A resolution. Biochemistry
35:5404–5417
33. Tunnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F,
Cardoso MC (2006) Cargo-dependent mode of uptake and
bioavailability of TAT-containing proteins and peptides in living
cells. FASEB J 20:1775–1784
34. Zhang M, Kho AL, Anilkumar N, Chibber R, Pagano PJ, Shah
AM, Cave AC (2006) Glycated proteins stimulate reactive oxygen
species production in cardiac myocytes: involvement of Nox2
(gp91phox)-containing NADPH oxidase. Circulation 113:1235–
1243
35. Ziegler A, Blatter XL, Seelig A, Seelig J (2003) Protein
transduction domains of HIV-1 and SIV TAT interact with charged
lipid vesicles. Binding mechanism and thermodynamic analysis.
Biochemistry 42:9185–9194
1412 J Mol Med (2007) 85:1405–1412
Chapter 2                                                                                                Results 
 73
2.6 Cargo-dependent mode of uptake and bioavailability of 
TAT-containing proteins and peptides in living cells. 
 
The FASEB Journal • Research Communication
Cargo-dependent mode of uptake and bioavailability of
TAT-containing proteins and peptides in living cells
Gisela Tu¨nnemann,* Robert M. Martin,* Simone Haupt,† Christoph Patsch,†
Frank Edenhofer,† and M. Cristina Cardoso*,1
*Max Delbru¨ck Center for Molecular Medicine, Berlin, Germany; and †Institute of Reconstructive
Neurobiology, Stem Cell Engineering Group, University of Bonn-Life and Brain Center and Hertie
Foundation, Bonn, Germany
ABSTRACT Cell-penetrating peptides (CPPs) are ca-
pable of introducing a wide range of cargoes into living
cells. Descriptions of the internalization process vary
from energy-independent cell penetration of mem-
branes to endocytic uptake. To elucidate whether the
mechanism of entry of CPP constructs might be influ-
enced by the properties of the cargo, we used time
lapse confocal microscopy analysis of living mamma-
lian cells to directly compare the uptake of the well-
studied CPP TAT fused to a protein (>50 amino acids)
or peptide (<50 amino acids) cargo. We also analyzed
various constructs for their subcellular distribution and
mobility after the internalization event. TAT fusion
proteins were taken up largely into cytoplasmic vesicles
whereas peptides fused to TAT entered the cell in a
rapid manner that was dependent on membrane poten-
tial. Despite their accumulation in the nucleolus, pho-
tobleaching of TAT fusion peptides revealed their
mobility. The bioavailability of internalized TAT pep-
tides was tested and confirmed by the strong inhibitory
effect on cell cycle progression of two TAT fusion
peptides derived from the tumor suppressor p21WAF/Cip
and DNA Ligase I measured in living cells.—Tu¨nne-
mann, G., Martin, R. M., Haupt, S., Patsch, C., Eden-
hofer, F., Cardoso, M. C. Cargo-dependent mode of
uptake and bioavailability of TAT-containing proteins
and peptides in living cells. FASEB J. 20, 1775–1784
(2006)
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 PCNA  PBD  Cre recombinase
The phenomenon of transduction denotes the size-
independent in vivo delivery of a wide variety of cargoes
into cells and is mediated by cell-penetrating peptides
(CPPs). Although the internalization of fluorophores,
nucleotides, peptides, globular proteins, nanoparticles,
lipids, and drugs interconnected to CPPs into living
cells has been described in the literature and resulted
in measurable biological effects (1), the reported trans-
duction experiments need to be critically evaluated in
terms of the invasiveness of the detection methods
utilized (2). Most known CPPs are parts of viral proteins
or artificial derivatives thereof, and include several
arginines and/or lysines (reviewed in ref. 3). One of
the best-studied CPP is a basic amino acid peptide from
the transactivator of transcription (TAT) protein of the
HIV-1 with the minimal transduction domain compris-
ing amino acids 48–57 (4). The initializing step in the
mechanism of cellular entry of CPPs is thought to be
the strong ionic interaction between the positively
charged amino acid residues and negatively charged
plasma membrane constituents (5–7). Among the cat-
ionic groups mediating cellular uptake, the guani-
dinium group of arginine has been shown to be the
most effective (8–10). Subsequent events needed for
the internalization, however, differ between reports
and are often conflicting. The first mechanistic studies
led to the proposal that CPP internalization occurs
rapidly in a receptor- and energy-independent manner
(6, 9, 11–13) perhaps by destabilizing the lipid bilayer
or by the formation of inverted micelles with subse-
quent release of their contents within the intracellular
space (reviewed in ref. 14). More recently, an active
mechanism based on vesicular uptake has been pro-
posed as the general mode of internalization of CPP
constructs into cells (15–19).
To understand whether the mechanism of entry is
dependent on the cargo connected to the CPP, we
directly compared TAT fused to globular proteins and
TAT-containing peptides with respect to their uptake
kinetics and their intracellular distribution after inter-
nalization in living cells. Transduced constructs were
also analyzed for their ability to reach their targets
inside the cell and to exert their biological activity.
MATERIALS AND METHODS
Peptides and proteins
Peptides (complete description in Table 1) were synthesized
by Biosyntan GmbH (Berlin, Germany), Peptide Specialty
Laboratories (Heidelberg, Germany), and Bachem (Weil am
1Correspondence: Max Delbru¨ck Center for Molecular
Medicine, Robert-Ro¨ssle-Str. 10, Berlin 13125, Germany. E-
mail: cardoso@mdc-berlin.de
doi: 10.1096/fj.05-5523com
17750892-6638/06/0020-1775 © FASEB
Rhein, Germany). The PCNA binding domain (PBD) peptide
TAT-p21-PBD is derived from human p21WAF/Cip (20) and
the Lig1-PBD as well as TAT-Lig1-PBD from mouse DNA
Ligase I (21, 22). The peptides were analyzed by HPLC a
second time at the end of the experiments to assure their
stability under the storage conditions. The pI of the peptides
was calculated using the program ProtParam (http://au.
expasy.org/cgi-bin/protparam). His-NLS-TAT-Cre-recombinase
(TAT-Cre) protein was produced, purified (23), and labeled
with Alexa Fluor 633 or rhodamine as described (24).
BL21(DE3) cells (Novagen, Madison, WI, USA) were used for
production of His-PTD4-PCNA. Bacterial cultures were grown
at 37°C until early-mid log phase and expression was induced
by addition of 1 mM IPTG. Cells were harvested 3 h after
induction, lysed by lysozyme treatment and ultrasonification,
and His-tagged protein purified to 95% purity from cell
lysates by affinity chromatography using Talon resin material
(BD Bioscience, Franklin Lakes, NJ, USA) according to the
manufacturer’s instructions. The purified protein was labeled
with Atto 633 NHS ester (Fluka, St. Louis, MO, USA) in 0.1 M
bicarbonate buffer pH 8.5, then further purified and rebuffered
into PBS pH 7.4 over a G25-Sephadex column (Pharmacia,
Cambridge, MA, USA). BL21(DE3) CodonPlus-RIL cells (No-
vagen) were used to produce His-TAT-MK2 (MAPKAP kinase
2). Bacterial cultures were grown and induced as above, and
harvested cells were disrupted by 2-fold homogenization at a
1000 bar with a SLM AMINCO FrenchPress (Spectronic
Instruments, Leeds, UK). More than 98% pure protein was
obtained from the lysates upon Talon affinity chromatogra-
phy, as before (BD Bioscience). The purified protein was
labeled with Cy5 NHS ester (Amersham Bioscience, Arlington
Heights, IL, USA) in 0.1 M bicarbonate buffer pH 8.5, then
further purified and rebuffered into PBS pH 7.4 over a
G25-Sephadex column (Pharmacia). The Cy5-labeled strepta-
vidin (Amersham) was incubated for 30 min prior to the
experiments with NLS-biotin peptides at molar ratios of 1:1
for biotin and biotin binding sites at homotetrameric strepta-
vidin. The streptavidin-coated Quantum dots 525 were ob-
tained from Quantum dot Corp. (Hayward, CA, USA).
Cell culture
The C2C12 mouse myoblast cells and C2C12 mouse myoblasts
stably transfected with GFP-PCNA as a fluorescent cell cycle
marker were cultured as described (25, 26). Flp 3T3 mouse
fibroblasts were from Invitrogen (Carlsbad, CA, USA). 3T3-
FDR1.2 Cre reporter cells (27) were cultured in Dulbecco’s
modified Eagle medium (DMEM) containing 10% fetal calf
serum (Life Technologies, Inc., Grand Island, NY, USA). For
live cell microscopy, cells were plated onto 4- or 8-well LabTek
coverglass chambers (NalgeNunc, Rochester, NY, USA).
Transduction assays and inhibitor treatments
All peptide and protein transduction experiments, except for
the Cre recombinase assay (see below), were performed
exclusively with living cells plated on 4- or 8-well LabTek
coverglass chambers using an objective heated to 37°C. For
transduction experiments, the medium was removed and PBS
with the different peptides or proteins was applied directly to
the cells. After 10 min incubation, PBS was replaced with the
growth medium. Usually uptake was studied continuously
starting with the peptide application over a period of at least
2 h, followed by incubation of the cells at 37°C under
humidified atmosphere until additional image collection.
Transduction efficiencies of peptides were determined by
counting the numbers of cells with or without nucleolar
signals and internalization efficiencies of proteins by count-
ing cells with or without intracellular vesicles directly on the
fluorescence microscope in three fields of view, each contain-
ing 50 cells, or by a similar analysis performed on low
magnification overview images. Cell viability after peptide or
protein application was monitored by their ability to undergo
complete mitotic cell cycles and grow to confluency over a
period of 24 to 48 h. Membrane integrity was ascertained by
the Trypan blue exclusion assay. Cytochalasin D (Sigma, St.
Louis, MO, USA) was dissolved to 10 mg/ml in DMSO and
sodium azide (Sigma) to 10% (w/v) in ddH2O. Both stock
solutions were adjusted to 1PBS at the indicated final
concentrations (Fig. 2) before being applied to living cells.
The potassium buffer (Fig. 2) corresponds to PBS with all
sodium-containing compounds substituted for the equivalent
potassium-containing analogues. C2C12 mouse myoblasts
were preincubated for the indicated times (t in Fig. 2) with
different inhibitors in PBS or the potassium buffer. The
TAT-containing peptide and protein were applied directly to
the cells and mixed gently. For the potassium phosphate
buffer experiment, the protein was dialyzed against the
potassium buffer prior to application. After 10 min the cells
were washed twice and incubated for another 20–60 min (as
annotated in the phase contrast images for each treatment)
in DMEM medium, except for the potassium buffer treatment
where the medium was replaced by potassium buffer. Trans-
duction thresholds were determined by incubating C2C12
mouse myoblasts with CPP-containing peptides in medium at
different concentrations ranging from 0.1 to 500 M for 1 h.
The lowest peptide concentration leading to accumulation
TABLE 1. List of peptides and their uptake efficienciesa
Peptide and label aa sequence kDa pI
Peptide
concentration
Transduction
efficiency
Transduction
threshold
R-PTD4 YARAARQARA 1.13 11.71 10 m 0% 400 m
F(Ahx)-TAT YGRKKRRQRRR 1.93 12.31 1 m 90% 1 m
R-TAT (ri) rrrqrrkkrg 1.81 13.3 1 m 90% 1 m
bt-NLS SGYGPKKKRKVGG 1.93 10.68 10 m 0% n.a.
Lig1-PBD-F MQRDIMSFFQPTKEFKAKK 2.80 10.00 10 m 0% n.a.
R-TAT-HA2(ri) rrrqrrkkrg-gdimgewgneifgaiagflg 3.24 11.71 10 m 80% 0.1 m
F(Ahx)-TAT-Control YGRKKRRQRRR-TALDASALQTE 3.05 11.72 20 m 70% n.d.
R-TAT(ri)-p21-PBD rrrqrrkkrg-aaA-
GRKRRQTSMTDFYHSKRRLIFSa
4.96 12.43 20 m 90% 7.5 m
TAT-Lig1-PBD-R YGRKKRRQRRR-GGG-
MQRSIMSFFQPTKEGKAKK
4.38 12.14 10 m 80% 5 m
aR, TAMRA/rhodamine; F, FITC; Ahx, aminohexanoic acid; capital letters, L-amino acids; small letters, D-amino acids; ri, retro inverso; n.a., not
applicable; n.d., not determined.
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inside nucleoli was considered to be the transduction thresh-
old from which transduction occurs.
Microinjection and bead loading
Intracellular delivery of the Lig1-PBD-F peptide was accom-
plished by bead loading using 100 m silica beads. The beads
were washed first in ethanol, then in growth medium, and
finally pipetted onto the medium of cells grown in a self-made
culture dish with a coverglass bottom. The Lig1-PBD-F solu-
tion was added subsequently and the chamber was shaken a
few times. The beads were removed for microscopic observa-
tion of the labeled cells. Microinjection of the NLS-biotin
peptide complexed with streptavidin-Cy5 was performed us-
ing an Eppendorf microinjection and micromanipulation
system mounted on a Zeiss LSM510Meta inverted microscope
setup. The parameters for cytoplasmic microinjection were
set to 0.7 s injection time with 15 fPa injection pressure.
Cre recombinase double reporter assay
3T3-FDR1.2 cells (27) were cultured to 50% confluency in
6-well plates. The pFDR reporter gene construct allows detec-
tion of bioactive Cre recombinase by switching from consti-
tutive HcRed to GFP expression (Fig. 1 D). For transduction,
the cells were incubated with 2 M TAT-Cre protein diluted
into a 50:50 mixture of PBS and DMEM for 3 h, washed once
with PBS, then cultivated in normal medium. Fluorescence
microscopy was performed 24 h after transduction.
Live cell assay for cell cycle inhibition
C2C12 mouse myoblasts stably expressing GFP-PCNA (26)
were synchronized by mitotic shake-off and plated onto 8-well
LabTek coverglass chambers. After becoming adherent, the
number of cells that entered S-phase was counted and cells
Figure 1. Differences in subcellular distribution of proteins
and peptides fused to TAT after internalization in living cells.
TAT-Cre and TAT-HA2 were applied to the cells for 10 min,
followed by a washing step and change to growth medium
without the protein/peptide. Confocal microscopy of live
cells was started immediately and cells were returned to the
incubator between time points, which are indicated. Repre-
sentative images and time points are shown. A) Uptake of 2.5
M TAT fusion protein TAT-Cre (rhodamine-labeled) in
living mouse myoblasts. After application of TAT-Cre, inter-
nalization started throughout the plasma membrane in the
form of vesicles. The next day vesicles containing fluorescent
TAT-Cre accumulated in the cytoplasm. B) Diffused and
vesicular distribution of the TAT-HA2 peptide (rhodamine-
labeled, 5 M final concentration) soon and a long time after
application. C) Simultaneous application of 2.5 M TAT-Cre
protein (Alexa Fluor 633-labeled; 1.7 label to protein ratio)
and 5 M TAT-HA2 peptide (rhodamine-labeled) on living
cells resulted in prominent vesicular uptake of the protein
into the cytoplasm, whereas the TAT-HA2 peptide also dis-
plays a diffuse distribution in cytoplasm and nucleoplasm,
and accumulation in nucleoli. The fluorescent fusions colo-
calize in the majority of vesicles. Nucleoli are indicated by
arrowheads. Scale bar  10 m. D) Analysis of Cre recombi-
nase activity in TAT-Cre-treated reporter cells. 3T3-FDR1.2
reporter cells contain a loxP-flanked HcRed gene, followed by
a nonexpressed GFP gene. TAT-Cre treatment induces re-
combination of the reporter gene, resulting in a shift from
red to green fluorescence (scheme). Untreated control cells
do not exhibit green fluorescence. Cells were incubated with
2 M TAT-Cre for 3 h and analyzed by fluorescence micros-
copy 24 h later. Scale bar  50 m.
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were transduced with fluorescently labeled TAT-p21-PBD,
TAT-Lig1-PBD, and the unspecific TAT control peptide at 20
M concentration in PBS. 10 min later the solutions were
aspirated, and the cells were washed twice with medium and
kept in growth medium thereafter. The percentage of cells in
S-phase was determined directly from the subnuclear focal
pattern of GFP-PCNA by counting 10 fields of view at the
indicated time points for each peptide. Data of three inde-
pendent experiments were evaluated.
Microscopy, image acquisition, and analysis
Live cell microscopy was performed with a Zeiss LSM 510
Meta confocal setup mounted on an Axiovert 200 M inverted
microscope using a 63  phase contrast plan apochromat oil
objective NA1.4. For all acquisition settings, the main beam
splitter was HFT UV/488/543/633. The parameters specific
for each fluorochrome were: FITC, excited at 488 nm light,
detected with a 500-530 nm bandpass (BP) filter; TAMRA or
rhodamine excited with 543 nm, detected with 565-615 BP
and Cy5 or Alexa633 excited at 633 nm and detected with a
650 nm longpass filter.
Image acquisition was done sequentially to minimize cross-
talk between the fluorophores. Phase contrast images were
recorded simultaneously with FITC/GFP fluorescence in the
transmission channel. Fluorescence recovery after bleaching
(FRAP) experiments (Fig. 3) was performed on a Zeiss LSM
5 Live confocal microscope with 100% power of a 75 mW
DPSS 532 nm laser. The bleaching was performed in a stripe
for 0.44 s, followed by a time series with 400 images recorded
at 20 frames per second. Using the Zeiss LSM 510 software
version 3.2, the mean fluorescence intensity in the bleached
nucleoli and cytoplasm was determined over the time course
and averaged for 10 cells. Fluorescence intensity was normal-
ized to zero at the start of recovery and to one at equilibrium
to directly compare the curves for both subcellular regions.
The FRAP curves were generated with Origin 7 software.
RESULTS
Direct comparison of TAT-mediated peptide and
protein uptake in living cells
To study the characteristics of TAT-mediated introduc-
tion of globular proteins into living cells, the rhoda-
mine-labeled fusion protein R-TAT-Cre consisting of
the CPP TAT moiety and the site-specific Cre recombi-
nase of bacteriophage P1 (23) was applied onto C2C12
mouse myoblasts. As soon as the fluorescent solution
was washed off (after 10 min of incubation), fluores-
cent vesicles emerging from the intracellular side of the
plasma membrane were detectable by confocal micros-
copy (Fig. 2A, upper panel). After additional overnight
cultivation, all cells showed a substantial amount of
internalized protein stored in vesicles, but release of
the protein from the vesicles could not be detected by
this method (Fig. 2A, lower panel). Other recombinant
proteins showed identical trapping in cytoplasmic vesi-
cles (data not shown) independent of 1) which short
basic CPP they were fused to, 2) the fluorophore they
were conjugated to, and 3) their known subcellular
localization. For instance the nuclear protein His-PTD4-
PCNA (Atto 633-labeled) as well as the nuclear and
cytoplasmic protein His-TAT-MK2 (Cy5-labeled) could
only be detected inside cytoplasmic vesicles after inter-
nalization, and refused to localize at their targets
during an observation period of up to 48 h. Proteins
lacking a transduction domain could also be internal-
ized in the same manner but the efficiency of internal-
ization was shown to be much lower (23). TAT-Cre was
also tested at concentrations between 0.1 and 10 M with
no difference in the uptake behavior (data not shown).
A recent report proposed that the uptake of proteins
fused to TAT belongs to the class of rapid lipid raft-
mediated macropinocytosis and that the protein could
be released from macropinosomes by cotransduction of
the fusogenic peptide TAT-HA2 (17). We therefore
used TAT-HA2 (Table 1) to 1) work out the character-
istics of TAT-mediated peptide (50 amino acids; ref.
28) transduction and 2) try and liberate the TAT fusion
protein trapped into vesicles. Compared to the inter-
nalization of proteins, uptake of the TAT-HA2 peptide
occurred on a quite different time scale and also
showed dissimilarities in its subcellular localization.
During the first 3–5 min of incubation with the peptide
Figure 2. Different mode of uptake of proteins and peptides
fused to TAT in living cells. Simultaneous incubation of living
mouse myoblasts with 2.5 M TAT-Cre and 5 M TAT-HA2
was as shown in Fig. 2C. Confocal images show representative
snapshots at the indicated time points in the phase contrast
image. The numbers in the images reflect the overall percent-
age of cells showing intracellular vesicles for the TAT fusion
protein and the nucleolar signal for the TAT-HA2 peptide.
Substances at the concentrations indicated were preincu-
bated with the cells before addition of the TAT fusions for the
indicated time (t) and kept in the culture medium or buffer
throughout the experiment. A) Control C2C12 mouse myo-
blasts treated with the TAT-containing protein and peptide
mixture showed internalization in 100% and 90% of the cells,
respectively. B) Preincubation of the cells with 100 M of the
F-actin elongation inhibitor cytochalasin D blocked protein
uptake completely, but the peptide still transduced into the
cells. C) ATP depletion with 10 mM sodium azide reduced
entry of both species, albeit a third of the cells still took up the
peptide. D) 5 min incubation of the cells in sodium-deficient,
iso-osmolar PBS strongly reduced peptide transduction and
blocked protein uptake. tpreincubation time, scale bar10m.
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solution, fluorescence signals had already become visi-
ble in the nucleoli; after exchange of the fluorescent
solution against medium, a diffuse distribution
throughout the cell, with accumulation in the nucleoli,
could be detected (Fig. 2B, upper panel, arrowheads;
see also supplemental movie) in addition to a few
developing vesicles adjacent to the membranes. Over
longer periods of observation, the diffuse population of
the peptide in the cytoplasm, nucleoplasm, and nucle-
oli became markedly weaker, and in most of the cells
vanished overnight. In stark contrast, the peptide-
containing cytoplasmic vesicles seemed to be unaf-
fected and their number increased overnight, resulting
in a vesicular ring concentrated around the nucleus
(Fig. 2B, lower panel). The diffusely distributed frac-
tion of the transduced peptide was detected in 90%
of the cells (Table 1) whereas after overnight incuba-
tion all cells showed peptide uptake into vesicles. The
loss of diffusely distributed fluorescent peptide in the
cytoplasm and nuclei overnight cannot be just a conse-
quence of instability of the fluorophore/peptide in the
cell since 1) a rhodamine-labeled antibody (Ab) per-
sisted inside cells for  24 h (data not shown) and 2)
the fluorescently labeled peptide TAT-HA2 is com-
posed of protease-resistant D-amino acids.
To directly compare the mode and kinetics of uptake
of TAT peptides and globular proteins fused to TAT
into cells and determine whether TAT-HA2 could drive
release of the protein stored in macropinosomes, the
Alexa Fluor 633-labeled TAT-Cre protein and the rho-
damine-labeled TAT-HA2 peptide were applied simul-
taneously to living cells. The short- and long-term
uptake characteristics for both species remained mostly
unchanged (Fig. 2C). Detectable TAT fusion protein
was restricted to cytoplasmic vesicles whereas the TAT-
HA2 peptide, besides being trapped into vesicles, was
rapidly distributed throughout the entire cell. TAT-
HA2 and TAT-Cre colocalized in the majority of cyto-
plasmic vesicles (Fig. 2C, yellow color in merged images).
Although both species intermingled substantially, a re-
lease of the TAT fusion protein from macropinosomes
and entry into the nucleus could not be detected by this
method. To test the presence of a low level of TAT-Cre
within the nucleus, we used a far more sensitive reporter
assay based on Cre-mediated recombination. Since site-
specific recombination provides a stable and unambigu-
Figure 3. Subcellular localization and intracellular
mobility of TAT peptides. A) FITC- and rhoda-
mine-labeled TAT peptides (F-TAT 1 M, R-TAT 1
M) applied to mouse myoblasts were rapidly
internalized and accumulated in the nucleoli
(white arrowheads). The fluorescent label has no
influence on peptide distribution. B) In contrast,
the non-TAT-containing peptide Lig1-PBD (FITC-
labeled) delivered by bead loading showed a ho-
mogeneous distribution in nucleus and cytoplasm
whereas the addition of the TAT sequence in
TAT-Lig1-PBD (rhodamine-labeled) again led to
nucleolar accumulation. C) Mouse myoblasts were
transduced with 20 M of TAMRA-labeled TAT-
p21-PBD for 10 min, washed, then incubated in
growth medium. The FRAP experiment was per-
formed by bleaching a stripe (ba) encompassing
one nucleolus and a part of the cytoplasm as seen
in the prebleach image. After bleaching, a time
series was recorded at a time resolution of 20
frames/second over 20 s. False color images de-
picting the fluorescence intensity distribution as
color map (red denotes highest intensity) of one
photobleached cell are shown. The black arrow-
heads point to the bleached nucleolus and cyto-
plasmic regions in the first image after the bleach-
ing process (postbleach) and after full fluorescence
recovery (postrecovery). D) Curves represent the
normalized mean fluorescence intensity of the
fluorescence recovery in the nucleoli and cyto-
plasm averaged for 10 measurements. Albeit accu-
mulated in the nucleoli, the TAT-p21-PBD peptide
was highly mobile with a half-time of recovery of
1.98  0.097 s. In the cytoplasm, the half-time of
recovery is faster (1.170.013 s). Scale bar 5 m.
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ous read-out for protein transduction (23, 29–31), we
used a NIH-3T3 Cre reporter cell line containing a stably
integrated gene cassette consisting of a constitutively
expressed HcRed gene, followed by a nonexpressed GFP
gene. Upon Cre recombinase-mediated site-specific re-
combination, excision of the HcRed gene takes place with
concomitant expression of the GFP gene (Fig. 2D; L.
Nolden and F. Edenhofer, personal communication).
Using this more sensitive assay, several cells within the
culture exhibited GFP expression upon incubation with
TAT-Cre overnight (Fig 2D). These data indicate that a
low level of TAT-Cre below the detection range of confo-
cal microscopy was biologically available and could exert
its enzymatic activity.
Different mode of entry of proteins and peptides
fused to TAT in living cells
To test whether TAT fusion proteins and TAT-contain-
ing peptides use different routes of entry and can, as a
result, be affected differently in their uptake by treat-
ment with inhibitors, mouse myoblasts were preincu-
bated with inhibitors or buffers, followed by simulta-
neous application of TAT-Cre and TAT-HA2 (as in Fig.
2C). Subsequently, cells were washed twice and kept in
the indicated buffer or medium with constant inhibitor
concentration throughout the entire experiment.
Endocytosis requires the formation and migration of
vesicles along the cytoskeleton. Therefore, constant
concentrations of the F-actin depolymerizing drug cy-
tochalasin D should delay or block internalization of
the endocytosed TAT constructs at the membrane level
(32, 33). After cytochalasin D treatment, the TAT
fusion protein and TAT-HA2 showed strong membrane
association, but the diffused fraction of the TAT-HA2
peptide was still detectable inside the cells in nucleoli,
albeit the transduction efficiency (as scored by the
percentage of cells showing intracellular fluorescence)
was reduced to half. All vesicular uptake was abolished
(Fig. 1B). Despite the round appearance of the cells
indicative of the disruptive effect of the drug on the
actin cytoskeleton, the membrane integrity was not
decreased as assayed by Trypan blue exclusion (data
not shown).
Endocytosis is an energy-consuming process and is
therefore blocked by the metabolic inhibitor sodium
azide. Accordingly, treatment with 10 mM sodium azide
resulted in almost complete inhibition of the internal-
ization of the TAT fusion protein (scored by the
absence of intracellular vesicles), whereas the diffused
population of the TAT-HA2 was still detected in about
one-third of the cells (Fig. 1C).
A recent report proposed that synthetic guani-
dinium-rich molecules traverse biological membranes
by formation of lipophilic ion pairs between the guani-
dinium groups and abundant phosphate, sulfate, and
carboxylate functions on the membrane surface, allow-
ing cell entry by diffusion along the membrane poten-
tial and subsequent release of the positively charged
CPP into the cytoplasm (5, 10). The directionality of
this process is achieved by the membrane potential and
the latter can be efficiently reduced by addition of an
isotonic buffer with potassium concentrations equiva-
lent to those found intracellularly (34, 35). We tested
this hypothesis by preincubating the cells for 5 min with
potassium-enriched, isotonic PBS and adding the pep-
tide/protein solution in the same buffer. This treat-
ment abolished the vesicular internalization of both
TAT species. Furthermore, it resulted in strong inhibi-
tion of the uptake mode responsible for the intracellu-
larly diffused fraction of TAT-HA2 (Fig. 1D). In sum-
mary, in contrast to TAT fused to globular proteins,
TAT fusion peptides transduce into cells by a different
and very rapid mode that is dependent on the plasma
membrane potential. We therefore further investigated
the transduction potential and biological applicability
of TAT fusion peptides.
Uptake and intracellular availability of TAT-
containing peptides
In the first minutes of incubation, the TAT-HA2 pep-
tide flooded into living cells and accumulated in nucle-
oli; later it was also localized in cytoplasmic vesicles
(Fig. 2B, C). To test whether these uptake characteris-
tics were influenced by the HA2 moiety or instead were
a general feature of TAT-mediated peptide internaliza-
tion, several TAT peptide complexes were analyzed for
their transduction behavior and intracellular distribu-
tion after internalization. Table 1 summarizes the pep-
tides and their respective transduction efficiencies de-
termined, as earlier, by counting the percentage of cells
showing intracellular diffused fluorescence upon 10
min incubation with the indicated peptide concentra-
tions and analyzed by confocal microscopy of living
cells. The most efficient peptide was the 11 amino acid
TAT peptide covalently linked to either a FITC (F) or a
rhodamine (R) fluorophore, which was transduced
into 90% of all cells at 1 M concentration within the
first 3 min of observation. The fluorescent signal ap-
peared diffused in the cytoplasm and nucleoplasm and
showed strong accumulation of the labeled peptide in
nucleoli (Fig. 3A). To test whether the nucleoli accu-
mulation was due to the TAT moiety, we used non-TAT-
containing peptides (Lig1-PBD in Fig. 3B and NLS-
biotin peptide complexed with streptavidin-Cy5 [data
not shown]) and delivered them into the cytoplasm
using either bead loading or microinjection. Both
peptides were stable intracellularly and able to enter
the nucleus, but were not accumulated in the nucleoli
(Fig. 3B and data not shown). The same Lig1-PBD
peptide fused to TAT (TAT-Lig1-PBD) transduced into
cells and again showed nucleolar localization (Fig 3B),
indicating that the nucleolar localization is dependent
on the TAT characteristics. We investigated other re-
ported CPPs—namely, PTD4 (36)—which showed only
detectable uptake (Table 1) at very high concentrations
(400 M). This suggests that nucleolar association is
mediated by the high concentration of positive charges
due to arginine and lysine residues.
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Since TAT fusion peptides exhibited accumulation
in the nucleolar compartment whereas the cargo pep-
tide or protein may perform its function in a different
subcellular compartment, we tested the overall bioavail-
ability of cargoes connected to TAT by directly measur-
ing the mobility in living cells using fluorescence
photobleaching analysis. Cells transduced with a TAT-
containing peptide (TAT-p21-PBD, Table 1) were im-
aged, and a rectangular region was selected to include
one nucleolus and a stripe of cytoplasm. The peptide
fluorescence in this stripe was subsequently photo-
bleached with a high intensity laser beam, and redistri-
bution of fluorescence was measured over time until
full equilibrium was regained. The peptide intensity
distribution before (prebleach), immediately after
(postbleach), and at full recovery (postrecovery) is
shown in representative false color images in Fig. 3C.
The recovery of fluorescence in the bleached region
indicates the mobility of peptides from unbleached
cellular regions into the bleached area, and therefore is
a direct measure of peptide mobility in the living cells.
The kinetics of recovery (Fig. 3D) indicated that the
peptides, although concentrated in the nucleoli, were
mobile with a half-time of recovery of 1.98 and 1.17 s in
the nucleoli and cytoplasm respectively. This kinetic
difference between nucleoli and cytoplasm suggests
binding of the TAT-PBD-p21 within the nucleoli. The
high intracellular mobility of the TAT peptides raises
the possibility of achieving successful biological effects
despite the unfavorable subcellular accumulation.
Cell cycle inhibition by transduced PCNA binding
peptides
To directly test whether the transduced TAT peptides
in view of their high mobility could be effective in
reaching their intracellular targets and exerting a bio-
logical effect, we used fusions of TAT with two different
peptides comprising the proliferating cell nuclear anti-
gen (PCNA) binding domain (PBD) of p21WAF/CIP and
DNA Ligase 1 (Table 1). These two peptides have been
shown to bind to PCNA (20, 22). We reasoned that
since several PCNA interacting proteins required for
S-phase progression utilize the same binding interface
on the surface of PCNA, competition for binding
should ensue and inhibition of cell cycle progression
would be expected. Mouse myoblasts stably expressing
the cell cycle progression marker GFP-PCNA (26) were
synchronized in the G1 phase of the cell cycle by mitotic
shake off. After becoming adherent, the G1 synchro-
nized cells were incubated for 10 min with either of
these two TAT-PBD peptides as well as a control TAT
fusion peptide (37). After washing, peptide uptake
efficiency was controlled for by counting the percent-
age of cells showing intracellular peptide fluorescent
signal as before. At different times thereafter, the ability
of cells to progress into S-phase was determined by
counting the number of S-phase cells scored by the
characteristic focal GFP-PCNA subnuclear distribution
pattern (see green subnuclear signal in the examples
shown in images in Fig. 4 and ref. 26) directly under
the fluorescent microscope. The results of this live cell
cycle assay are summarized in Fig. 4. While 70% control
cells and cells incubated with TAT control peptide were
in S-phase 6 h after peptide incubation, only 40%
TAT-PBD-treated cells entered S-phase within the same
time. This inhibition is even more noteworthy if one
considers that the peptides were incubated with the
cells for only 10 min, after which they were washed
away. Toxic effects were not detected by either the
Trypan blue exclusion test or by changes in cell mor-
phology. These data demonstrate that both TAT-PBD
peptides were bioactive and capable of decelerating cell
cycle progression despite the short incubation time and
their accumulation in the nucleolus (see also red
fluorescence peptide signal in the images in Fig. 4).
DISCUSSION
Although it is generally agreed that the first step in the
internalization process of CPP-mediated transduction is
the strong ionic interaction between the cationic CPP
and negatively charged plasma membrane constituents
(6, 15, 38), subsequent steps for CPP-induced cell entry
differ in the recent literature and range from endocytic
(15, 19) to a rapid and energy-independent process (6,
12). Most studies so far have used fixed cell analysis,
which has been shown to result in artificial internaliza-
Figure 4. Effect of transduced PBD-containing TAT peptides
on cell cycle progression. After mitotic shake-off, GFP-PCNA-
expressing mouse myoblasts were allowed to attach and were
incubated with different peptides (20 M) for 10 min,
followed by washing and a change to growth medium. The
percentage of S-phase cells was determined at various time
points by the subnuclear replication foci pattern of GFP-
PCNA. Representative confocal microscopy images of mouse
myoblasts transduced with the TAMRA-labeled TAT-p21-PBD
peptide (red) show either a diffused distribution of GFP-
PCNA (green) in the nucleus, indicating G1- or G2-phase or
focal GFP-PCNA labeling of replication foci during early, mid
and late S-phase. Data points of three independent experi-
ments were fitted logarithmically. Control cells, pink squares;
TAT control peptide, green spheres; TAT-Lig1-PBD peptide,
yellow triangles; and TAT-p21-PBD peptide, blue diamonds.
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tion of CPP-containing constructs. In this work we used
exclusively live cell analysis and tested whether the
mode of entry is dependent on the cargo connected to
the CPP and what the fate and bioavailability of the
transduced peptides is.
By directly comparing the uptake of TAT connected
to peptides and globular proteins into living cells, we
found that the mechanism of entry depends on the size
of the cargo fused to TAT. The major fraction of
TAT-containing proteins or peptides was taken up into
living cells by distinct modes, with the proteins mostly
ending up in cytoplasmic vesicles and the peptides
distributing throughout the cell and accumulating in
the nucleoli (Fig. 2).
The vesicular storage inside the cytoplasm was a
general feature of different recombinant proteins fused
to a CPP and was independent of protein function, CPP
(data not shown), and fluorescent label (Fig. 2A, C). A
small population of TAT fusion protein reached the
cytosol and nucleus via a different pathway or leaked
out from the vesicles, as we detected Cre recombination
activity in the nuclei using an extremely sensitive and
unambiguous reporter assay for TAT-Cre. This fraction
of bioavailable TAT-Cre was not high enough, however,
to be detected by direct confocal microscopy of the
labeled TAT-Cre protein whereas the population
trapped in vesicles was easily detectable. Furthermore,
cotransduction of the fusogenic peptide TAT-HA2 (17)
did not substantially increase the release of the differ-
ent TAT fusion proteins from cytoplasmic vesicles as
assayed by live cell confocal microscopy (Fig. 2C).
Unlike CPP fusion proteins, TAT fusion peptides
could be seen diffusely distributed throughout the cell
and concentrated in nucleoli (Fig. 2 and Table 1).
Uptake occurred rapidly within 3–5 min after applica-
tion of the TAT construct on living cells. Upon longer
observation times, the diffusively distributed fraction of
the TAT peptides disappeared and cytoplasmic vesicles
containing the peptides became apparent, suggesting
that the peptides were either redistributed or under-
went an additional vesicular uptake.
In addition to different uptake kinetics and localiza-
tion after internalization of proteins and peptides fused
to CPPs, inhibitors of endocytosis efficiently blocked
the vesicular uptake of both species while having a
minor effect on the TAT peptide transduction (Fig. 1),
indicating that the latter does not depend on vesicle
formation and/or traffic along the cytoskeleton. In
fact, the only treatment capable of blocking not only
the vesicular uptake of CPP-containing proteins and
peptides, but also the rapid translocation of TAT
peptides leading to a diffuse intracellular distribution,
was incubation of the cells with a sodium-deficient iso-
osmolar buffer (Fig. 1), indicating an alternative distinct
cellular entry pathway based on membrane potential.
To understand which properties of cargoes fused to
TAT allow the rapid membrane transduction, we com-
pared the cellular entry of various TAT-containing
constructs (Table 1). Fluorescently labeled TAT had
already appeared inside the nucleoli of 90% of living
cells at a concentration of 1 M. The uptake efficien-
cies were decreased for TAT fusion peptides. By com-
parison, differences in the overall pI of TAT due to the
addition of a cargo resulted only in minor effects on
transduction efficiencies, whereas the amino acid com-
position of the CPP itself seemed to be more important.
For instance, PTD4 containing three arginines trans-
duced into living cells only at concentrations of 400
M whereas TAT peptides with eight positive charges
(six of them arginines) transduced quite efficiently in a
range of 0.1–10 M (Table 1). Most transduction
efficiencies were tested for the CPP TAT at concentra-
tions of 10 M and resulted in comparable high
percentages of transduced cells. However, differences
for individual peptides were found to be dependent on
the concentration used; for instance, the TAT-HA2
peptide was already diffusively distributed inside cells at
a concentration of 0.1 M, whereas for TAT-p21-PBD
uptake was restricted to endocytosis below a concentra-
tion of 7.5 M, and only above 7.5 M did the peptide
enter rapidly and appear in the nucleoli (Table 1). The
existence of such a concentration threshold can also
explain conflicting reports assigning CPP-mediated
membrane translocation to endocytosis (19, 39) or to
an unknown mechanism, resulting in a homogeneous
distribution in the whole cell (7). Another parameter
that should be taken into account is the stability of the
transducible peptides themselves since it was shown
that CPP peptides could be degraded by extra- and
intracellular proteases (40). However, we have not
observed dramatic differences in the transduction effi-
ciencies between TAT-HA2 consisting of D-amino acids
and other potentially degradable peptides consisting of
L-amino acids at comparable concentrations (Table 1).
The TAT-containing peptides exhibited a strong
affinity to the nucleolar compartment, with a lower
steady-state concentration in the rest of the cell. Alter-
natively, their enrichment in the nucleoli could be due
to a higher viscosity in this subnuclear compartment.
However, our fluorescence photobleaching results
(Fig. 3) revealed that despite their accumulation in the
nucleolus, TAT peptides were mobile and able to reach
their targets in the nucleus and cytoplasm. Measure-
ments of protein dynamics in the cell nucleus showed
half recovery times of 3 s, and so the peptide dynam-
ics measured for TAT-p21-PBD in nucleoli and cyto-
plasm (2 s) can be considered to be similar (41). As a
direct test of their bioavailability, we investigated the
cell cycle effects of TAT fusion to PBD peptides. PCNA
forms a sliding clamp around DNA and plays a central
role in DNA replication (reviewed in ref. 42). Multiple
factors required for DNA synthesis and cell cycle pro-
gression bind PCNA (20) via a consensus PBD Qxx(M/
L/I)xxF(Y/F) (43). We fused two different PBD pep-
tides to TAT and tested their effect on cell cycle
progression using a novel live cell cycle progression
assay. In fact, incubation of the cells with both peptides
for as little as 10 min substantially inhibited cell cycle
progression (Fig. 4). These data clearly showed that,
albeit accumulated in nucleoli, the peptides are fully
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able to reach their biological targets elsewhere in the
cell and exert a biological effect.
In summary, our data indicate that the translocation
of TAT-containing constructs through biomembranes
takes place with high efficiency, but at least two func-
tionally distinct mechanisms are involved. Complexes
with a globular structure like TAT fused to Q-dots (Fig.
5) or TAT fusion proteins seem to be mostly restricted
in their uptake to an endocytic mechanism that is
associated with trapping in cytoplasmic vesicles. A mi-
nor fraction of internalized TAT fusion proteins, unde-
tectable by confocal microscopy but sufficient to induce
enzymatic activity, seems to escape vesicles in the cells.
Besides being endocytosed, TAT-containing peptides
have the ability to enter living cells by a different
pathway. The exact underlying mechanism for this
rapid translocation is unknown and could be explained
by transient membrane perturbations (14) or lipophilic
ion pair diffusion along the membrane potential (5,
10). In general, increasing positive charge of the CPP
itself and decreasing size of the cargo fused to the CPP
allows rapid internalization to occur in addition to the
slow process of adsorptive endocytosis (Fig. 5). The
latter implies that CPP-mediated uptake of globular
proteins is restricted to cell types capable of endocyto-
sis. CPP-containing peptides can rapidly transduce all
cell types tested and, despite their high affinity to the
nucleolus, transduced peptides have access to all intra-
cellular compartments, thus making them an ideal tool
for therapeutic applications.
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3. Discussion & Outlook 
 
Delivery of hydrophilic compounds over the plasma membrane of living cells 
provides the fascinating possibility to exploit the macromolecular repertoire of 
the cell for life sciences and molecular medicine. CPPs promote the uptake of 
several types of cargoes, like oligonucleotides, proteins, peptides, drugs and 
nanoparticles11,28,30,31,33-35. We focused in our work on the subclass of 
arginine-rich peptides (RRPs) and assessed their uptake, toxicity and vector 
properties.  
 
In the comparative live-cell microscopy study 2.1 oligo-lysines were only taken 
up via endocytic pathways, whereas oligo-arginines exhibited an additional 
uptake mode, associated with immediate presence inside cyto- and 
nucleoplasm and referred to as transduction. This observation underscores 
the huge differences between individual CPPs depending on the arginine 
content. The analysis of the transduction abilities of consecutive oligo-
arginines R5 to R12 revealed increasing transduction with an increasing 
number of arginine residues and increasing concentration. Toxicity was 
monitored concomitantly as the percentage of cells that took up propidium 
iodide (PI) from the outer solution. R9 and R10 exhibited high transduction 
rates with low toxicity and R9 was subjected to a more detailed toxicity 
analysis with non-degradable (D-amino acid) peptides. At concentrations 
higher than 50 M and short time incubation toxicity was detected by trypan 
blue inclusion indicating membrane damage and by the MTT assay as a 
marker for enzymatic activity. However, long-term effects on the cell cycle 
could be excluded. The formation of pores during transduction was addressed 
via concomitant incubation of R9 with PI (2.1) or FITC (2.2). In both 
experimental setups transduction took place without concomitant 
internalization of the small chemical compounds, which argues against the 
formation of transient pores that were discussed in two recent publications 
94,140. Even simultaneous application of the L- and D-R9 with different 
fluorescent labels resulted in selective earlier uptake of the non-degradable D-
isoform ( 2.1, movie M1). One possible explanation for this behaviour could be 
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that multimeric peptide complexes on the membranes are required to provoke 
transduction and these can only be formed by peptides generated from one 
isoform. Since L-arginines are susceptible to proteolytic degradation, while the 
non-degradable D-isomers stay intact, the latter transduced in some cells 
earlier or selectively. Such coordinative effects would also explain the 
presence of a critical concentration or transduction threshold (2.6). 
The portion of bioavailable and freely diffusing RRPs can arise from two 
different pools: (i) Either they are released after endocytic uptake from 
pinocytic vesicles (endosomes or lysosomes) or (ii) they cross the plasma 
membrane by a more direct process. In 2.2 we examined if the endocytic 
pathways clathrin- and caveolin-dependent endocytosis that were published 
to be responsible for CPP uptake, are involved in the uptake of the RRP TAT. 
By inhibiting specifically these pathways we found no change in the freely 
diffusing portion of TAT and by reduction of the temperature to 4°C we could 
rule out that the mechanism of TAT-translocation is dependent on any kind of 
endocytosis. Furthermore, the kinetics of RRP uptake was shown to be cell-
type specific as displayed by Fig. 5 in 2.2 and movies M2-11, although all 
used cell types were susceptible to transduction.  
To further understand the mechanism of transduction we investigated 
structural properties of different CPPs and RRP-fusion peptides by 
sedimentation velocity ultracentrifugation. In general, an extended 
conformation of all RRP-containing peptides could be demonstrated, but this 
conformation was not the conditio sine qua non for transduction. A calculation 
of charges per calculated length (obtained by analytical ultracentrifugation) 
revealed that the clustering of positive charge derived from arginines is 
decisive for transduction. This was further tested by the generation of a cyclic 
variant of the RRP TAT (cTAT) that was realized without the introduction of 
further charges. Analyzing transduction by live-cell confocal fluorescence 
microscopy revealed that the circular form transduced more effectively as 
indicated by a lower average initiation time of transduction and resulted in 
higher amounts of intracellular peptide than the linear form of TAT (movie 
M12). Thus cTAT represents a novel RRP with enhanced transduction 
potential. In the light of cooperative effects, that are necessary for 
transduction, this might reflect different arrangement of both forms on the 
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membrane surfaces (2.3). Moreover, the planar ring-like structure of cTAT led 
to the planar and outwards orientation of the arginine sidechains and thus 
resulted in a larger interface with the membranes. 
Cargoes attached to TAT CPP influence its mode of uptake. Proteins, DNA / 
RNA, peptides and drugs connected to RRPs were taken up by a CPP-
enhanced pinocytic mechanism, but only low molecular weight cargoes 
(fluorophores, drugs, peptides) showed - at intermediate concentrations - the 
option to enter living cells by transduction (2.6). Nevertheless after pinocytosis 
the transducible TAT-Cre was able to reach the nucleus, as demonstrated by 
a switch from hc-Red expression to GFP expression that was caused by Cre- 
recombination activity in cells containing a reporter gene. Although release of 
TAT-Cre could not be visualized directly by confocal microscopy this 
observation proves that at least a marginal amount of a TAT-fusion protein 
could escape from vesicles and exerted functional effects detected by this 
sensitive and self-amplifying assay (2.6).  
Exploiting the transduction mode of uptake for direct delivery in an instantly 
bioavailable form, we showed that RRP-mediated translocation is a tool for 
labeling certain intracellular compartments in cell cultures, either by the 
intrinsic property of RRPs to enrich in the nucleolar compartment or in 
connection to a actin-targeting peptide in cardiomyocytes (2.4 and 2.5).  
Transduction led to the bioactive delivery of TAT-fusion peptides and was 
used to investigate protein interactions in two examples: (i) A peptide derived 
from ventricular light chain-1 (VLC-1) was introduced into adult 
cardiomyocytes. This construct enhanced muscle contractility without causing 
a change in Ca2+-levels. (ii) Peptides derived from two proteins that bind to 
the PIP-box of PCNA were delivered to cell cultures by TAT CPP (2.6). This 
constructs were able to inhibit cell cycle progression after a short incubation 
time of 15 minutes and thus may serve as antiproliferative drugs in the future. 
Finally, RPP-mediated delivery of peptides is also well suited for functional 
studies in primary cells, like human polymorphonuclear neutrophils or 
cardiomyocytes (2.5) 131,141 that are both short-lived and resistant to 
transfection. The latter involves gene expression and consequently biological 
effects can only be assayed hours to days after transfection.  
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General considerations for peptide and protein delivery by CPPs 
 
Strikingly, non-vesicular transduction of RRPs does not compromise living 
cells at intermediate concentrations and, at the same time, results in high 
intracellular bioavailable concentrations. 
The use of degradable CPP constructs (composed of L-amino acids) has the 
additional advantage to allow for the proteolytic degradation of the non-target 
bound excess peptide, whereas non-degradable D-amino acid containing 
CPP constructs will forcedly elicit sustained effects. Internalized degradable 
CPP constructs can be shielded from the intracellular proteolytic machinery 
when bound to their targets, while the remaining unbound fraction is rapidly 
degraded providing a natural control over excess CPP constructs. The 
attractiveness of this system does of course not apply for non-degradable 
compounds linked to CPPs, e.g., drugs, heavy metals or retro-inverso and 
other non-natural peptoids. 
Although transduction is sometimes described to occur ‘seemingly energy-
independent’, there has to be a driving force for this kind of cellular uptake. 
Macromolecular concentration gradients in and out of the cell or the 
membrane potential are possible parameters and experimental data supports 
both 38,70. This would imply that transduction could only proceed in one 
direction, which has though not yet been experimentally demonstrated. 
Translation of in vitro CPP transduction onto in vivo applications should be 
feasible but the verification is difficult since most often fixation protocols are 
used to check for uptake in the different organs and the latter leads to artificial 
redistribution of the substances delivered. Nevertheless, irrespective of the 
mode of cellular uptake (transduction or endocytosis) several in vivo studies 
have demonstrated uptake and/or biological effects of CPP-mediated delivery 
of cargoes (see introduction and Table 1).  
A priori, the fast uptake and hydrophilic nature of most CPPs should make 
their use more suitable for topical delivery to the target tissue, which would 
also provide specificity, rather than for systemic delivery, which would require 
deep tissue penetration to reach certain organs and cell types. However, TAT-
proteins applied in vivo, were found in all organs and were even able to cross 
the blood brain barrier 33,112. A summary of several successful CPP-mediated 
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in vivo delivery experiments in the last years is listed in Table 1. How can 
these discrepancies between the marginal penetration of CPP-cargoes and 
the encouraging effects measured in animals in several studies be explained? 
At least in part, it might be due to the fact that most studies tackled either 
inflammatory and apoptotic processes or tumor tissues. The former are 
associated with enhanced tissue and membrane permeability and the latter 
with high vascularization, increased interstitial space and the absence of a 
lymphatic network 142. Therefore, compromised tissue may be reached more 
facile by CPP-entities circulating in the bloodstream and uptake into harmed 
cells might be enhanced.  
The constraints of the animal experiments do not apply to the exciting 
possibilities of CPP-mediated cargo delivery in ex vivo cell applications, 
including labeling of cells and subcellular structures, cell-based assays, and 
modulation of cellular functions. Since all cells so far have proven to be 
susceptible to transduction by low molecular weight cargoes linked to CPPs, 
this mode of uptake can be utilized directly. Application of large cargoes (e.g., 
proteins) that become internalized exclusively by pinocytosis though, require 
the future optimization of non-toxic strategies to release the CPP cargoes 
from the vesicles. With the recent developments in cell replacement therapies, 
this non-DNA based approaches will be extremely useful. 
Thus CPP-mediated and in particular RRP-mediated transduction enables the 
usage of the subclass of hydrophilic compounds with intracellular targets for 
therapeutical applications. Depending on the CPP chosen and the cargo itself, 
two different uptake modes can be observed that can be exploited differently. 
While the instantly bioavailable modus will permit delivery to even primary 
cells and can be used for interference of LMW cargoes with intracellular 
targets in ex vivo cultures, the more general endocytic uptake, applicable for 
all types of cargoes, can be utilized for systemic delivery in vivo. 
Hence, CPP-mediated delivery will vastly increase the number of potential 
drug targets and lead to the development novel therapeutics in the future. 
  
 
 
 
 
Chapter 3                                                                          Discussion & Outlook 
 89
Table 1: CPP-mediated delivery of peptides & proteins in vivo. 
 
 
Effect Specific effect Cargo CPP Animals Application Citation 
Reduced cerebral infarct 
size 
Bcl-xL TAT C57BL/6 mice i.p. 143 
Resistant to sepsis-
induced apoptosis, 
increased survival 
Bcl-xL, 
BH4-peptide 
TAT Bcl-xL 
overexpressed in T-
lymphocytes, 
transgenic mice 
s.c., 
miniosmotic 
pumps 
123 
Reduced hippocampal 
damage in excitotoxic 
seizure model 
BH4-domain of Bcl-xL TAT Sprague-Dawley 
rats 
injection 
into dental 
gyrus 
144 
Blocked inflammation 
and tumor angiogenesis 
Caveolin-1 peptide 
(amino acids 82-101) 
Pen Swiss mice pretreated 128 
ROS-reduction Cu, Zn-superoxide 
dismutase 
PEP-1 gerbil i.p. 127 
Prevented delayed 
neuronal cell death after 
transient global 
ischemia 
FNK (Bcl-xL) TAT gerbil i.p. 145 
Protection against 
chemotherapy-induced 
alopecia 
FNK (Bcl-xL) TAT Wistar rats topical  146 
Amelioration of 
established colitis 
NBD-peptide 
(Nemo-binding 
domain) 
K8 IL-10 -/- mice i.p. 147 
Inhibition of caspase-3 
activity 
D-JNKl1 peptide, c-Jun 
N-terminal kinase 
inhibitor 
TAT Wistar rats i.p. 126 
Decreased infarcted 
myocardium 
p27 
(Heat shock protein 27) 
TAT Sprague-Dawley 
rats 
i.p. 148 
Inhibition of OVA-
induced lung 
inflammation 
STAT-6 inhibitory 
peptide 
PTD4 BALB/c mice i.n. 129 
Anti-apoptotic, 
Anti-inflammatory 
Reduction of caspase-3 
and -9  
XIAP 
(X-linked inhibitor of 
apoptosis) 
Pen Sprague-Dawley 
rats 
i.p. 149 
Anti-diabetic Elevates insulin levels in 
diabetic mice 
Pdx1  
(pancreatic duodenal 
homeobox-1) 
TAT BALB/c mice i.p. 150 
Anti-
neurodegenerative 
Suppressed 
polyglutamine-induced 
neurodegeneration 
QBP1 
(Aggregate inhibitor 
peptide poly Q binding 
peptide 1) 
TAT UAS-MJDtr-Q78 
transgenic 
Drosophila fly line 
mixed with 
food 
151 
Anti-proliferative Attenuates cell migration 
and metastasis 
Grb7 (growth factor 
receptor-bound protein 
7) inhibitory peptide 
Pen BALB/c nu/nu mice i.p. 108 
Apoptotic effects on 
tumor 
R7 athymic nude mice injected into 
tumor  
122 Pro-apoptotic 
Apoptotic effects on 
tumor 
Kla-peptide 
(klaklakklaklak) 
PTD-5 C57BL/6 mice injected into 
tumor  
152 
Protection of 
microvasculature 
Reduced infarct size 
following an acute 
stroke 
dV1-1 
(PKC-derived peptide) 
TAT Sprague-Dawley 
rats 
i.p. 153 
Restores PNP-function 
in ko-mice 
PNP 
Purine nucleoside 
phoshorylase 
TAT PNP -/-  C57BL/6 
mice 
i.p. 130 
Restores functional 
dystrophin 
PMO altering pre-
mRNA splicing for 
dystrophin protein 
RRP mdx-mouse model 
with nonsense 
mutation in exon 23 
i.p. 154 
Rescue of function 
Delivery over the blood 
brain barrier restores 
function 
BDNF 
(brain-derived 
neurotrophic factor) 
TAT Kung Ming mice i.v. 155 
Abbreviations: i.p. intraperitoneal; i.v. intraveneous; K lysine; s.c. subcutaneous; ROS reactive oxygen species; RRP arginine-rich peptide; Pen 
penetratin; PTD protein transduction domain, R arginine 
Chapter 4                                                                                             Appendix 
 90 
4. Appendix 
 
4.1 Abbreviations 
 
AGA    a-galactosidase A 
AMD    actinomycin D 
 
BALB/c    albino laboratory mouse strain 
Bcl-xL    apoptosis regulator protein 
BH4    peptide derived from Bcl-xL 
BHK    baby hamster kidney  
BJ-hTERT    human fibroblast cell line 
BP    band pass 
 
Cav    caveolin 
C2C12    mouse myoblast cell line 
CD34 Cluster differentiation antigen 34 
CHC    clathrin heavy chain 
CHO    Chinese hamster ovary 
Cip    cycline dependent kinase inhibitor protein 
CLSM    confocal laser scanning microscopy 
CPP    cell penetrating (permeable) peptide  
Cre    Cre-recombinase (from P1 bacteriophage) 
 
D    dextrorotatory 
DHFR    dihydrofolatereductase 
(DIBAC)4    bis-(1,3-dibutylbarbituric acid)-trimethine oxonol  
DNA    desoxyribonucleic acid 
DMPC    di-meristyl-phosphatidylcholine 
DMEM    Dulbecco’s modified eagle medium 
DOPC    dioleolyl-phosphatidylcholine 
DOPS    dioleolyl-phosphatidylserine 
DRAQ5    Deep red florescing anthraquinone No. 5 
DSPC    di-sphingomyelin-phosphatidylcholine 
 
ECL    enhanced luminescence 
 
FACS    fluorescence activated cell sorting 
FCS    fetal calf serum 
FITC    fluorescein isothiocyanate 
Fluos    fluorescein 
FM     fluorescent marker 
FRAP    fluorescence recovery after photobleaching 
FS    fractional shortening 
FU    fluorouridine 
 
GFP    green fluorescent protein 
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Grb 7    growth factor receptor bound protein 7 
GUV    giant unilamellar cell 
 
HA2    hemagglutinin 2 
HBSS    Hank’s balanced salt solution 
HeLa    human cervical cancer cell line 
HEPES    N-2-hydroxyethylpiperazine-N’-2-ethane-sulfonic 
acid 
HFT    main beam splitter 
HIV    human immunodeficiency virus 
HPLC    high pressure liquid chromatography 
HPMA    N-(2-hydroxypropyl)methacrylamide 
HRP    horse radish peroxidase 
 
IgG    Immunoglobuline G 
IPTG    Isopropyl--D-thiogalactopyranosid 
 
c-Jun    gene coding for AP1 transcription factor 
JNK    c-Jun N-terminal kinases 
 
K    lysine 
KO    knock out 
 
L    levoratotory 
LDH    lactate dehydrogenase 
Lig    ligase 
LMW    low molecular weight 
LSCM    laser scanning confocal microscopy 
LSM    laser scanning microscope 
LUV    large unilamellar cell 
 
MAP    model amphipathic peptide 
MAPKAP    mitogen activated protein kinase activated protein 
MDCK    madine darby canine kidney 
MHC    myosine heavy chain 
MK2    MAPKAP kinase 2 
MLC    myosine light chain 
mRFP    monomeric red fluorescent protein 
mRNA    messenger ribonucleic acid 
M2S                      multi subunit DNA-binding protein  
MTP    membrane transduction peptide 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide 
 
NA    numerical apertur 
NBD    7-nitro-2-1,3-benzoxadiol-4-yl, 
    Nemo binding domain 
ND    neck domain 
NLS    nuclear localization sequence 
NMR    nuclear magnetic resonance 
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ON    oligonucleotides 
 
p21    protein 21 
PBD    PCNA binding domain 
PBS    phosphate buffered saline 
PC    phase contrast 
PCNA    proliferating cell nuclear antigen 
PEI    polyethylenimine 
PGLa    peptide starting with a glycine and ending with a 
    leucine amide 
pI    isoelectric point 
PI    propidium iodide 
PIP    PCNA-interacting protein 
PMO    phosphorodiamidate morpholino oligomer 
PNA    peptide nucleic acid 
PTD    protein transduction domain 
pre-mRNA    first transcript from a protein coding gene 
PreS2    domain from Hepatitis B virus 
 
Q-dot    nanocrystal 
 
R    arginine 
Rab    Ras-related in brain, protein family 
Ras    ‘rat sarcoma’, protein family 
REMD    replica exchange molecular dynamics 
RNA    ribonucleic acid 
RNAse     Ribonuclease  
RPMI    medium (Roswell Park Memorial Institute) 
RRP / R-RP   arginine-rich peptide 
 
SE    sticky end 
SEM    standard error of the mean 
shRNA    small hairpin ribonucleic acid 
siRNA    small interfering ribonucleic acid 
STAT-6    signal transducer and activation of transcription-6 
SynB1    synthetic pegalin derivative, CPP 
 
TAMRA    5,6-carboxy-tetramethyl rhodamine 
TAT    transactivator of transcription 
Tet    tetracycline 
tetR    tetracycline repressor protein 
Tf    transferrin 
tTA    tetracycline controlled transcription activator 
 
UC    ultracentrifugation 
 
VLC    ventricular light chain 
VP16     transcriptional activator from Herpes simplex VP22
    viral protein 22 
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WAF    wild type p53-activated fragment 
wt    wild type 
WKY    Wistar Kyoto strain of Rattus norvegicus 
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4.2 Declaration of contributions 
 
Introductory chapter 1 is modified from an invited book chapter with the title 
‘Cell penetrating peptides – Uptake, toxicity and applications’ written by Gisela 
Tünnemann and M. Cristina Cardoso, that is accepted for publication in 
‘Membrane-active peptides: methods and results on structure and function" 
(tentative title); IUL (International University Line, La Jolla, California, USA; 
www.iul-press.com).   
 
Results 2.1 
Live-cell analysis of cell penetration ability and toxicity of oligo-
arginines. 
The idea to perform a systematical assessment of the transduction ability and 
toxicity of oligoarginines was developed jointly by me, Robert Martin and M. 
Cristina Cardoso. Gohar Ter-Avetisiyan performed, evaluated and illustrated 
all transduction experiments to assess the transduction frequencies of 
oligoarginines of different chain length in living cells by confocal microscopy 
(Fig. 1). Martin Stöckl analyzed the transduction frequency of selected NBD-
labeled peptides in large unilamellar vesicles (LUVs) by using a 
spectrofluorometer (supplementary Fig. 1). Robert Martin supervised pilot 
experiments and contributed to the movie data analysis (supplementary 
movie). Andreas Herrmann provided expertise and equipment for the LUV-
experiments and M. Cristina Cardoso accompanied all stages of the 
development of this paper with scientific advice and allocated the laboratory 
and microscopic facilities. 
I contributed to the outline of the paper, supervised (Fig. 1) or performed, 
evaluated and illustrated the experiments displayed in Fig. 2 and Fig. 3, 
illustrated supplementary Fig. 1 and wrote the manuscript.  
 
Results 2.2 
Cell entry of arginine-rich peptides is independent of endocytosis. 
M. Cristina Cardoso, Andreas Herrmann and me developed the initial outline 
for this paper. Matthias Nitschke and Marek Drab provided cell lines. Gohar 
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Ter-Avetisyan performed and analyzed all experiments and wrote the 
manuscript on the basis of my day-to-day supervision. 
 
Results 2.3 
Circularization and charge clustering promotes cellular uptake of 
arginine-rich cell penetrating peptides (Manuscript in preparation) 
The initial idea to use analytical ultracentrifugation to gain structural 
information about CPPs came from Ingo Morano. Joachim Behlke performed 
the ultracentrifugation analysis, Caroline Palm synthesized some of the 
peptides and investigated their stability. Manuel Prinz and Daniel Hoffmann 
modeled the peptide structures. M. Cristina Cardoso supported experiments 
and the manuscript throughout with scientific advice and provided the 
laboratory and the confocal microscope facility for live cell imaging.  
I coordinated the project, performed, evaluated and illustrated the confocal 
microscope experiments and wrote the manuscript.  
 
Results 2.4 
Nucleolar marker for living cells. 
Robert Martin and M. Cristina Cardoso had the idea to use oligoarginines as a 
live cell marker for the nucleolar compartment. Robert Martin performed and 
analyzed all experiments, except for the transduction into primary cells (Fig. 
1A) and wrote the manuscript. I provided images for the transduction into 
primary cells and did proofreading of the manuscript. 
 
Results 2.5 
Modulation of muscle contraction by a cell permeable peptide. 
Adult rat cardiomyocytes were isolated by Wolfgang Schlegel and Petra 
Pierschalek. Peter Karczewski and Hannelore Haase carried out the 
measurements for the shortening amplitude and for the systolic and diastolic 
cytoplasmic Ca2+ fluctuations in paced cardiomyocytes, evaluated and 
illustrated the results summarized in fig. 4. M. Cristina Cardoso had the initial 
idea for project, supported experiments and manuscripts with scientific advice 
and provided the laboratory and the confocal microscope facility for live cell 
imaging. I performed the microscopic transduction assay and the analysis of 
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intracellular localization of transduced VLC-1-TAT peptide in contracting 
cardiomyocytes, evaluated and illustrated the results (fig. 1 - 3) and wrote the 
manuscript. 
 
Results 2.6 
Cargo-dependent mode of uptake and bioavailability of TAT-containing 
proteins and peptides in living cells. 
Robert M. Martin conducted, evaluated, illustrated and wrote the respective 
part of the manuscript for the FRAP experiments (fig. 3) and also took part in 
the accomplishment for the cell cycle progression assay (fig. 4). Moreover he 
contributed data for table 1. Simone Haupt, Christoph Patsch and Frank 
Edenhofer provided the TAT-Cre-reporter gene construct  (3T3-FDR1.2 cells) 
and fluorescently labeled recombinant TAT-Cre protein. They also performed, 
evaluated and illustrated the result that is described in fig. 1 D. M. Cristina 
Cardoso supported experiments and manuscripts with scientific advice and 
provided the laboratory and the confocal microscope facility for live cell 
imaging. 
I performed, evaluated and illustrated the experiments summarized in fig 1A-C 
and 2 and contributed to the cell cycle progression analysis (fig 4). Moreover I 
wrote the manuscript except the part describing the FRAP experiments.  
 
The discussion is modified from an invited book chapter with the title ‘Cell 
penetrating peptides – Uptake, toxicity and applications’ written by Gisela 
Tünnemann and M. C. Cardoso, that is submitted to be published in 
‘Membrane-active peptides: methods and results on structure and function" 
(tentative title); IUL (International University Line, La Jolla, California, USA; 
www.iul-press.com). 
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Declaration according to the “Promotionsordnung der LMU München für die 
Fakultät Biologie” 
 
Betreuung:  Hiermit erkläre ich, dass die vorgelegte Arbeit am Max-Delbrück-
Centrum für Molekulare Medizin von Frau Dr. M. C. Cardoso 
betreut wurde. 
Anfertigung: Hiermit versichere ich ehrenwörtlich, dass die Dissertation 
selbstständig und ohne unerlaubte Hilfsmittel angefertigt wurde. 
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im Kapitel 4.2 Rechenschaft abgelegt und die eigenen 
Leistungen wurden aufgelistet. 
Prüfung: Hiermit erkläre ich, dass die Dissertation weder als ganzes noch 
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(Gisela Tünnemann) 
 
Chapter 4                                                                                             Appendix 
 98 
4.3 Acknowledgements 
 
This work would not have been accomplished without the help of many 
people. Within my present lab I want to thank all group members for the 
readiness to share knowledge and experience and to take over some tasks, 
which enabled me to work part-time for certain periods of time. Especially, I 
want to mention Petra Domaing, who started together with me with great 
enthusiasm on the project of protein transduction and introduced me to the 
basics of cell culture work and of confocal fluorescence microscopy. The 
delivery of peptides into living cells was in wide parts a teamwork with Robert 
Martin, whose profound biological knowledge helped in many cases. I would 
like to thank Gohar Ter-Avetisyan, who joined recently on the same subject, 
for the good cooperation throughout. 
Science is always fun, but in some laboratories it is more fun than in others. 
Therefore I want to thank M. Cristina Cardoso for the possibility to work in her 
very well organized laboratory and for the cultivation of a nice and helpful 
atmosphere. Especially her constant and altruistic scientific support has been 
invaluable for the progress of all projects and for the development of my 
understanding of biological sciences.  
Besides all these people I want to gratefully acknowledge our cooperation 
with Ingo Morano’s group at the MDC. Especially I want to thank Wolfgang 
Schlegel and Petra Sakel for reliable preparation of adult cardiomyocytes and 
Peter Karzcewski, Hannelore Haase and Ingo Morano for help and advice on 
the VLC-1-TAT project. Martin Stöckl and Andreas Herrmann from Humboldt 
University Berlin helped with their expertise on artificial membrane vesicles 
and kindly performed a number of transduction experiments with arginine-rich 
CPPs. Last but not least from the scientific part, I want to thank all the 
members of Heinrich Leonhardt’s group in Munich for their support in 
bureaucratic as well as scientific questions. Special thanks go to Andrea 
Rottach for the close cooperation within the p21-project, Uli Rothbauer for 
sharing his experience in biochemical methods and to Heinrich Leonhardt for 
scientific advice in many of the projects and the support for my thesis.  
Chapter 4                                                                                             Appendix 
 99
Personally I am indebted to my family. I want to express my deep thanks to 
my father, who will be happy that something I started long time ago is about to 
finish, to my two little daughters, who delight my days, and of course to Stefan 
for giving me unfailing support and for keeping the sense of humor even in 
tough times. 
 
Chapter 4                                                                                             Appendix 
 100 
4.4 References 
 
1. Frankel, A.D. & Pabo, C.O. Cell. 55, 1189-93 (1988). 
2. Green, M. & Loewenstein, P.M. Cell. 55, 1179-88 (1988). 
3. Perez, F. et al. J Cell Sci. 102 ( Pt 4), 717-22 (1992). 
4. Joliot, A. et al. Prog Neurobiol. 42, 309-11 (1994). 
5. Elliott, G. & O'Hare, P. Cell. 88, 223-33 (1997). 
6. Murphy, A.L. & Murphy, S.J. Gene Ther. 6, 4-5 (1999). 
7. Elliott, G. & O'Hare, P. J Virol. 73, 4110-9 (1999). 
8. Machova, Z. et al. Chembiochem. 3, 672-7 (2002). 
9. Trehin, R. et al. Pharm Res. 21, 33-42 (2004). 
10. Oess, S. & Hildt, E. Gene Ther. 7, 750-8 (2000). 
11. Fawell, S. et al. Proc Natl Acad Sci U S A. 91, 664-8 (1994). 
12. Vives, E., Brodin, P. & Lebleu, B. J Biol Chem. 272, 16010-7 (1997). 
13. Derossi, D. et al. J Biol Chem. 269, 10444-50 (1994). 
14. Fischer, P.M. et al. J Pept Res. 55, 163-72 (2000). 
15. Dathe, M. et al. Biochemistry. 35, 12612-22 (1996). 
16. Oehlke, J. et al. Biochim Biophys Acta. 1414, 127-39 (1998). 
17. Scheller, A. et al. J Pept Sci. 5, 185-94 (1999). 
18. Futaki, S. et al. J Biol Chem. 276, 5836-40 (2001). 
19. Marshall, N.B. et al. J Immunol Methods. 325, 114-26 (2007). 
20. Mi, Z. et al. Mol Ther. 2, 339-47 (2000). 
21. Wender, P.A. et al. Proc Natl Acad Sci U S A. 97, 13003-8 (2000). 
22. Crespo, L. et al. J Am Chem Soc. 124, 8876-83 (2002). 
23. Fernandez-Carneado, J. et al. Angew Chem Int Ed Engl. 43, 1811-4 
(2004). 
24. Fernandez-Carneado, J. et al. Biopolymers. 76, 196-203 (2004). 
25. Lin, Y.Z. et al. J Biol Chem. 270, 14255-8 (1995). 
26. Langel, U. et al. Regul Pept. 62, 47-52 (1996). 
27. Chaloin, L. et al. Biochemistry. 36, 11179-87 (1997). 
28. Rothbard, J.B. et al. J Med Chem. 45, 3612-8 (2002). 
29. Rothbard, J.B. et al. Nat Med. 6, 1253-7 (2000). 
30. Shibagaki, N. & Udey, M.C. J Immunol. 168, 2393-401 (2002). 
31. Astriab-Fisher, A. et al. Pharm Res. 19, 744-54 (2002). 
32. Nagahara, H. et al. Nat Med. 4, 1449-52 (1998). 
33. Schwarze, S.R. et al. Science. 285, 1569-72 (1999). 
34. Lewin, M. et al. Nat Biotechnol. 18, 410-4 (2000). 
35. Torchilin, V.P. et al. Proc Natl Acad Sci U S A. 98, 8786-91 (2001). 
36. Richard, J.P. et al. J Biol Chem. 278, 585-90 (2003). 
37. Silhol, M. et al. Eur J Biochem. 269, 494-501 (2002). 
38. Tunnemann, G. et al. FASEB J. 20, 1775-84 (2006). 
39. Fittipaldi, A. et al. J Biol Chem. 278, 34141-9 (2003). 
40. Lundberg, M., Wikstrom, S. & Johansson, M. Mol Ther. 8, 143-50 
(2003). 
41. Nakase, I. et al. Biochemistry. 46, 492-501 (2007). 
42. Ruan, G. et al. J Am Chem Soc. (2007). 
43. Wadia, J.S., Stan, R.V. & Dowdy, S.F. Nat Med. 10, 310-5 (2004). 
44. Richard, J.P. et al. J Biol Chem. 280, 15300-6 (2005). 
Chapter 4                                                                                             Appendix 
 101
45. Brooks, H., Lebleu, B. & Vives, E. Adv Drug Deliv Rev. 57, 559-77 
(2005). 
46. Duchardt, F. et al. Traffic. 8, 848-66 (2007). 
47. Mann, D.A. & Frankel, A.D. Embo J. 10, 1733-9 (1991). 
48. Tyagi, M. et al. J Biol Chem. 276, 3254-61 (2001). 
49. Ziegler, A. & Seelig, J. Biophys J. 86, 254-63 (2004). 
50. Goncalves, E., Kitas, E. & Seelig, J. Biochemistry. 44, 2692-702 
(2005). 
51. Peitz, M. et al. Proc Natl Acad Sci U S A. 99, 4489-94 (2002). 
52. Nolden, L. et al. Nat Methods. 3, 461-7 (2006). 
53. Dietz, G.P. & Bahr, M. Mol Cell Neurosci. 27, 85-131 (2004). 
54. Maiolo, J.R., 3rd, Ottinger, E.A. & Ferrer, M. J Am Chem Soc. 126, 
15376-7 (2004). 
55. Caron, N.J., Quenneville, S.P. & Tremblay, J.P. Biochem Biophys Res 
Commun. 319, 12-20 (2004). 
56. Shiraishi, T., Pankratova, S. & Nielsen, P.E. Chem Biol. 12, 923-9 
(2005). 
57. Hogset, A. et al. Somat Cell Mol Genet. 27, 97-113 (2002). 
58. Shiraishi, T. & Nielsen, P.E. FEBS Lett. 580, 1451-6 (2006). 
59. Vives, E. J Mol Recognit. 16, 265-71 (2003). 
60. Kaplan, I.M., Wadia, J.S. & Dowdy, S.F. J Control Release. 102, 247-
53 (2005). 
61. Magzoub, M. et al. Biochem Biophys Res Commun. 348, 379-85 
(2006). 
62. Mai, J.C. et al. J Biol Chem. 277, 30208-18 (2002). 
63. Ziegler, A. et al. Biochemistry. 44, 138-48 (2005). 
64. Fretz, M.M. et al. Biochem J. 403, 335-42 (2007). 
65. Brugidou, J. et al. Biochem Biophys Res Commun. 214, 685-93 (1995). 
66. Derossi, D. et al. J Biol Chem. 271, 18188-93 (1996). 
67. Futaki, S. et al. Biochemistry. 41, 7925-30 (2002). 
68. Martin, R.M. et al. Histochem Cell Biol. 127, 243-51 (2007). 
69. Bjorklund, J. et al. Biophys J. 91, L29-31 (2006). 
70. Rothbard, J.B. et al. J Am Chem Soc. 126, 9506-7 (2004). 
71. Rothbard, J.B., Jessop, T.C. & Wender, P.A. Adv Drug Deliv Rev. 57, 
495-504 (2005). 
72. Afonin, S. et al. Chemphyschem. 7, 2134-42 (2006). 
73. Shaw, J.E. et al. J Struct Biol. (2007). 
74. Glaser, R.W. et al. Biophys J. 88, 3392-7 (2005). 
75. Bellet-Amalric, E. et al. Biochim Biophys Acta. 1467, 131-43 (2000). 
76. Ziegler, A. et al. Biochemistry. 42, 9185-94 (2003). 
77. Sheldon, K. et al. Proc Natl Acad Sci U S A. 92, 2056-60 (1995). 
78. Mitchell, D.J. et al. J Pept Res. 56, 318-25 (2000). 
79. Hallbrink, M. et al. Biochim Biophys Acta. 1667, 222-8 (2004). 
80. Lindberg, M. et al. Biochemistry. 40, 3141-9 (2001). 
81. Dathe, M. & Wieprecht, T. Biochim Biophys Acta. 1462, 71-87 (1999). 
82. Matsuzaki, K. et al. Biochemistry. 35, 8450-6 (1996). 
83. Futaki, S. Biopolymers. 47, 75-81 (1998). 
84. Thoren, P.E. et al. FEBS Lett. 482, 265-8 (2000). 
85. Tunnemann, G. et al. J Pept Sci. 14, 469-76 (2008). 
86. Hallbrink, M. et al. Biochim Biophys Acta. 1515, 101-9 (2001). 
Chapter 4                                                                                             Appendix 
 102 
87. Berlose, J.P. et al. Eur J Biochem. 242, 372-86 (1996). 
88. Derossi, D., Chassaing, G. & Prochiantz, A. Trends Cell Biol. 8, 84-7 
(1998). 
89. Joliot, A. & Prochiantz, A. Nat Cell Biol. 6, 189-96 (2004). 
90. Magzoub, M., Eriksson, L.E. & Graslund, A. Biophys Chem. 103, 271-
88 (2003). 
91. Binder, H. & Lindblom, G. Biophys J. 87, 332-43 (2004). 
92. Luedtke, N.W., Carmichael, P. & Tor, Y. J Am Chem Soc. 125, 12374-
5 (2003). 
93. Chung, H.H. et al. Biopolymers. 76, 83-96 (2004). 
94. Herce, H.D. & Garcia, A.E. Proc Natl Acad Sci U S A. 104, 20805-10 
(2007). 
95. Eilers, M. et al. Philos Trans R Soc Lond B Biol Sci. 319, 121-6 (1988). 
96. Verner, K. & Schatz, G. Science. 241, 1307-13 (1988). 
97. Bonifaci, N., Sitia, R. & Rubartelli, A. Aids. 9, 995-1000 (1995). 
98. Becker-Hapak, M., McAllister, S.S. & Dowdy, S.F. Methods. 24, 247-56 
(2001). 
99. Kwon, H.Y. et al. FEBS Lett. 485, 163-7 (2000). 
100. Saar, K. et al. Anal Biochem. 345, 55-65 (2005). 
101. El-Andaloussi, S. et al. Biochem J. 407, 285-92 (2007). 
102. Jones, S.W. et al. Br J Pharmacol. 145, 1093-102 (2005). 
103. Cardozo, A.K. et al. Biochim Biophys Acta. 1768, 2222-34 (2007). 
104. Moschos, S.A. et al. Bioconjug Chem. 18, 1450-9 (2007). 
105. Abes, S. et al. J Control Release. 116, 304-13 (2006). 
106. Youngblood, D.S. et al. Bioconjug Chem. 18, 50-60 (2007). 
107. Amantana, A. et al. Bioconjug Chem. 18, 1325-31 (2007). 
108. Tanaka, S. et al. J Natl Cancer Inst. 98, 491-8 (2006). 
109. Josephson, L. et al. Bioconjug Chem. 10, 186-91 (1999). 
110. Zhao, M. et al. Bioconjug Chem. 13, 840-4 (2002). 
111. Christian, N.A. et al. Bioconjug Chem. 18, 31-40 (2007). 
112. Polyakov, V. et al. Bioconjug Chem. 11, 762-71 (2000). 
113. Bullok, K.E. et al. Bioconjug Chem. 13, 1226-37 (2002). 
114. Bullok, K.E. et al. Mol Imaging. 5, 1-15 (2006). 
115. Jiang, T. et al. Proc Natl Acad Sci U S A. 101, 17867-72 (2004). 
116. Haase, H. et al. Faseb J. 20, 865-73 (2006). 
117. Nori, A. et al. J Control Release. 91, 53-9 (2003). 
118. Nori, A. et al. Bioconjug Chem. 14, 44-50 (2003). 
119. Rousselle, C. et al. Mol Pharmacol. 57, 679-86 (2000). 
120. Rousselle, C. et al. J Drug Target. 10, 309-15 (2002). 
121. Okuyama, M. et al. Nat Methods. 4, 153-9 (2007). 
122. Law, B. et al. Mol Cancer Ther. 5, 1944-9 (2006). 
123. Hotchkiss, R.S. et al. J Immunol. 176, 5471-7 (2006). 
124. Sugioka, R. et al. Oncogene. 22, 8432-40 (2003). 
125. Ono, M. et al. Eur J Cardiothorac Surg. 27, 117-21 (2005). 
126. Repici, M. et al. Neuroscience. 150, 40-9 (2007). 
127. Eum, W.S. et al. Free Radic Biol Med. 37, 339-49 (2004). 
128. Bernatchez, P.N. et al. Proc Natl Acad Sci U S A. 102, 761-6 (2005). 
129. McCusker, C.T. et al. J Immunol. 179, 2556-64 (2007). 
130. Toro, A. & Grunebaum, E. J Clin Invest. 116, 2717-26 (2006). 
131. Tunnemann, G. et al. J Mol Med. 85, 1405-12 (2007). 
Chapter 4                                                                                             Appendix 
 103
132. Turner, J.J. et al. Nucleic Acids Res. 33, 6837-49 (2005). 
133. Abes, S. et al. Nucleic Acids Res. 35, 4495-502 (2007). 
134. Moulton, H.M. et al. Biochem Soc Trans. 35, 826-8 (2007). 
135. Endoh, T., Sisido, M. & Ohtsuki, T. Nucleic Acids Symp Ser (Oxf). 127-
8 (2007). 
136. Simeoni, F. et al. Nucleic Acids Res. 31, 2717-24 (2003). 
137. Unnamalai, N., Kang, B.G. & Lee, W.S. FEBS Lett. 566, 307-10 (2004). 
138. Gratton, J.P. et al. Nat Med. 9, 357-62 (2003). 
139. Lavigne, M.D. et al. Faseb J. (2008). 
140. Mishra, A. et al. Angew Chem Int Ed Engl. 47, 2986-9 (2008). 
141. Chen, L. et al. Proc Natl Acad Sci U S A. 98, 11114-9 (2001). 
142. Takakura, Y., Mahato, R.I. & Hashida, M. Adv Drug Deliv Rev. 34, 93-
108 (1998). 
143. Cao, G. et al. J Neurosci. 22, 5423-31 (2002). 
144. Ju, K.L., Manley, N.C. & Sapolsky, R.M. Exp Neurol. (2007). 
145. Asoh, S. et al. Proc Natl Acad Sci U S A. 99, 17107-12 (2002). 
146. Nakashima-Kamimura, N. et al. Life Sci. 82, 218-25 (2008). 
147. Dave, S.H. et al. J Immunol. 179, 7852-9 (2007). 
148. Kwon, J.H. et al. Biochem Biophys Res Commun. 363, 399-404 (2007). 
149. Li, T. et al. Exp Neurol. 197, 301-8 (2006). 
150. Koya, V. et al. Diabetes. (2007). 
151. Popiel, H.A. et al. Mol Ther. 15, 303-9 (2007). 
152. Mai, J.C. et al. Cancer Res. 61, 7709-12 (2001). 
153. Bright, R., Steinberg, G.K. & Mochly-Rosen, D. Brain Res. 1144, 146-
55 (2007). 
154. Fletcher, S. et al. Mol Ther. 15, 1587-92 (2007). 
155. Zhou, J.P. et al. Brain Res. 1191, 12-9 (2008). 
 
Chapter 4                                                                                             Appendix 
 104 
4.5 Curriculum Vitae 
 
Name:  Gisela Tünnemann 
Date of birth:  24.07.1970 
Place of birth  Fröndenberg 
 
Education 
 
1990   Allgemeine Hochschulreife 
   Walburgisgymnasium 
   Menden, Germany 
 
1990-1997  Diploma in chemistry 
   Carl von Ossietzky University Oldenburg 
   Oldenburg, Germany 
 
2003- present PhD in biology (LMU, München, Germany) 
   Max Delbrueck Center for Molecular Medicine 
   Berlin, Germany 
 
Positions and teaching 
 
1997   student assistant in AG toxicology 
   Carl von Ossietzky University Oldenburg 
   Oldenburg, Germany 
 
1998-2003  scientist in AG crystallography 
   Max Delbrück Center for Molecular Medicine 
   Berlin, Germany 
 
2003-present  graduate student in the group of M. Cristina Cardoso 
2007-now co-supervision of the diploma thesis of Gohar Ter-
Avetisyan 
Chapter 4                                                                                             Appendix 
 105
4.6 Conference contributions 
 
November 2004, Gisela Tünnemann & Robert M. Martin. “Minimal invasive 
methods to deliver macromolecules to living cells. “ Oral presentation at the 
Cardiovascular Retreat of the Max Delbrueck Center for Molecular Medicine 
in Groß-Dölln, Germany. 
 
November 2006, Gisela Tünnemann. “Transducible peptides in cardiovasular 
research: modulation of contractile mechanism. “ Oral presentation at the 
Cardiovascular Retreat of the Max Delbrueck Center for Molecular Medicine 
at the communication center Hubertusstock, Germany. 
 
March 2006, Gisela Tünnemann. “Delivery of proteins and peptides by cell 
penetrating peptides into living cells and their application to the modulation of 
cellular proliferation and differentiation. Invited oral presentation at the 
Wollenberger Seminar, Berlin, Germany. 
 
July 2006, Gisela Tünnemann, Robert M. Martin, Hannelore Haase, 
Wolfgang Schlegel, Petra Pierschalek, Ingo Morano und M. Cristina Cardoso. 
“Inhibition of cellular proliferation and modulation of muscle contractility by cell 
permeable TAT-peptide fusions.“ Poster at the International Symposium on 
optical analysis of biomolecular machines, Berlin, Germany. 
 
April 2007, Gisela Tünnemann, Robert M. Martin, Hannelore Haase, Peter 
Karczewski, Prisca Bosguerin, Rudolf Volkmer, Joachim Behlke, Ingo Morano 
and M. Cristina Cardoso. “Application of cell penetrating peptides in the 
modulation of cell proliferation and differentiation.“ Poster at the 2nd 
Workshop on Biophysics of membrane-active peptides, Lisbon, Portugal. 
 
May 2007, Gisela Tünnemann, Robert M. Martin and M. C. Cardoso. 
“Application of cell penetrating peptides in the modulation of cell proliferation 
and differentiation. “ Poster at the Biochemical Society meeting “Cell 
penetrating peptides“ at the University of Wolverhampton, Telford, UK. 
 
September 2007, Gisela Tünnemann, Robert M. Martin, G. Ter-Avetisyan 
and M. C. Cardoso. “Toxicity and applications of cell penetrating peptides in 
the modulation of cell proliferation and differentiation. “ Poster at the 2nd 
Intracellular delivery of therapeutic molecules, Grenoble, France. 
 
Chapter 4                                                                                             Appendix 
 106 
4.7 List of publications 
 
Haase, H., Dobbernack, G., Tünnemann, G., Karczewski, P., Cardoso, M. C., 
Petzhold, D., Schlegel, W., Lutter, S., Pierschalek, P., Behlke, J. & Morano, I. 
(2006). Minigenes encoding N-terminal domains of human cardiac myosin 
light chain-1 improve heart function of transgenic rats. FASEB J. 20, 865-873. 
Tünnemann, G., Martin, R. M., Haupt, S., Patsch, C., Edenhofer, F. & 
Cardoso, M. C. (2006). Cargo-dependent mode of uptake and bioavailabiltiy 
of TAT-containing proteins and peptides. FASEB J. 20, 1775-1784. 
 
Martin, R.M., Tünnemann, G., Leonhardt, H. & Cardoso, M.C. Nucleolar 
marker for living cells. Histochem Cell Biol. 127, 243-251. 
 
Von Vietinghoff, S. Tünnemann, G., Eulenberg, C., Wellner, M., Cardoso, M. 
C., Luft, F. C. & Kettritz, R. (2007). NB1 mediates surface expression of the 
ANCA antigen proteinase 3 on human neutrophils. Blood  109, 4487-4493. 
 
Tünnemann, G., Karzcewski, P., Haase, H., Cardoso, M. C. & Morano, I 
(2007). Modulation of muscle contraction by a cell-permeable peptide. J Mol 
Med. 85, 1405-1412. 
 
Tünnemann, G., Ter-Avetisyan, G., Martin, R. M., Stöckl, M., Herrmann, A. & 
Cardoso, M. C. (2008). Live-cell analysis of cell penetration ability and toxicity 
of oligo-arginines. J Pept Sci. 14, 469-476. 
 
Nitschke, M., Korte, T., Tielesch, C., Ter-Avetisyan, G., Tünnemann, G., 
Cardoso M. C., Veit, M. & Herrmann, A (2008). Equine arteritis virus is 
delivered to an acidic compartment of host cells via clathrin-dependent 
endocytosis. Virology. 377, 248-254. 
 
Tünnemann, G. & Cardoso, M. C. Cell penetrating peptides – Uptake, toxicity 
and applications. In "Membrane-active peptides: methods and results on 
structure and function", edited by M. Castanho, IUL (International University 
Line, La Jolla, California, USA; www.iul-press.com), In Press. 
 
Ter-Avetisyan, G., Tünnemann, G., Nowak, D., Nietschke, M., Herrmann, A., 
Drab, M. & Cardoso, M. C. Cell entry of arginine-rich peptides is independent 
of endocytosis. Submitted. 
 
Ciobanasu, C., Harms, E., Tünnemann, G., Cardoso, M. C. and Kubitscheck, 
U. Cell-penetrating HIV1 TAT peptides float on anionic model lipid bilayers. 
Submitted. 
 
Tünnemann, G., Behlke, J., Morano, I., Palm, C., Prinz, M., Hoffmann, D & 
Cardoso, M. C. Circularization and charge clustering promotes cellular uptake 
of arginine-rich cell penetrating peptides. Manuscript in preparation. 
 
Chapter 4                                                                                             Appendix 
 107
4.8 Movies 
 
M1: Confocal microscopy time lapse of the transduction of the L- and D-
isomers of R9 simultaneously applied to C2C12 mouse myoblasts at a 
concentration of 10 M. Derived from Tünnemann et al., J Pept Sci. 14, 469-
476.  
 
M2-M8: Confocal microscopy time lapses of the transduction of TAT into 
BHK21-tTA/anti-clathrin heavy chain) hamster kidney cells at a concentration 
of 10 M. M2=control cells, M3-8 transduction in cells after day 1-6 after 
knock down of the clathrin heavy chain-protein. Derived from Ter-Avetisyan et 
al., submitted. 
 
M9-M10: Confocal microscopy time lapses of the transduction of TAT into an 
endothelioma cell line from wildtype (WT) and caveolin-1 knockout (KO) mice 
at a concentration of 10 M. M9=wt, M10=KO. Derived from Ter-Avetisyan et 
al., submitted. 
 
M11: Confocal microscopy time lapses of the transduction C2C12 mouse 
myoblasts at a concentration of 10 M at different temperatures. M11=37°C. 
M12= 4°C. Derived from Ter-Avetisyan et al., submitted. 
 
M12: Confocal microscopy time lapses of the transduction of linear and 
circular TAT into C2C12 mouse myoblasts at a concentration of 20 M at 
different temperatures. M11=37°C. M12= 4°C. Derived from Tünnemann et 
al., manuscript in preparation. 
 
M13: Confocal microscopy time lapse of the transduction of the nucleolar 
marker into C2C12 mouse myoblasts at a concentration of 10 . Derived from 
Martin et al., Histochem Cell Biol. 127, 243-251. 
